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ABSTRACT
This thesis describes the genetic events that can lead to the loss of expression of 
HLA class 1 on tumour cells. Earlier studies, in colorectal cancer, have shown 
both complete loss of surface HLA A, B & C expression and loss of single allele 
products using antibodies recognizing either monomorphic or polymorphic 
HLA determinants. Data presented demonstrates that complete loss of HLA 
class 1 expression correlates with mutations in P2 iriicroglobulin. In a study of 52 
colorectal cell lines, 8 showed mutations in p2 iriicroglobulin leading to loss or 
reduced HLA expression. In fresh colorectal tumours 9/147 had mutations in 
p2 iriicroglobulin, occurring at single or di-nucleotide repeat sequences. From 
these tumours 71 were analyzed for microsatellite instability, associated w ith 
the loss of DNA mismatch repair, and 7 (10%) found to be unstable.
P2 microglobulin mutations were identified in 5 of these tumors. Therefore, 
m utations in P2 microglobulin occur more frequently in m ism atch repair 
defective tumours than in colorectal tumours in general (p<0.01)
The colorectal cell line HCA-7 lacks expression of HLA-A'^OlOl based on 
studies with the polymorphic antibody 142.2, but the normal B cell line (EVA- 
1224) from the same patient expresses A*0101. This thesis shows that the 
A'^OlOl gene, in HCA-7, contains an insertion of a cytidine in a cytidine repeat 
sequence in exon 4. This mutated A'^OlOl gene has the similar sequence to that 
of a rare A*0104'nulT allele reported to lack A*0104 expression.
In a model system a p2microglobulin-HLA-A’^ 0201 construct was transfected, 
using an ecdysone inducible expression system, into CHO cells and expression 
shown to be under the control of the inducer, Ponasterone A. Functional 
studies demonstrated the construct to be capable of presenting the flu virus 
peptide GILGFVFTL to a clone of human A*0201 restricted cytotoxic T cells and 
for the T cells to efficiently lyse the CHO cells.
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CHAPTER 1
INTRODUCTION
1.1.1 The Immune System.
Early work on the immune system indicated that it divided fairly equally into 
two areas, the mechanisms a body used to produce antibodies to neutralize 
foreign molecules, called humoral immunity, and the processes involving cell to 
cell surveillance leading to removal of suspect cells, called cellular immunity. 
With the aid of modern technology the immune system has now been shown to 
be extremely complex, but the primarily role is still to defend the body against 
invasion from  m any organism s, diseases and foreign m olecules. The 
lymphocytes, which are distributed throughout the body in blood vessels and 
lym ph nodes, are the cells mainly involved in im m une responses. These 
morphologically similar cells have been subdivided according to their expression 
of surface m em brane differentiation molecules. B cells express surface 
immunoglobulin reactive to native antigens whilst T cells express specialized 
receptors which recognize foreign molecules, presented at the surface of most 
cell types in the body, in the form of peptides associated with the HLA system in 
humans. The T lymphocytes have been further divided into those which express 
CD8 and recognize small peptides, predom inantly from cytoplasmic protein 
degradation, in association with class I (HLA-A, B & C) molecules and those 
which express CD4 which recognize larger peptides, frequently from endosomal 
and lysosomal protein degradation, in association with class II (HLA-DP, DQ & 
DR) molecules. A further compartment of the immune system has now  been 
described composed of cells derived from a precursor in common w ith T cells; 
these are the Natural Killer or NK cells. Unlike T cells, which require stimulation
and clonal expansion to become effective, NK cells express various receptors 
constitutively and are able to respond immediately by either lysis of infected 
cells or release of a series of cytokines and chemokines leading to a more general 
inflammatory response. Many NK cells recognize HLA class I molecules through 
surface receptors, which inhibit, rather than activate, a response by the NK cells. 
Cells with reduced or lacking HLA class I expression, such as some tumours and 
cells infected by certain viruses, may therefore become targets for NK activity.
This thesis concentrates on cellular immunity and in particular on cases where 
loss of expression of HLA molecules has occurred. The following sections of 
chapter 1 outline what is currently known about these mechanisms.
1.1.2 History of the HLA system.
The earliest report relating to what has become known as the H2 system in mice 
was made by Peter Gorer in 1938. He identified a murine red blood cell antigen 
(antigen II) which segregated in mouse genetic crosses with the acceptance of 
subsequent tum our transplants (Gorer, 1938). Later the antigen II locus was also 
linked to a fused tail deformity and had become know as H 2 , later to be re­
named H-2 (Gorer et al., 1948). About ten years later, Counce et al. reported the 
rejection of tissue grafts between different strains of mice and linked this 
rejection to a series of histocompatibility loci in the congenic mice strains used 
and the graft survival (Counce et al., 1956). The genes in the strong (major) 
histocompatibility locus were reported to have a greater effect on rejection than 
those genes found at the weaker (minor) histocompatibility locus. The major 
histocompatibility locus was later shown to be the same as Gorer's antigen II or 
H-2. Further studies in mice identified three closely linked histocompatibility 
loci, H2-K, H-2D and H2-L(Klein and Shreffler, 1972; Snell et al., 1971) which 
encode the mouse major histocompatibility antigens, and many more alleles have 
been identified at each locus using the terms H2-K^, H2-K^ and so on.
The major histocompatibility antigens were first reported in hum ans (now 
known as HLA, the hum an equivalent of H2) following the observation that 
serum samples from multiparous women were capable of agglutinating certain 
leukocytes. This led to the identification of the LA antigens (Payne et al., 1964) 
and the 4a and 4b antigens (van Rood, 1962). These became known as HLA-A 
and HLA-B respectively, and were mapped to the short arm of chromosome 6 
(6q21.3) where three closely linked genetic loci were discovered, HLA-A and B 
and later a third locus C. These loci were seen to be highly polymorphic and by 
1987 using serological typing 24 HLA-A, 50 HLA-B and 11 HLA-C alleles had 
been defined (Bodmer et al., 1987) and with the advent of molecular biological 
techniques, such as PCR, typing directly from DNA samples has been possible 
and the current number of alleles identified is 266 HLA-A, 511 HAL-B and 128 
HLA-C (EBBL-EBI Database at w w w .ebi.ac.uk/im g t/h la  /stats.h tm l, January 
2003). Some of these new alleles are extremely rare and may even be limited to a 
single individual.
In humans, further genes have been identified on chromosome 6 at 6q21.3 and 
these form the HLA or MHC region. Historically, these fall into three regions: 
class I HLA (the highly polymorphic HLA class I alleles), class II HLA (including 
HLA class II plus TAP, LMP and tapasin genes) and HLA class III (including the 
complement proteins and cytokines such as TNF).
1.1.3 Structure of HLA class I.
HLA class I is a heterodimeric molecule composed of a highly polym orphic 
heavy chain glycoprotein of 45 kDa (HLA-A, -B & -C) non-covalently associated 
with an invariant light chain of 12 kDa (p2 -microglobulin) and an endogenously 
processed peptide usually of about 9 amino acids in length (Townsend et al., 
1989; Wilson and Fremont, 1993). The classical class 1 molecules are generated
from three loci on chromosome 6 (HLA-A, -B & -C) whilst p2 -m icroglobulin is
encoded on chromosome 15 (Goodfellow et al., 1975b). They are expressed at the 
surface of most nucleated cells and have a major role in presentation of peptide
antigens to CD8^ T cells. The non-classical class I HLA molecules are HLA-E, -F 
& -G which have a similar structure to the classical molecules and associate with 
P2 -microglobulin but tend to be less widely expressed and at much lower levels. 
HLA-E appears to have a much more limited repertoire for peptide binding and 
is involved in NK cell recognition (Brand et al., 1998b) (see section 1.1.6), HLA-G 
is predominantly expressed on the trophoblast (Kovats et al., 1990; Rinke et al., 
1990).
HLA class I genes have 8 exons. Exon 1 encodes a signal peptide, exons 2-4 the 
three extracellular domains, a l ,  a l  and a3, exon 5 encodes the hydrophobic 
transmembrane domain and exons 6-8 encode the cytoplasmic domain (Strachan 
et al., 1984). With the crystal structure of HLA-A2, Bjorkman et ai. showed that 
the m em brane distal a l  and a  2 dom ains form ed a groove for pep tide 
presentation and that the a3 domain was non-covalently associated w ith P2 - 
microglobulin (Bjorkman et al., 1987). Each domain is formed of approximately 
100 amino acids and the a l  and a l  domains form two antiparallel a-helices 
which form the sides of a peptide binding groove with the floor of the groove 
made up of an eight stranded antiparallel p-sheet, each domain contributing 4 
strands. This binding groove is orientated away from the surface membrane, 
allowing interaction with T cell and NK cell receptors, and is supported by the
immunoglobulin-like a3 domain non-covalently linked w ith p2 -microglobulin. 
The a l  and a l  domains are highly polymorphic with a majority of the amino 
acid differences occurring in the antiparallel a-helices. A pocket may be deep or 
shallow and have charged, polar, neutral or hydrophobic residues, all of which 
determine the compatibility of the pocket with peptide residues and their side 
chain characteristics (Matsumura et al., 1992).
The specificity of peptide binding has been show n to be defined by the 
individual characteristics of the six pockets (A-F) (Colbert et al., 1993; Fruci et al.,
1993; Kubo et al., 1994; Tussey et al., 1994). The most important appear to be the 
A and F pockets, which accommodate the amino- and carboxyl- ends of the 
peptide respectively. At least one of the other pockets (B, C, D & E) forms an 
"anchor" to complete the specificity of peptide binding to a particular HLA
heavy chain. The A pocket has three important amino acids contributing to the 
structure, these are three tyrosine residues at positions try7, try 159 and tryl71. 
The amino terminus of the peptide is buried into the A pocket leaving the side 
chain of this first residue pointing upw ards into the solvent. There is little 
preference for any particular amino acid at the amino end of the peptide (Falk et 
al., 1990). In contrast, the F pocket has distinct preferences for particular residues 
at the carboxyl end of the peptide. Some F pockets examined are hydrophobic in 
nature and predom inantly bind side chains which are similarly hydrophobic. 
HLA-A2, for example, has a preference for a peptide with valine or leucine at the 
carboxyl terminus, where as HLA-B27 has an acidic F pocket that binds basic 
side chains such as those seen on arginine (Madden et al., 1991). The interactions 
between the amino- and carboxyl- ends of the peptide and pockets A and F have 
a stabilizing effect on the HLA/peptide complex and the F pocket initiates some 
degree of specificity. Some other pockets have a limited repertoire of residues 
that can be accommodated, these have become known as "anchor" residues. 
(Barouch et al., 1995).
The binding specificity of the peptide into a groove can be optimized further by 
w ater molecules. In a study of HLA-B53, Smith et al. have show n that two 
pep tides w ith  w idely different P4-P7 residue sequences w ere equally 
accommodated in the groove. One peptide, Is6, derived from a malarial parasite 
protein, had an aspartic acid at P7 with this residue orientated away from the 
groove leaving a space filled with 7 water molecules. This formed a network of 
hydrogen bonds stabilizing the peptide backbone in the groove. The second 
peptide, HIV-2, from the viral gag protein, had a glutamine at P7 which was 
buried low within the groove causing displacement of the water molecules. Both 
peptides had an anchor residue of proline at P2 (Smith, 1996).
Only certain residues of the peptide constitute anchor residues and occupy 
particular pockets in the groove. The remaining pockets can be occupied by a 
m uch wider diversity of amino acid residues. This allows for a large range of 
peptides derived from entirely different protein sources to be expressed by a 
given HLA molecule. The frequency of specific amino acid sequences, w ith the 
relevant anchor residues included, w ithin the general protein pool will also 
determine the number of possible peptides a particular HLA molecule can bind.
If a particular HLA molecule has a rare order for anchor binding this would limit 
the num ber of peptides presented. The order of anchor residues required by 
HLA-A'^0201 are relatively common in proteins and so a large num ber of 
peptides can be presented (Falk et al., 1991).
1.1.4 The role of HLA Class I in the peptide presentation pathway.
HLA class I peptide antigen presentation is an intriguing story involving a 
complex pathway. The pathway is best illustrated by following the progress of a 
protein, expressed in the cytoplasm, from proteolytic breakdown through to 
expression on the cell surface membrane. A simplified illustration of this process 
is shown in Figure 1.
Antigen processing starts with the modification of proteins and polypeptides 
from the resident protein pool in the cell cytoplasm. This protein pool is made up 
of endogenous proteins, proteins synthesized in the cell following pathogen 
infection and "foreign", often functionally impaired, proteins synthesized from 
altered DNA following a mutational event. These proteins undergo modification 
into short peptides by proteolysis involving a series of proteasom es. The 
structure of the 20S proteasome (Baumeister et al., 1998), is cylindrical, consisting 
of four rings, each made up of seven sub-units. The two outer a  sub-units are 
concerned w ith m aintaining the molecular structure and interacting w ith 
proteasom e regulatory sub-units, and may also be involved w ith  cellular 
localization. The two inner P units, forming the centre of the barrel, contain the 
proteolytic activity (Zwickl et al., 1994). These units are made up of a series of 
subunits which were initially called LMP-2 and LMP-7, the transcription of 
which was shown to be inducible by y IFN (Monaco and McDevitt, 1986). Later a 
third ylFN inducible sub-unit (LMP-10) was reported together with three further
sub-units which are not ylFN induced and may even be down-regulated by ylFN, 
LMP-9, LMP-17 and LMP-19 (Nandi et al., 1996). The latter are thought to be 
constitutively expressed. It has been suggested that the p sub-units can be made 
up of different combinations of the LMP subunits and that this m ay result in 
proteasomes that preferentially or more effectively generate peptides capable of
FIGURE 1
A simplified representation of the assembly pathw ay of 
HLA Class I molecules
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HLA Class I assembly. Nascent HLA heavy chain binds to the chaperone molecule Calnexin in the 
cytoplasm (1) and is transported to the endoplasmic reticulin (2). Here p^microglobulin binding 
occurs (3) and Calnexin ^ replaced by Calreticulin and ERp57 (4) to aid folding and stabilization of 
the HLA class 1/ P^microglobulin complex. Tapasin then forms a bridge between the HLA class 
1/P^microglobulin complex and the TAP complex carrying peptide (5). Here the peptide is loaded 
on to the HLA class 1/ p^microglobulin complex. Binding of the peptide triggers disassociation of 
TAP/Tapasin (6) allowing the HLA class I/P^microglobulin/peptide complex to leave the 
endoplasmic reticulin and enter the Golgi (7) where maturation takes place. Finally, the mature 
complex is expressed on the surface membrane (8) for presentation of the peptide antigen to CDS 
Cytotoxic T cells and NK cells.
high affinity binding to HLA class I molecules. In addition, the preferential 
incorporation of ylFN inducible sub-units into newly transcribed proteasomes 
m ay increase the num ber of functionally distinct proteasom e complexes, 
generating a larger repertoire of different peptides from a given protein antigen 
(Gaczynska et al., 1993). As proteins pass through the cylindrical shaped 
proteasom e complex, proteolysis occurs, releasing into the cytoplasm short 
peptides of between 9 and 23 amino acids. The peptides are then taken up by the 
TAP complex for transport from the cytoplasm into the endoplasmic reticulum 
(ER).
TAP is a member of the ABC (ATP-binding cassette) transporters and was 
discovered about ten years ago. Trowsdale et al. reported several new genes in 
the hum an MHC class II region, two of which were called RING4 and RIN G ll, 
which had characteristic CpG island sequences (Trowsdale et al., 1990). Several 
other groups at about the same time were searching for a candidate gene/s that 
could be involved in peptide antigen processing and identified in rodents HAM l 
and 2 (Monaco et al., 1990) and m tpl and 2 (Deverson et al., 1990). By 1991 these 
had all been sequenced and shown to be homologs of two genes which have 
come to be known as TAPI and TAP2 (Transporter associated w ith Antigen 
Processing), the names being accepted by the WHO nomenclature committee 
(WHO, 1991).
Both TAPI and TAP2 have a similar gene structure with 11 exons and both have 
an ylFN stimulation response element (ISRE) 198 and 573 bases upstream  of exon 
1 respectively (Beck et al., 1992). TAPI encodes a protein of 748 amino acids 
while TAP2 encodes a protein of 686 amino acids. They norm ally exist as a 
heterodim er of TAPI and TAP2 as indicated by im m unoprécip itation  
experiments with a TAPI specific antibody (Kelly et al., 1992). The TAP genes in 
humans have shown to be polymorphic, with four alleles reported for TAPI and 
six for TAP2. The majority of these polymorphisms occur in the transmembrane 
and nucleotide binding dom ains, but the exact functional consequences 
polymorphisms are not known. In an early study of Caucasians, TAPIA had a 
frequency of 81% and TAP2A 62% (Powis et al., 1993).
The TAP complex (TAPI, TAP2 and peptide) has a fourth component in the form 
of a 48 kDa glycoprotein which was first reported in co-immunoprecipitation 
experiments by Ortmann et al. (Ortmann et al., 1994). This glycoprotein has been 
named Tapasin (TAP associated glycoprotein) and is thought to have a bridging 
role in the association of TAP/peptide complexes with the HLA class I complex, 
described below. Sadasivan et al. have shown, in a series of immunoprécipitation 
experiments using the p2 "^^icroglobulin negative cell line, Daudi, (which lacks 
HLA class I complexes) that tapasin is capable of binding to TAP independently 
of its association with the HLA class I complex (Sadasivan et al., 1996). The exact 
role of tapasin in the TA P/peptide complex is not known, bu t it has been 
proposed that tapasin may act as a tether for the TAP-HLA class I interaction, or 
it may play a more active role in the uptake of peptides by TAP.
As well as serving as carrier to transport peptides into the ER, the TAP complex 
also functions as a hub in the ER for newly assembled HLA class I complexes. 
These complexes have been formed from newly synthesized HLA class I heavy 
chains assembled with p2 -microglobulin along a pathw ay involving a series of 
ER chaperone molecules. Initially, the chaperone calnexin associates w ith free 
unfolded class I heavy chains by interactions with both the protein component 
and monoglycosylated N-linked glycans on the class I molecule. This, however, 
has been shown not to be an obligatory association as the calnexin negative cell 
line CEM-NKR is still capable of assembling, and expressing at the cell surface, 
functional class I molecules (Scott and Dawson, 1995) probably using alternative 
chaperone molecules such as BiP which has been reported to have functions 
similar to calnexin (Noessner and Parham, 1995). Partial folding of the class I 
m olecule takes place together w ith  the covalent association w ith  p2 " 
microglobulin. Once p2 -microglobulin has become involved calnexin is replaced 
by a second chaperone molecule, calreticulin. The binding of HLA class I /P 2 - 
microglobulin to calreticulin is p2 -microglobulin dependent, however the exact 
sequence of events is unclear as definitive experiments have proved difficult. 
Sadasivan et al. have suggested that calnexin may interact only briefly w ith 
partially folded HLA class I /p 2 -microglobulin and is quickly replaced by 
calreticulin. However, the same workers have shown that the HLA class I will
not bind to calreticulin in the absence of P2 "^icroglobulin (Sadasivan et al., 
1996).
In the sequence of events leading to HLA class I assembly, it is clear that calnexin 
and calreticulin chaperone the HLA class I heavy ch a in /p 2 -microglobulin 
complexes on the ER and that tapasin forms a bridge linking the complex to TAP. 
It has been suggested that the chaperone molecules serve to aid the folding of the 
HLA class I molecule and together with p2 -i^icroglobulin help to maintain the 
integrity of the all-important peptide-binding groove of the HLA class I chain. In 
addition, the chaperones m ay be involved in the processes leading to 
degradation of misfolded and unstable empty HLA class 1/ p2 -microglobulin 
complexes by m arking them  for degradation by the proteasom es in the 
cytoplasm (Wiertz et al., 1996).
Recently, another ER chaperone molecule has been identified by SDS-PAGE 
following co-immunoprecipitation with a series of antibodies against calnexin, 
calreticulin, TAP and HLA class I. This chaperone has an apparent molecular 
weight of 59 kDa and has been identified as ERp57, a molecule w ith  thiol 
oxidoreductase activity (Hughes and Cresswell, 1998). ERp57 will bind to the 
HLA class 1 /P2 -microglobulin complex in a similar manner to calreticulin, in the 
absence of TAP, but the ERp57 binding to the HLA class I /  p2 -microglobulin 
complex is tapasin dependent (Hughes and Cresswell, 1998; Morrice and Powis,
1998). The role of ERp57 is still speculative, it has been suggested that it may play 
a part in the folding of the HLA class I heavy chain molecules by controlling and 
maintaining the disulphide bonds within the heavy chain. ERp57 shares some 
homology with the protein disulphide isomerase (PDI) (Hirano et al., 1995). 
Alternatively, ERp57 (also known as ER-60) has been implicated in the process of 
degrading misfolded glyco-proteins, such as the fully oxidised HLA class I heavy 
chain/ p2 -naicroglobulin complex, by assisting in reducing and denaturing them 
in the ER before they are shunted back to the cytoplasm for degradation by the 
proteolytic machinery (Otsu et al., 1995).
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The finally assembled complexes in the ER, which lead to peptide loading, 
involve the HLA class I heavy chain/P2-microglobulin/calreticulin/ERp57 
complex linked via a tapasin bridge to the TA P/peptide complex. The TAP 
molecule acts as a hub with up to four HLA class I complexes associated with it, 
each with a tapasin bridge. It has been proposed that the tapasin bridge interacts 
with both the TAPI and TAP 2 moieties of the TAP heterodimer, each interacting 
with two HLA class I complexes (Androlewicz et al., 1994; Ortmann et al., 1997). 
Although not proven, there has been a suggestion that the interaction of empty 
HLA class I molecules with either TAPI or TAP 2 may enhance the delivery of a 
particular peptide to an HLA allele expressing a groove w ith a high specificity 
for that peptide sequence (Watts and Powis, 1999). There is evidence that if the 
peptide is longer than preferred, additional trimming can take place w ithin the 
ER, but it is unclear if this takes place before or after loading into the groove. The 
specificity of the groove is outlined in section 1.1.3. The transfer of a peptide 
from TAP into the binding groove of an HLA class I molecule has the effect of 
stabilizing the HLA class 1 /p2 -microglobulin and releasing it from TAP. 
Srivastava et al. have reported the presence of a chaperone molecule (gp96) that 
may protect the peptide from rapid degradation before it is loaded into the 
empty groove (Srivastava et al., 1994).
Once d isasso c ia ted  from  TAP, the s tab ilized  HLA class I /P 2 - 
microglobulin/peptide complex is released from the ER and is transported to the 
cell surface via the secretory pathway through the golgi apparatus (Brodsky et 
al., 1996; Williams et al., 1996).
HLA class 1 /p2 -naicroglobulin/peptide complexes are expressed on m ost cell 
types in the body. There are, however, reports of cells lacking HLA class I 
expression including spermatozoa (Law and Bodmer, 1978) and placental villous 
trophoblasts (Goodfellow et al., 1976), w hilst other cells such as cortical 
thymocytes, neurones and hepatocytes express little or no HLA class I (Daar et 
al., 1984a; Janossy et al., 1980).
Severe down-regulation of HLA class I an d /o r HLA class II has been described 
in a comparatively rare num ber of individuals, most of whom  fall into the
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classification of type I Bare Lymphocyte Syndrome (BLS). Type II BLS is 
characterised as demonstrating down-regulation of HLA class II molecules 
(Touraine, 1978). The type I BLS classification has been further sub-divided into 
three groups according to the clinical and immunological characteristics:
Group 1. These patients demonstrate loss of HLA class I and P2 -i^icroglobulin at 
the cell surface, but characteristically have detectable serum levels of HLA class I 
and p 2 "^icroglobulin . Therefore, these patients are not thought to have 
alterations in the HLA class I and P2 -microglobulin genes. Heterozygous HLA 
haplotypes in these patients has also suggested that the gene(s) responsible for 
the loss of HLA expression are not located in the HLA coding region. Only 4 
patients have been reported with type I (group 1) BLS, all of which died of 
infectious complications within 3 years of life, having suffered from repeated 
severe bacterial, fungal and parasitic infections from an early age (Schuurman, 
1979; Tour aine, 1981; Touraine, 1978).
G roup 2. These individuals are clinically asym ptom atic and the only 
immunological finding has been the down regulation of cell surface expression 
of HLA class I and p 2 -microglobulin. Decreased levels of mRNA have been 
reported for both HLA class I and P2 -microglobulin. Only two cases have been 
recorded, and these are children from the same family. Both children have been 
HLA typed and were found to have different heterozygous HLA haplotypes 
(Payne, 1983; Sullivan, 1985).
Group 3. Patients in this group survive into adulthood but are subjected to 
recurrent bacterial infections and often develop necrotizing granulomatous skin 
lesions, particularly of the nose and nasal passages. This group, of which there 
are about 15 reported cases, have reduced or low cell surface expression of HLA 
class I (Gadola, 2000). Close analysis of 10 of these patients has shown them all to 
be homozygous at their respective HLA loci and in about half these individuals 
an underlying defect in the TAP genes has been linked with the reduced levels of 
HLA class I expression. Examples involving the TAPI gene include an individual 
w ith loss of HLA class I expression exhibiting a homozygous deletion of a G at 
position 778 in exon 2 of TAPI, leading to a prem ature stop codon (de la Salle,
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1999). A Japanese patient has been reported with a homozygous m utation in 
TAPI, at the slice site between exons 1 and 2. This mutation was identified as a G 
deletion in codon 200 at the beginning of exon 2 leading to an altered slice site 
and a frameshift causing a stop codon at codon 228 (Furukawa, 1999). A similar 
mutation involving the splice site between exons 1 and 2 of TAP 1 was recorded 
in the fibroblasts of isolated from another patient with BLS (de la Salle, 1999). A 
mutation in TAP2 has been identified in two children from the same family in 
Moroco. A brother and sister both exhibit the same hom ozygous m utation 
causing a stop codon at codon 253, resulting in a truncated TAP2 leading to a 
non-functional TAP complex (De La Salle et al., 1994).
1.1.5 The HLA Class II Pathway.
The HLA class II determinants differ from HLA class I in many ways. As already 
stated in 1.1.1 above, they present larger peptides, frequently from endosomal 
and lysosomal protein degradation, to the CD4 expressing compartment of the T 
cell population. HLA class II is a heterodimer of two proteins chains, encoded by 
the DQ, DP and DR genes, of approximately 30 kD known as a  (32 kD) and 
p (29kD) chains. The difference in size is attributed to N-linked glycosylation. 
Each chain has two domains (a l, a2 and pi, p2 respectively) with the membrane
distal a l  and p i domains combining to form a single peptide binding groove 
composed of two antiparallel a-helical loops, the sides, supported by a floor 
made of eight antiparallel p strands (Ting and Trowsdale, 2002). HLA class II 
molecules are synthesized de novo in the ER where they combine w ith  the 
invariant (li) chain which acts as a chaperone molecule for HLA class II 
assembly. li chains have two portions, one associating w ith the HLA class II 
heterodim er, and the other portion, known as CLIP (class II associated li 
peptide), occupies the peptide binding groove (Ghosh et al., 1995). Small 
peptides present in the ER following proteasome degradation, that usually bind 
to HLA class I molecules, are prevented, by the presence of the CLIP portion, 
from  binding  to HLA class II m olecules. The CLIP functioning  as a 
'stuffer'(Bikoff et al., 1993). The li/H L A  class II complexes pass from the ER 
along the secretory pathway into the Golgi and into the trans-Golgi netw ork
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where they divert and enter the endocytic pathway. From here they accumulate 
in the lysosomes.
There is still some controversy over how the li/H LA  class II complexes arrive in 
the lysosomes. Some favour the idea that the complexes pass straight from the 
trans-Golgi netw ork into the lysosome (Peters et al., 1991). H ow ever, 
W armerdam et al. suggested that the complexes pass to the cell membrane where 
they are internalised by the endosomes passing into the lysosomes (Warmerdam 
et al., 1996). Others favour the idea of trafficking from the trans-Golgi network 
via early endosomes into the lysosome (Pond and Watts, 1999). It would seem 
that the favoured route of li/H L A  class II complexes depends on the model 
system and the cell type used, and indeed Hiltbold and Roche have pointed out 
that utilization of all these trafficking routes by newly synthesized HLA class II 
molecules w ould ensure maximum exposure of these molecules to foreign 
peptides present in the many different intracellular compartments particularly 
the lysosomal-like antigen-processing compartments or pre-lysosomes (Hiltbold 
and Roche, 2002).
Having reached the pre-lysosomes the li/H L A  class II complexes undergo a 
series of proteolytic enzyme mediated events. First, the li is degraded leaving 
just CLIP occupying the binding groove. This digestion of li is m ediated by two 
cysteine protease cathepsins. Cat L and Cat S. At this point two further HLA 
class II molecules, HLA-DM and HLA-DO associate with the CLIP/HLA class II 
complex. DM and DO are heterodimers similar in structure to DR, are encoded 
in the HLA class II region, assemble in the ER and form a pool circulating 
between the cytoplasm and the pre-lysosomes. Unlike DR, DM and DO show 
only limited polymorphisms. The role of DM is to assist in the removal of CLIP 
from the binding groove and the substitution of a peptide from the pre- 
lysosomal pool. DM is thought to associate with the HLA class II complex to 
prevent it from being degraded once CLIP has been removed. A lthough DM is 
not involved in the peptide binding, it has been suggested that it is able to 
catalyze the dissociation of sub-optimal peptides, including CLIP, and therefore 
to have a role in editing peptide binding by selecting the m ost stable 
peptide/H LA  class II complex associations (Kropshofer et al., 1997; Lanzavecchia 
et al., 1992).
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The function of DO appears to be a still a matter for debate. DO is known to 
require an association with DM to enable it to leave the ER and very little DM 
has been identified without DO associated (Alfonso and Karlsson, 2000). Several 
experiments indicated that the presence or absence of DO influenced the number 
of HLA class II molecules expressed at the cell surface w ith CLIP occupying the 
binding groove (Denzin et al., 1997).
The mode of antigen internalization is diverse and can include such processes as 
m acropinocytosis, phagocytosis and receptor-m ediated uptake, bu t these 
processes are closely regulated. The uptake depends on both the type of antigen 
and the type of antigen presenting cell involved and these will dictate the 
endocytic compartment to which the antigen will be targeted (Lanzavecchia, 
1996). Once an antigen has entered the antigen presenting cell it travels along the 
endocytic pathw ay and encounters en route a series of enzymes capable of 
processing the antigen. It is not completely destroyed, but is broken down into 
polypeptides of variable length that are able to bind into the HLA class II groove. 
Initial breakdow n takes place at low pH  w ith the activity of GLIT (ylFN- 
inducible lysomal thiol reductase) which catalyses the reduction of disulphide 
bonds (Aruncchalam et al., 2000). This unfolds the antigen allowing access by 
other proteolytic enzymes such as cysteine, aspartic and serine proteases and 
metalloproteases. These proteases make up the cathepsin enzymes of which Cat 
L and Cat S have already been mentioned in connection with li digestion. There 
are at least 7 known Cat enzymes which are synthesized in the ER as pro­
enzymes which become active in the endocytic pathw ay w ith the aid other 
proteases (Riese and Chapman, 2000; Turk et al., 2001; Watts, 1997). Once Cat 
activity has started, early binding to HLA class II may occur, this protects the 
permissive peptide sequence that will bind in the groove leaving the overlapping 
ends to be trimmed at a later stage (Villadangos and Ploegh, 2000; W atts et al., 
1998).
The peptide/H LA  class II complex leaves the endosome and becomes expressed 
on the cell membrane. The route of trafficking is not properly understood. It has 
been suggested that the lysosomes fuse directly w ith the cell m em brane 
(Wubbolts et al., 1996), alternatively, small vesicles, derived from the endosomes,
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m ay carry the pep tide/H L A  class II complex to the cell m em brane for 
presentation to effector cells (Amigorena et al., 1994).
1.1.6 Antigen presenting cells.
HLA class 1 /P2 -m icroglobulin/peptide complexes are expressed on m ost cell 
types in the body with the exception of certain cells such as spermatozoa and 
placental villous trophocytes mentioned above in section 1.1.4. The distribution 
of HLA class II expression is, however, more restricted than HLA class I. 
Normally, HLA class II is found on B lymphocytes and some macrophages, and 
on certain specialized antigen presenting cells such as dendritic cells in lymphoid 
tissues, Langerhans cells in the skin and on epithelial cells found in the thymus 
(Daar et al., 1984b; Janossy et al., 1980). Many cell types that do not normally 
express HLA class II molecules can be induced to express them  following 
stimulation with lymphokines such as ylFN, although the mechanism of antigen 
presentation after ylFN simulation is not clear (Basham and Merigan, 1983).
Probably the most important antigen presenting cells are the Dendritic Cells 
(DC). These are bone m arrow derived cells which represent a heterogeneous 
family of cells with different functional capacities. DC's are found throughout 
the body, but are concentrated in areas of potential antigen entry, especially near 
epithelial and mucosal surfaces, where they capture and process exogenous 
antigens. In addition, DC's are found in the thymus, where they have a role in 
establishing tolerance to self-reactive antigens, and in secondary lym phoid 
organs, where they present antigens to specific T cells (Jefford et al., 2001). 
Resting steady state DC's present in blood and other non-lymphoid tissues reside 
there as immature cells with morphologically distinct cytoplasmic extensions 
that are short and veil-like, and demonstrate a weak capacity to stimulate naive T 
cells. Disruption of this steady state during inflammation triggers the release of 
mediators that induce both the maturation and migration of DCs. D uring this 
process DC's translocate H LA /peptide complexes to the cell surface, increase 
expression of T-cell costimulatory molecules such as CD40, CD80, CD86 (and 
activation marker CD 83 in humans) and the intercellular adhesion molecules
16
(CD54 and CD58) involved in cell/cell interactions between D C s and T cells. In 
addition, the morphology of D Cs changes with lengthening of the cytoplasmic 
extensions (Nijman et al., 1995). Mature D Cs express the chemokine receptor 
CCR7 and migrate through the lymphatic vessels to T cell areas of lymph organs 
in response to chemotactic gradients of the CCR7 ligands CCL19 and 21 (Morelli 
and Thomson, 2003).
In hum ans and in mice D Cs are quite rare cells, and w ithout a lineage specific 
m arker having been identified, have been difficult cells to study in detail. 
However, multiple subsets of D C s have been identified, based mainly on the 
expression of a series of cell surface markers, and also on their functional 
characteristics. The major subsets in humans are the CD llc^ myeloid and the 
C D llc ' plasmacytoid DCs. The equivalent CDllc^ myeloid D C s in mice express 
myeloid markers such as C D llb , 33D1 and adhesion related F4/80 (Wilson and 
O'Neill, 2003). These cells are found in the marginal zones of lymph nodes and 
spleen but migrate to the T cell areas of the spleen upon stimulation. They are 
efficient stimulators of CD4^ and CD8^ T cells and show effective MHC class II 
presentation to antigen-specific CD4^ T cells (Pooley et al., 2001). Plasmacytoid 
C D llc ' D Cs differ, and in humans express high levels of CD68, CD36, BDCA-2, 
IL-3a (IL-3-recepter a  chain) and ILT3 (an inhibitory receptor) (Salio et al., 2003). 
Morphologically these cells very rarely show the cytoplasmic extensions and 
they are thought to enter the lymph nodes directly from the blood via the high 
endothelial venules, possibly aided by the expression of the chemokine receptor 
CXCR3 and CD62L (L-selectin). Upon activation these D C s produce large 
am ounts of IFN type I (Celia et al., 1999). It has been found in mice that 
plasmacytoid DC's express low levels of MHC class II and that this set of DC's 
may play a role in the maintenance of peripheral tolerance, however, in hum ans 
mature plasmacytoid DC's are capable of inducing proliferation of naive CD4^ T 
cells and more recently, in an in vitro system, to efficiently present an 
endogenous antigen, via the HLA class I pathway, to an HLA class I restricted 
CD8+ T cell clone (Salio et al., 2003; Wilson and O'Neill, 2003).
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It has generally been accepted that peptides derived from viral and other 
intracellular infectious agents are presented on the cell surface by HLA class I to 
CD8^ cytotoxic T cells. Exogenous proteins, on the other hand, are processed via 
phago-lysozomes and replace the invarient clip fragment associated w ith HLA 
class II for presentation to CD4"^(Th) cells and usually involve specialized antigen 
presenting cells such as DC's. However, there has long been evidence that 
exogenous antigens are capable of being presented to CD8^ cytotoxic T cells via 
HLA class I expression on certain DC's (Heath and Carbone, 2001). This has 
become known as cross-priming or cross-presentation of exogenous antigens 
which has been defined as the presentation of exogenous antigen via the HLA 
class I pathw ay for the generation of stimulatory or tolerogenic responses in 
CD8^ cytotoxic T cells (Zinkernagel, 2002). This concept was based on the idea 
that activation of CD4‘*'(Th) cells or CD8^ cytotoxic T cells requires antigen (signal 
1) plus costimulation (signal 2) whilst encounters involving signal 1 alone result 
in anergy or deletion.
Identification of the subsets of DC's capable of either prim ing or inducing 
tolerance in vivo has provided evidence on whether the same or different DC 
subsets initiate tolerance or priming. A CD8 (CD205'*') DC subset has been shown 
to cross-present antigens derived from ovalbumin-loaded spenocytes and induce 
prim ing of CD8^ cytotoxic T cells (den Haan et al., 2000). This same DC subset 
appears to be responsible for the cross-presentation of pancreatic auto-antigens 
to induce cross-tolerance (Belz et al., 2002). As the same DC subset seems capable 
of eliciting both outcomes, it is likely that a quiescent DC constitutively sampling 
self-antigens in the periphery is tolerogenic and requires further specific stimuli 
to convert it into a mature DC able to deliver all the signals necessary for CD8^ T 
cell priming (Bonifaz et al., 2002). In the absence of inflammatory signals, most 
DC's in vivo will be functionally immature and are likely to induce tolerance.
The generation of cytotoxic T cells against tum our antigens may occur either by 
the direct recognition of antigens on tum our cells, or by cross-presentation of 
tum our antigens involving professional antigen presenting cells such as DC's. 
The major route of tumour antigen presentation is still controversial. Several
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studies support cross-presentation as the predominant mechanism (Huang et al., 
1994; Wolfers et al., 2001), whilst other workers suggested cross-presentation 
m ay not contribute to the generation of cytotoxic T cells (Kundig et al., 1995; 
Ochsenbein et al., 2001). These type of studies have been acknowledged as 
difficult because of the limited num ber of DC's available to study and with 
problems involving the efficiency of HLA class I presentation on tumours and it 
has been suggested that tum our progression may occur despite efficient cross­
presentation of tum our antigens and generation of antigen-specific CD8^ 
cytotoxic T cells (Nelson et al., 2001).
Some understanding of DC involvement in tum our antigen presentation has 
come from the numerous attempts to treat cancer patients by imm unotherapy 
using DC's. Also more efficient methods have been established for the isolation 
of DC's and for manipulating them in culture, allowing preparation of both 
immature and mature DC's. These cells have then been loaded w ith different 
sources of tum our associated antigens. Vaccination using DC's peptide-pulsed, 
w ith a peptide derived from a known tum our associated antigen, has been 
show n to induce both peptide-specific CD8^ and CD4^ T cells in healthy 
volunteers and in melanoma patients (Dhodapkar et al., 2000; Schuler-Thumer et 
al., 2002). Exosomes, formed by the fusion of the plasm a m em brane w ith 
multivesicular endosomes and contain various adhesion and costim ulatory 
molecules and heat shock proteins, are secreted by DC's and tum our cells. 
Tumour-specific cyotoxic T cells have been activated with DC's loaded w ith 
exosomes derived from tum our cells and, in mice, exosomes derived from 
peptide-pulsed DC's have been shown to induce anti-tumour responses (Wolfers 
et al., 2001; Zitvogel et al., 1998).
Several speculative rationales have been proposed which could im prove the 
efficiency of DC-based immunotherapy. Infecting mature DC's with recombinant 
viruses containing the cDNA from a given tum our antigen is one possible 
approach. In a model system, the EBNA-3A peptide, derived from Epstein-Barr 
virus, and introduced into m ature DC's, was efficiently presented inducing 
antigen-specific cytotoxic T cells in vitro (Subklewe et al., 1999). To circumvent 
the problems associated with viral vectors. Smith et al. introduced into m ature
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DC's a plasm id containing the full length DMA of a melanoma associated 
polyepitope and were able to demonstrate the induction of multiple cytotoxic T 
cell responses (Smith et al., 2001). Another proposal was to let DC's phagocytose 
whole tum our cells (which were dead or dying) and tum our cellular fragments, 
w ith the intention of inducing cross-presentation of tum our antigens on both 
HLA class I and II molecules, allowing the simultaneous induction of tum our 
specific cytotoxic T cells and CD4‘^ helper cells (Mandruzzato et al., 1997; Toes et 
al., 1999). But it has been pointed out that such a strategy bears the risk of 
inducing autoim munity, as the DC's could present self-peptides as well as 
tum our-specific antigens, however, Steinman et al. have suggested that 
immature DC's will induce tolerance to self-antigens derived from apoptotic cells 
(Steinman et al., 2000).
1.1.7 The Effector cells: Cyotoxic T Lymphocytes and NK cells.
The effector cells can be divided roughly into three compartm ents, (i) CDS 
expressing cytotoxic T lymphocytes (CTL's), (ii) Natural Killer (NK) cells and (iii)
CD4 expressing T cells mostly not cytotoxic. The CD8^ CTL's and certain
receptors found on NK cells interact with HLA class 1 /peptide complexes and
the CD4^ CTL's recognize longer peptides in association w ith MHC class II
molecules.
(i) Naive CD8^ CTL's are triggered to proliferate and enter a differentiation 
pathw ay when their T cell receptors (TCR) bind to self-HLA class I/p ep tid e  
complexes expressed on a virus-infected cell. This peptide presentation is usually 
performed by HLA-A and B (Young and Uhrberg, 2002). Upon activation, the
CD8^ CTL's express CD56 and the inhibitory receptor Ig-like transcrip t 2
(ILT2)/ leukocyte Ig-like receptor 1 (LIRl), a receptor belonging to the leukocyte- 
receptor complex (LRC) which is a polymorphic cluster of related genes found 
on Hum an chromosome 19, at 19ql3.4, and encodes a series of Ig super-family 
protein receptors. ILT2/LIR1 has been shown to recognize a wide range of HLA 
class 1 molecules (Young et al., 2001). In addition, during activation the CTL
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begins the synthesis of a set of cytokine molecules, perforin and granzymes that 
become localized into secretory granules. A majority of these activated CTL's 
enter the effector pool and when they recognize further virally infected cells are 
able to release the granules onto the surface of the infected cell. The perforin 
forms pores in the membrane allowing the granzymes to enter and initiate a 
complex pathway leading to apoptotic cell death through the direct cleavage of 
pro-caspase-3 or indirectly through caspase-8 (Barry and Bleackley, 2002). A 
majority of the activated CTL's are destined to die through activation-induced 
cell death (AICD), but a small proportion survive to become memory T cells
(Marrack et al., 2000). The precise events, which influence an activated CD8^ CTL 
to become a memory T cell, are still controversial. One hypothesis suggests that 
the cells deleted by AICD express only the ILT2/LIR1 receptor from the LRC, 
whilst those that go on to become memory cells additionally express one of the 
killer-cell Ig-like receptors (KIRs), that are also encoded in the LRC, and acquires 
resistance to apoptopic cell death by increased expression of Bcl-2 (Grayson et al., 
2000; Young et al., 2001).
(ii) N atural killer (NK) cells represent approximately 15% of the circulating 
lymphocytes and were originally named because of their ability to kill in a non­
specific m anner (Kiessling et al., 1975). NK cells have a large granular 
m orphology and are able to lyse certain cells in the absence of stim ulation 
(Trinchieri, 1989). In the bone marrow NK cells share a common precursor with T 
cells, which is distinct from that giving rise to B cells. NK cells are derived from
CD34^, IL15R^ cells in response to IL15 released from the bone m arrow stromal
cell population. During this development a sub-set of NK cells acquire CD16 
expression. CD16 is a transmembrane-anchored 70 kD glycoprotein of the Ig 
superfam ily also expressed on activated monocytes and a subset of T cells 
(Daeron, 1997). It is a low affinity Fey III receptor, expressed in association with 
FceRI-y w hich binds to IgG coated target cells and signals th rough  an 
im m unoreceptor tyrosine-based activation m otif (ITAM), located in the 
cytoplasmic tail of FceRI-y (Aramburu et al., 1995; Galandrini et al., 1996). On
CD16 mediated-activation, the CD16^ sub-set of NK cells release of a series of
cytokines and lyse target cells by antibody-dependent cellular cytotoxicity 
(ADCC) (Perussia et al., 1984).
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During IL15 induced development, NK cells also acquire the expression of CD56 
(Cooper et al., 2001) together with a number of receptors from both the LRC Ig
superfam ily, also present on some CD8^ T cells, and the C-type lectin 
superfamily. The members from the LRC Ig superfamily include the KIR and ILT 
receptors, which are structurally similar transmembrane molecules, classified by 
their structure. For example KIR-2D, the predominant type in humans, has two 
extracellular Ig domains and KIR-3D has three extracellular Ig domains. Both 
KIR-2D and KIR-3D can be sub-classified according to their cytoplasmic 
structure as -long, containing one or more of the ITIM (I/VxYxxL/V) inhibitory 
sequences, or -short, lacking the ITIM, but exploiting a m em brane-bound, 
hom odim eric  ad ap te r m olecule (DAP12) th a t con ta ins an ITAM 
(immunoreceptor tyrosine-based activation motif) sequence that activates NK 
activity (Lanier et al., 1998; Natarajan et al., 2002). Thus, based on their structure, 
KIR's and ILT's when binding to their ligands can either activate or inhibit NK 
activity. In a recent review by Vilches and Parham over 100 sequence variations 
have been reported for the KIR family and these have been divided into 13 
groups according to their structure (Vilches and Parham, 2002). The ligands for 
KIR's and ILT's have been shown to be the HLA class I molecules, but in only a 
few cases has the specificity been identified. Most work has been done w ith 
inhibitory KIR's (KIR-2DL2 and -2DL3) that recognize HLA-C alleles.
Members of the C-type lectin superfamily of receptors also become expressed 
during IL15 induced development of NK cells. Most members of this family are 
heterodimeric, composed of a 30kDa glycoprotein invariant chain, CD94, linked 
by disulphide bonds to one of the 43kDa glycoprotein receptors, NKG2. These 
are all closely linked genes on hum an chromosome 12pl2.3-pl3.1 at the 'NK 
gene complex' (Yabe et al., 1993). CD94 is a single gene with very limited allelic 
polymorphisms, whilst the NKG2 family is composed of four genes, NKG2A, -C, 
-E and -D, with a splice variant of NKG2A known as NKG2B. The extracellular, 
ligand-binding domains of NKG2A, -B, -C and -F share a high degree of 
homology, but the cytoplasmic regions are different. NKG2A and -B have long 
domains, with two ITIM inhibitory motifs in their tails, whilst NKG2C and -F 
have short tails that do not signal directly, but associate w ith the signaling
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m olecule KARAP12/DAP12 which contains a dimeric ITAM activating 
component (Burshtyn et al., 1997; Selvakumar et al., 1996). NKG2D has only 20%- 
30% sequence identity with the other NKG2 family members and is expressed as 
a homodimer associated with the adapter molecule, DAPIO, through which it 
triggers an activating signal (Cifone et al., 1997). Early studies on the ligands for 
the CD94/NKG2 indicated recognition of HLA-A, -B, -C, and -G, based on 
cytotoxicity experiments using anti-CD94 and anti-CD94/NKG2 antibodies 
(Phillips et al., 1996; Soderstrom et al., 1997). More recent work on possible 
ligands for CD94/NKG2A have shown it to recognize HLA-E that is expressing 
peptides derived from the leader sequences of other HLA heavy chains (Borrego 
et al., 1998). In detailed studies using tetrameric complexes of HLA-E, only 
transfectants expressing CD94/NKG2A, -B, or -C stained positively (Braud et al., 
1998a). The NKG2D homodimer recognizes MICA and MICB, which are non- 
classical MHC-1 homologs, composed of a l ,  a2 and a3  domains but do not 
associate with p2 "i^^icroglobulin and do not bind peptides. MICA and MICB are 
minimally expressed on normal tissue and are upregulated on stressed cells and 
in epithelial tumours (Groh et al., 1999).
NK cells have been sub-divided according to their expression of CD16 and CD56. 
A majority (approximately 90%) of cells express high levels of CD16 (the Fey III 
receptor) with low or absent expression of CD56 whilst the minority of NK cells 
show low or even lack expression of CD16 but have high expression of CD56. 
These two subsets of NK cells also have differing expression of other NK 
receptors. The CD56 (high) cells express little KIR and ILT2 and have high 
expression of CD94/NKG2A. In contrast the CD56 (low) cells express high levels 
of KIR and ILT2 but CD94/NKG2A is low or absent (Cooper et al., 2001).
Activation of NK-cell cytotoxicity is brought about by a balance of inhibitory and 
activatory signals mediated by the NK cell receptor repertoire w ith additional 
information from various adhesion and costimulatory molecules (Leibson, 1997). 
Resting CD56 (low) NK cells appear to be more naturally cytotoxic, but after IL2 
activation both subsets have similar levels of cytotoxicity. The CD56 (high) 
subset are the major source of ylFN produced by NK cells, w hilst the more 
granular CD56 (low) NK cells exhibit greater levels of ADCC (Nagler et al., 1989).
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(iii) CD4^T cells, which recognize larger peptides presented via the HLA class II 
molecules, initiate a series of events that lead to the proliferation of the antigen- 
peptide presenting cells. Naive T helper cells become activated by their first 
contact with peptide/H LA  class II complexes in the lymph nodes leading to the 
secretion of a series of cytokines including IL-1, 2, 3, 4, 5,10 and ylFN. The IL-1 
signals local dendritic cells to leave the tissue areas and migrate into the lymph 
vessels where they mature and present ingested antigen, at the cell surface, as 
peptide/H LA  class II complexes, together with newly synthesized B7 molecules 
(Jenkins et al., 2001). After recognition by antigen-specific CD4 T cells, naive T 
cells secrete high levels of IL-2 and undergo rapid proliferation in an IL-2 
independent m anner, in response to an unidentified T cell grow th factor 
(Khoruts et al., 1998). During this proliferation stage, IL-12, produced in response 
to adjuvant activity in the antigen-presenting dendritic cells, and ylFN, from NK 
cell sources, then induce differentiation of the T cells into Th-1, or inflammatory 
T cells (Kearney et al., 1994; Scott, 1993). Many of these cells die in the T cell 
areas, but some survive in response to the anti-apoptotic effect of adjuvants on 
dendritic cell IL-12 production. Of the T cell survivors, those that divided the 
most and received the highest concentrations of IL-12 lose chemokine receptor 7 
(CCR7) expression, gain the P-selectin ligand and have the capacity to produce 
ylFN and other cytokines which activate macrophages. This increases their ability 
to kill phagocytosed microorganisms, and to recruit macrophages, lymphocytes 
and neutrophils to the site of activation. Those T cells that received lower 
concentrations of IL-12 retain CCR7 and acquire rapid IL-2 producing potential,
but lack the ability to produce ylFN. The CCR7^ cells are able to re-circulate
through the lymph tissues whilst the CCR7 cells are excluded from the lymph 
areas and circulate in the blood and tissues that express P-selectin. If antigen is 
cleared most of the CCR7 cells die but small numbers can revert to the CCR7^ 
status and become part of the T memory pool (Jenkins et al., 2001; Travers, 2000).
In the early stages of differentiation, IL-12 leads to the polarization of naive T 
cells into Th-1 cells. It has been suggested that at this time the presence of ylFN 
has little effect on the developing Th-1 cells, but may inhibit their differentiation
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into Th-2 cells (Constant and Bottomly, 1997). When the IL-12 level decreases, IL- 
4, secreted by basophils, mast cells and N K l.l^  CD4 cells, can induce naive T 
cells to differentiation into Th-2 cells. The Th-2 cells produce a cocktail of 
cytokines including IL-4, 5, 6 and 10 which have the effect of activating B cell 
differentiation into antibody producing cells (Constant and Bottomly, 1997; 
Travers, 2000).
1.1.8 Immunosurveillance.
The idea that tumours m ust "escape" from immune recognition contains the 
assum ption that immune responses are capable of destroying tum our cells, 
however, w ithout immunological pressure there would be no requirement for 
tum ours to escape immunosurveillance. The immunosurveillance hypothesis 
dates back to the 1950's when Burnet suggested that the immune system of a host 
could recognize antigens of newly arising tumours and eliminate these tumours 
before they became clinically evident (Burnet, 1957; Burnet, 1967). Progressive 
cancer was thought to be a rare event, only seen when the tum our cell escaped 
the efficient control of the immune system. More recent ideas claim that the 
imm une system dose not play this central role in controlling early tum our 
development, however, the contribution of the host immune system and the 
relevance of T and B cells in combating tumour growth are still subject to debate 
(Pardoll, 2001; Smyth et al., 2001).
Several studies have dem onstrated that the immune system is capable of 
m ounting a response to tum our cells during the early stages of tum our 
development. Two studies involving NK cells and yÔ T cells have examined their 
potential roles in immunosurveillance. The first study explored antitum our 
immune responses elicited by tumours transduced with the NKG2D ligands, 
retinoic acid early transcripts lb  (Rae-lb) or H-60 and found that NK a n d /o r  
CD8^ T cells mediated potent antitunour immunity (Diefenbach et al., 2001). The 
study used NKG2D ligand-transduced cell lines that express high am ounts of 
Rae-lb of H-60. Although this study demonstrated a possible mechanism for 
im m unosurveillance involving NK cells, it was pointed out that NKG2D
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expression on spontaneous tumours would probably be much lower than in the 
experimental system. A second study has reported a possible role for NKG2D^ yô 
T cells at the early stage of tum our development (Girardi and al, 2001). Both 
these studies were carried out in mice using comparatively short time scales, and 
high concentrations of antigen that could alert the immune system to respond, 
and it has been questioned how relevant these finds are to the hum an situation 
where tumours may take years to develop, usually with a low antigen expression 
(Khong and Restifo, 2002).
The development of the immune system may well have been to protect an 
individual against infection from pathogens and viruses, and the immune system 
coevolved with infectious diseases in a way that allows the survival of the host 
and the pathogen. Protection from these diseases is particularly im portant in 
young individuals both from the point of view of the survival of the individual 
and the survival of the species at large. Cancers, on the other hand, usually arise 
in individuals beyond the reproductive age and are more of a threat to the 
individual rather than the population as a whole. Thus, the immune system did 
not develop special strategies to combat tumours, but instead has to deal with 
tum ours using mechanisms initially shaped to protect an individual from 
infectious pathogens and viruses.
The specific immunological mechanisms activated for the efficient removal of a 
bacterial or viral infection are dependent on the route of entry used by the 
infectious agent. Haematogenously spread infections such as Streptococcus 
pneumonia, Haemophilus influenzae, enteroviridae, measles, and poxvirus are 
controlled by neutralizing antibodies of the IgM and IgG classes and protect the 
vital organs (Baumgarth et al., 2000; Fenner et al., 1974). In contrast, 
noncytopathic viruses, for example hepatitis B and C, that infect the peripheral 
solid organs are largely controlled by activated T lymphocytes which have the 
capacity to extravasate and enter the infected tissue to lyse infected cells 
(Zinkernagel et al., 1996). Solid tumours, which frequently express cell-associated 
tum our antigens, appear to the immune system to resemble viral infections of 
peripheral tissues and may elicit a similar response to that used to protect against
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a noncytopathic vims. This response would predominately be the activation of 
cytotoxic T lymphocytes (Ochsenbein, 2002).
At least two ideas have been put forward as to how tumours are able to grow. 
One model suggests that the successful growth of a tum our happens when the 
tum our "escapes" from the early mechanisms of immunosurveillance (such as 
described above) and that as the tum our develops, in the presence of constant 
surveillance, it progressively "shapes" it's immunological phenotype to avoid 
immune recognition. A second model suggests that established tumours are able 
to grow without immune-mediated rejection because they appear to the immune 
system to be normal cells. In this model the cells are thought to resemble normal 
healthy cells that do not send out danger signals to activate an immune response 
because they express neither microbial immune-recognition patterns nor releases 
distress signals to alarm the innate immune cells (Restifo and al, 2002). During 
progressive growth, a tumour may become more immune-activating. This can be 
the result of a number of factors such as damage or disruption to surrounding 
cells, triggering of stress responses caused by outstripping of nutrients and 
oxygen supplies which may lead to pH  imbalances, generation of reactive 
oxygen radicals, up regulation of stress protective factors (such as heat shock 
proteins) and death by necrosis or apoptosis. In addition, as the tum our grows 
progressively, dysregulated genetic and epigenetic events will lead to the 
potential expression of increasing numbers of neoantigens (Khong and Restifo, 
2002).
Both the humoral and cellular components of the immune system are capable of 
m ounting a response to tum our antigens. D uring m ost CTL antitum our 
responses production of tum our specific antibodies has also been seen. These 
antibodies are not toxic to the tum our cell per se, bu t act by blocking vital 
signaling molecules on the cell surface or by a secondary effector mechanism 
including ADCC (involving NK cells) and complement-dependent cytotoxicity 
(Carter, 2001). In mice, antimelanoma antibodies inhibit tum our grow th in a 
FcyR-dependent manner (Clynes et al., 1998) and clinically important antibodies 
in humans, transtuzumab (Herceptin) and rituximab (Mabtera, Rituxan), have 
also been shown to function via a Fc- FcyR interaction (Clynes et al., 2000).
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Lymphocytes (T and B cells) and the professional antigen presenting cells (such 
as macrophages and DC's) have been implicated in contributing tow ards an 
im m une response to tum our antigens. These cells tend not to function as 
individual cells, but interact and collaborate in organized lymphoid tissues such 
the follicles, marginal zones, germinal centres, and red pulp associated w ith 
lymph nodes and spleen. These anatomical structures determine the localization 
of antigen, cytokines, and bystander contacts through costimulatory molecules 
(Zinkernagel et al., 1997). The time scale taken and the amount of viral or tumour 
antigen that reaches the secondary lymphoid organs is crucial for the induction 
of CTL's. Antigens that never reach these organs in sufficient am ounts are 
ignored by the immune system. Some viruses have developed strategies for 
avoiding immune recognition such as the Papilloma virus that infects the basal 
layers of epidermal cells and replicates only in kératinocytes w ithout infecting 
Langerhan's cells, hence staying outside the lymphoid tissues (Frazer, 1992; 
Ochsenbein et al., 2001). Tumours tend to arise from a single cell in the 
periphery, outside the secondary lymphoid organs, and early expansion of the 
tum our results in either no or very few of the tum our cells reaching the 
secondary lymphoid organs. In a study of various solid tum our cells, transfected 
and expressing a glycoprotein from the lymphocytic choriomeningitis virus 
(LCMV-GP), tumours were either transplanted peripherally into mice as solid 
fragments or injected subcutaneously (s.c.) as a single cell suspension. The solid 
fragments grew well outside the lymphoid organs and no tum our cells were 
detected in the lymph nodes and no LCMV-GP specific CTL's were induced. In 
contrast, the single cells injected s.c. reached the lym ph nodes and antigen 
specific CTL's were identified. The same study demonstrated that the peripheral 
solid tum ours did not tolerize the mouse immune system, because w hen 
replicating LCMV or antigen-expressing DC's were introduced to the animals, a 
tum our specific CTL response was detected. In addition, suspensions of tum our 
cells introduced s.c. into mice already bearing a peripheral solid tum our load 
mounted a tumour specific response indicating that the initial solid tum our had 
not tolerized the mouse (Ochsenbein et al., 1999; Ochsenbein et al., 2001). These 
experiments indicate that the immune system can be ignorant of the presence of 
small early solid tumours but that early trapping of tumour cell in the secondary 
lymphoid tissues can be beneficial in eliciting an immune response. However, 
the detection of tum our cells in the secondary lymphoid organs of patients
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usually indicates a worsening situation, and the fact that tum our cells are 
detectable in the secondary lymphoid organs suggests the tumour cell m ust have 
evaded recognition by the immune system to have migrated to these organs.
The CTL response is usually to antigens that become transiently presented in the 
organized lymphoid organs and they do not react to antigens continuously 
present. Indeed, continuously present antigens can actively delete T cells specific 
for that antigen by T cell exhaustion. Some noncytopathic infections have been 
reported to delete T cells by this mechanism and an overwhelming infectious 
dose of a rapidly replicating virus can also cause this form of tolerance 
(Moskophidis et al., 1993). The development of lymphohaematopoietic tumours 
that infiltrate the secondary lymphoid organs should induce an efficient immune 
response. The fact that this could happen may explain the increase incidence of 
these type of tumours in immunosuppressed patients (Kelly et al., 1998).
T cell activation has been shown to require two distinct signals. The first signal is 
the interaction of the T cell receptors with HLA class I molecules expressing 
peptide antigens. The second signal is a more nonspecific signal provided by 
costimulatory molecules such as the interaction of CD28 on T cells with members 
of the B7 family of molecules on professional antigen presenting cells, and 
members of the TNFR family (CD 40 and CD27) as well as soluble molecules, for 
example IL-2 and IL-12. T cell receptor stimulation alone, w ithout a second signal 
leads to T cell anergy or deletion (Matzinger, 1994; Schwartz, 1990; Townsend 
and Allison, 1993). For efficient activation of T cells, the costimulatory molecules 
are required to be present, and to be of sufficient concentration, especially in the 
secondary lymphoid organs. Tumour antigen and second signal-expressing 
tum ours w hen introduced into lymph node deficient a ly /a ly  mice failed to 
induce a specific T cell response. The same result was seen if the cells were 
injected as single cells or as solid tum our fragments. In these mice, which lack 
secondary lymphoid organs, the immune system ignored the tum our cells 
(Ochsenbein et al., 2001). Some observers claim that tum ours expressing 
costimulatory molecules are usually rejected more efficiently than control, non­
costimulatory molecule expressing, tumours. However, these studies do not 
distinguish between induction and enhanced maintenance of effector T cells 
(Marie et al., 1998; Townsend and Allison, 1993).
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Tumour cells can produce a variety of cytokines and chemikines that can have a 
negative effect on the m aturation and function of an immune response. For 
example, tumours of the lung, head and neck as well as breast cancers frequently 
secrete vascular endothelial growth factor (VFGF). In vitro studies show VFGF 
inhibits the differentiation and m aturation of DC's through the suppression of 
the transcription factor NF-kB in haematopoietic stem cells (Oyama and al., 
1998). An inverse correlation has been reported in gastric cancers between VFGF 
expression and density of DC's within the tum our, a finding that has been 
associated w ith a poor prognosis (Saito et al., 1998). An elevated serum  
concentration of IL-10 is also frequently seen in cancer patients. IL-10 can exert 
an inhibitory effect on DC differentiation and m aturation from stem  cell 
precursors and has been reported to inhibit IL-12 production and induction of T 
helper type 1 responses (Sharma and al., 1999). In addition IL-10 enhances DC 
apoptosis (Ludewig and al., 1995) and may protect tum our cells by down- 
regulating HLA class I (by down regulation of TAPI and TAP2), HLA class II 
and ICAM-1 expression (Salazar-Onfray and al., 1997; Yue and al, 1997).
Many tumours have been reported to use varying strategies to evade recognition 
by the immune system, for example, down regulation of HLA class I (see section 
1.2.6), antigen loss, antigen modulation, and the expression of molecules that 
inhibit the immune response (Chenn et al., 1998; Garrido et al., 1997; Johnson et 
al., 1998). How ever, various antigenic tum ours have been reported  to 
successfully grow in immunocompetent hosts, including melanom as, renal 
cancers and breast cancers, and in some of these cases tum our infiltrating 
lymphocytes have been identified (Whiteside, 1994) indicating evidence of an 
immune response, but one unable to eradicate the tumour. Patients who are 
im m unosuppressed have been reported to be at a higher risk of developing 
virally triggered tumours and tumours of lymphohaematopoietic or vascular 
origin, but these individuals are not thought to show an increased incidence of 
the more common tumours of the breast, colon, lung (Kelly et al., 1998).
Whatever the role/s of immunosurveillance are, it is usually accepted that once a 
tum our is clinically detectable, spontaneous regression is very rare for a vast 
majority of tumour types. Whether tumours need to escape immunosurveillance
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is not clear from current knowledge. Also, there is limited evidence that the 
immune system is capable of initiating a response to tum ours and that the 
responses seen are capable of causing tumour destruction (Restifo and al, 2002). 
Some claims contradict the idea that the immune system spontaneously mounts 
a lethal attack on tum our cells and that cycles of immune activity contribute to 
the shaping of a tum our phenotype, allowing it to progressively escape such 
immune responses. However, established solid tumours generally do not have 
growth spurts, they tend to grow, and keep growing bigger (Khong and Restifo, 
2002).
1.1.9. Tumour Antigens
60 years ago. research using mice showed that immune responses could lead to 
the rejection of a sarcoma transplanted between genetically homogeneous C3H 
mice w ithout toxicity to the norm al tissues in the anim als (Gross, 1943). 
However, in hum ans, it was not until 1989 that the first naturally occuring 
'tum our specific antigens' were identified that could elicit a cytotoxic T cell 
response to an autologous melanoma (Knuth et al., 1989). Since then, m any 
tum our antigens have been identified and by targeting them meaningful clinical 
responses have been seen.
Tumour antigens can be broadly speaking divided into four different categories: 
i) Tumour antigens consisting of proteins that are expressed only in the normal 
adult tissue counterparts of cancer cells, and are defined as differentiation 
antigens, ii) Antigens generally not detectable in norm al adult tissues and 
expressed by different tumours of the same histology, iii) Antigens not expressed 
by normal tissues, but detectable on a wide variety of histologically unrelated 
tumours, iv) Tumour antigens in the form of epitopes generated by m utated 
proteins; in most cases these tum our antigens are individual antigens uniquely 
expressed by the tumour bearing the particular mutation (Renkvist et al., 2001).
The identification of specific tum our antigens has been m ade using several 
different strategies. The 'biochemical' strategy has been to acid-elute peptides
31
bound to HLA class I molecules from tumour cells, followed by fractionation of 
the peptides with reverse-phase high performance liquid chromatography. The 
resulting peptide fractions were then assayed for their ability to sensitize HLA 
class I matched target cells for lysis by tumour specific cytotoxic T cells. With this 
approach yeilds are small, but in several cases sufficient m aterial has been 
isolated to allow sequencing of the peptide, hence allowing a search of various 
data bases to identify the gene/s encoding the antigenic peptide (Cox et al., 
1994).
The 'genetic' strategy has been employed in several forms. One approach has 
been to isolate cytotoxic T cell clones with specificities for autologous tum our 
cells, then attempt to identify by cDNA expression cloning, the gene/s, within 
the tum our cells, that code for the T cell-recogized epitopes. Again this approach 
has mainly been used to identify HLA class I restricted epitopes, but a recent 
report has indicated that similar methods can be used to identify HLA class II 
epitopes (van der Bruggen et al., 1991; Wang et al., 1999). A second 'genetic' 
stratergy has been the development of the SEREX technique w hereby an 
expression library of potential tumour antigens, expressed as a 7,-phage library, 
is screened using serum taken from cancer patients. This m ethod assumes that 
the serum will contain antibodies directed to recognize specific tum our antigens 
(Chen et al., 1998). In the future, more tum our antigens may be identified using 
DNA mico-array technology to search for genes that are over-expressed, 
however, this approach will not measure the immunogenicity of a potential 
antigen and will require careful choice of control/normal material.
The third strategy for identifying tum our antigens is the 'reverse immunology' 
method. This approach is the 'reverse' of the previous strategies in that the initial 
observation has been the identification of a protein that is m utated or over­
expressed on a given tumour cell. Peptides, derived from the sequence of the 
identified protein, are then selected for by high binding affinity to a specific HLA 
class I molecule, and are loaded onto antigen-presenting cells to stim ulate 
lymphocytes in vitro. Demonstration that the peptide is a tum our antigen is 
acheived by showing that the stimulated cytotoxic T cells are able to kill the 
given tum ours cells expressing the putative tum our antigen presented by 
matched HLA class I molecules (Smith and Cerundolo, 2001).
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A considerable num ber of tum our antigens have now been reported. In the 
examples given below all have been demonstrated to elicit T cell responses and 
in many cases the peptide sequences identified that are capable of priming CLT's 
for these responses. Where known the presenting HLA class is indicated.
MAGE -  This represents a family of over 20 tumour antigens first identified in 
melanoma (Lucas et al., 2000; van den Eynde et al., 1995). These genes encode the 
cancer-testis antigens. Peptides from MAGE 1 are presented by HLA-Al and 
MAGE 3 by both HLA -A l and -B44 (Nestle et al., 1998). Other members of this 
family include BAGE (Boel et al., 1995) and GAGE (De Backer et al., 1999). 
FRAME -  Preferentially Expressed Antigen of Melanoma was first isolated as a 
hum an melanoma antigen recognized by CTL's. The expression has now  been 
reported on norm al testis and on various solid tum ours and on a series of 
leukaemias including AML. CML, ALL, lymphoma and multiple myeloma. Five 
epitopes have been identified which have been used to prime CTL responses, 
these have been associated with HLA-A*0201 and -A ’^ 2402 (Matsushita et al., 
2003).
NY-ESO-1 -  This is another cancer-testis antigen which has high expresssion on 
a num ber of different tumours including breast (30%), prostate (25%), ovarian 
(25%) and melanoma (45%) (Chen et al., 1997). This antigen has been used in 
immunotherapy studies where patients, with metastatic disease, have received 
injections of three HLA-A2 binding peptides derived from NY-EOS-1. Some of
the patients in the study were later shown to have peptide specfic CD8^ T-cell 
responses and several individuals demonstrated stabilization of disease w ith 
some regression of individual métastasés (Jager et al., 2000). 
gplOO -  Glycoprotein-100 is a differentiation antigen expressed on melanomas 
and also expressed on normal melanocytes. Several HLA-A2 binding peptides 
including (gplOO 209-217) and (gplOO 280-289) have been successfully used to 
induce CTL responses in patients with metastatic melanoma. However, it has 
been pointed out that these immune responses may affect norm al melanocytes 
(Salgaller et al., 1996).
MUC-1 -  H um an epithelial m ucin is a large polym orphic transm em brane 
glycoprotein that is expressed on most simple epithelia. The extracellular domain
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is composed of 20 amino-acids tandom  repeats w ith highly O-glycosylated 
regions rich in serine, threonine and proline (Gendler et al., 1990). Over­
expression of MUC-1 has been reported in breast, lung, pancreatic, colon and 
ovarian tum ours where it is usually seen as having shorter, more heavily 
sialylated carbohydrate side chains when compared to MUC-1 expression on 
tissues of similar origin (Gendler and Spicer, 1995). Two HLA-A2 restricted 
peptides have been identified, one in the terminal repeat domain (M l.l) and a 
second in the leader sequence (Ml .2) (Brossart et al., 1999).
CEA -  Carcinoembryonic antigen is a large (200 kDa) protein  and is a 
differentiation antigen expessed on a sub-set of normal epithelial tissues and has 
high expression on tum ours of the colon, pancreas, breast and lung and their 
métastasés. CEA is released from tumour cells into the circulation and has been 
used in post-operative surveillance for the presence of residual tum our cells 
(Macdonald, 1999; Thompson, 1995). One peptide has been identified, CEA 
CAPl (codons 571-579) which is presented on HLA-A2. This peptide has been 
used in immunotherapy studies where patients immunized with CEA CAPl (or 
a derivative, CEA CAP1-6D, in which the sixth amino acid, asparagine, has been 
replaced by a glutamic acid) have been shown to develop reactive CTL's both by 
CTL assay and by tetramer staining (Fong et al., 2001).
TGFpRII- Transforming Growth Factor p receptor type II is expressed in normal 
epithelial cells, but the expression of a mutated form has been reported in certain 
colorectal cancers where the mutated form is only expressed in the tum our cells. 
About 90% of these colorectal tumours type as microsatellite unstable, associated 
w ith the RER phenotype, and demonstrate a m utation in the from a single 
adenosine deletion in a poly(A)tract located in the coding sequence of the 
TGFpRII gene. This frame shift mutation creates a peptide sequence capable of 
stim ulating T cells, via in vitro presentation by HLA-DR, w hich later 
dem onstrated antigen-specific T cell responses (Saeterdal et al., 2001). 
Interestingly, the HLA-DR restricted sequence encompasses a smaller peptide 
sequence which can be naturally processed by HLA-A2 and able to prime, in 
healthy donors, a good antigen-specific T cell response (Linnebacher et al., 2001) 
SART-3 -  This is a potential colorectal tum our specific antigen. Expression has 
been reported on a number of colorectal tumours, and on normal testis and foetal 
liver. The only records of expression on other normal cells are on cultured 
fibroblasts and PHA stimulated T cells. In a study by Ito et al. three epitopes
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drived from SART-3 were used to stimulate uncloned CTL's and later used to 
monitor tumour cell lysis. Killing was resricted to allogeneic colorectal carcinoma 
cell lines expressing HLA-A2 (Ito et al., 2000).
EpCAM -  EpCAM is another differentiation antigen identified many years ago 
using antibody AUA-1. Immunohistochemical analysis indicated reactivity in 
colonic epithelial cells w ithin colon tumours, but no rectaivity w ith norm al 
m ature gastric mucosa (Makin, 1985). Since then Nagorsen et al. have reported 
an HLA-A2 restricted epitope, codons 263-271, capable of prime T-cells from 
patients with metastatic disease, and demonstrated a T cell response in in vitro 
CTL assays (Nagorsen et al., 2000).
Her-2/neu (also known as c-erb-B2) -  This belongs to the family of epithelial 
growth factor receptors that have been shown to be over-expressed on 30% of 
breast and ovarian carcinomas and on a sub-set of colorectal tum ours. It is 
widely expessed on normal epithelial tissues, including breast, in hum an fetuses 
and adults (King et al., 1985). One study, using a peptide consisting of codons 
654-662 was presented by HLA-A2 to uncloned T cells from patients w ith 
metastatic disease. CTL responses were then shown against H er-2/neu positive 
tum our cells expressing the same HLA class I (Nagorsen et al., 2000). However, 
in earlier studies, the stability of the H er-2/neu peptides had been questioned 
when little or no CTL responses had been identified. To address this a cocktail of 
three 15 aa peptides had been used to serially immunize patients w ith breast 
cancer. These peptides covered different regions of the gene previously 
suggested as tum our specific epitope sites. Presence of CTL activity was 
demonstrated by lysis of H er-2/neu positive tum our cells. In these studies the
CTL activity could still be detected one year later with both CD4^ and CD8^ cell
responses (Fisk et al., 1995; Rongcun et al., 1999).
K-ras -  K-ras is a proto-oncogene which has been shown to be m utated and over­
expressed in a number of different tumour types, and in colorectal cancer up to 
50% of tumours and cell lines, derived from carcinomas of the colon, carry a K- 
ras mutation. Interestingly, almost all the mutations occur in codons 12 and 13. 
The sequence of theses two codons are: GGT GGC, and it appears that the third 
base in each coldon is particularly prone to a point mutation. Two studies have 
looked at the immunogenicity of each of these codons. Abrams et al. isolated T 
cells from a HLA-A2 patient with a colon carcinoma carrying a m utation in
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codon 12 of K-ras. Pror to isolation of the T cells the patients had been 
immunized w ith peptides consisting of codons 5-14 of a m utated K-ras, with 
different aa's at codon 12. Stable T cell responses were demonstrated for both
CD4’*’ and CD8^ clones which reacted with colon cancer derived cell lines
carrying the same codon 12 mutation to the patient (Abrams et al., 1997). Possum
et al. on the other hand isolated CD8^ T cells from a patient carry a colon cancer
expressing a (Glyl3->Asp) mutation of K-ras. These T cells were maintained and 
primed with a long (25) peptide of codons 1-25 of K-ras, including the codon 13 
mutation. On CTL analysis, using colon cancer cell lines (including examples 
carrying a (Glyl3->Asp) mutation), showed cell lysis in a HLA-B44 restricted 
manor (Possum et al., 1995).
Most of the above examples of tumour specific antigens have been analyzed to 
some depth and specific epitopes identified that lead to immunoresponses such 
as isolation and prim ing of T cell clones. In a vast m ajority of cases the 
presentation of these epitopes has been by HLA class I molecules, especially A 
locus molecules, particular HLA-A2. However, evidence is now accumulating to 
show that occasionally B locus molecules are involved in presentation of tum our 
specific antigens and more recently increasing evidence shows that C locus has 
an important role in tumour antigen presentation.
T cell lines obtained from melanoma-infiltrated or noninfiltrated lym ph nodes, 
from a patient who had remained disease free after 8 years post surgery for 
melanoma, were demonstrated to elicit T cell responses to autologous melanoma 
cells. These effector cells were directed against the tyrosinase-related protein-2 
(TRP-2) and gplOO melanoma epitopes and shown to be presented in an HLA- 
Cw8 restricted manner. Further investigation using COS cells transfected w ith 
HLA-0^0802 identified specific peptides presented by HLA-C’^ 0802 for both TRP- 
2 and gplOO. These peptides were used to prime peripheral blood derived T cell 
clones from the melanoma patient and shown to efficiently lyse autologous 
melanoma cells in CTL assays (Castelli et al., 1999).
In an attem pt to identify peptides presented by HLA-Cw4, Buchsbaum et al. 
used a m ethod involving the transfection of cells w ith expression vectors to
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encode a truncated form of HLA lacking the transmembrane domain. These 
transfected cells secrete a soluble form of HLA (sHLA) into the growth medium, 
thus allowing accumulation of large amounts of sHLA with expressed peptides. 
Separation of the resulting peptides by capillary reversed-phase HPLC and 
analysis by tandem  mass-spectrometry identified over 54 different peptides 
presented by HLA-Cw4 from two transfected cell lines, MDA-231, a breast cell 
line, and UCI-107, an ovarian cell line (Buchsbaum et al., 2003). Using sequence 
databases proteins were identified that contained the peptide sequences. The 
majority of the peptides were derived from normal proteins, but several were 
related to tum our progression. HLA-Cw4 expressed on both cell lines peptides 
derived from FAS (Fatty Acid Synthase), Putative Prostate Tumour suppressor 
and Epithelial Cell Transforming oncogene. The breast cell line expressed 
peptides from Mucin-5B, Topoisomerase I and Rac lb  protein whilst only the 
ovarian cell line expressed ARTl (Adenocarcinoma antigen). A num ber of these 
genes have been reported to be abnormally expressed in tum our cells including 
ART-1 (Nishizaka et al., 2000), FAS (Kuhajda et al., 2000), Topoisomerase-I 
(Lynch et al., 2001) and Mucin-5B (Ferrais et al., 2001).
Panelli et al have dem onstrated that HLA-Cw*0702 is involved in the 
presentation of peptide 170-178 derived from the melanoma antigen MAGE-12. 
Experiments were performed using tum our infiltrating lymphocytes (TIL's) 
obtained from the same needle biopsy that lead to the establishm ent of the 
melanoma cell line, FOOl. Initial data indicated that the restriction element could 
have been either HLA B"^ 0702 or Cw*0702. However, using hum an embryonic 
kidney (293) cells transfected with an HLA-Cw*0702 construct, they were able to 
screen a cDNA library derived from the FOOl tumour cells. A 100-gene pool was 
identified and subsequent cloning of the pool lead to identifying a sequence 
homologous to MAGE-12. Synthetic peptides of various MAGE-12 sequences, 
predicted to bind to HLA-Cw'^0702, were screened using the TIL's in a IFN-y 
stimulation assay and peptide 170-178 elicited the strongest response (Panelli et 
al., 2000).
Tumour antigens have now become the focus of attention because they form the 
basis of the developm ent of anti-cancer vaccines and im m unotherapy. 
Fundamental to these deveolpments is the assumption that tum ours differ from
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norm al tissues by tum our antigens which are either unique, tum our specfic 
antigens (TSA), or relatively restricted to tum our tissue, tum our associated 
antigens (TAA). As a consequence of the presence of these TSA's or TAA's the 
tum our is capable of inducing a specific immune response in the form of a 
complex of integrated actions of a variety of immune cells (Begent, 1999; Herlyn 
and Birebent, 1999). However, as described above, tumour cells have developed 
m any mechanisms to escape immunesurveillance. Against this background 
different strategies have been used for the developm ent of experim ental 
im m unotherapy to cancer cells, the two main approaches being to elicit an 
effective anti-tum our immune response either by potentiation of the immune 
response or by modifying the tumour cell to become more immunogenic (Ada, 
1999; Ward and al., 2002). These strategies can take the form of 'active specific' 
and 'passive' immunization strategies.
The 'active specific' approach is to prime the naive immune T cells in vivo by 
presenting tumour antigens via antigen presenting cells, in the context of HLA 
along with the necessary costimulatory molecules. This has been achieved using 
intact irradiated tum our cells, gene-modified tum our cells, viral oncolysates, 
tum our peptides conjugated to an immunogenic carrier or adm inistered in 
combination with an immune adjuvant and recombinant viral vectors containing 
the tum our antigen encoding gene (Ockert et al., 1999). A variation of these 
techniques has been to use ex vivo loaded professional antigen presenting cells 
such as DC's (Wong et al., 1998). Antibodies can also m ediate the activity of 
various active, non-specfic effector systems. Tum our specfic m onoclonal
antibodies can mediate cytolysis either by engaging NK cells (the CD16^ sub-set
expressing the Fey III receptor) lysing tumour cells by ADCC or by complement 
activation. Antibodies used in this way have now been altered or 'hum anized' to 
reduce hum an anti-mouse reponses such as Herceptin (Trastuzumab) introduced 
to treat metastatic breast cancer (Huls et al., 1999; Vogel and al., 2001).
In 'passive' strategies, immune system components are added systemically or 
directly at the site of the tumour. This type of adoptive imm unotherapy can be 
performed by taking a patient's autologous immune effector cells and enriching 
them  for a sub-population of anti-tum our im m une cells, by sorting and
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expanding ex vivo the anti-tumor effector cells of interest are re-introduced to the 
patient (Morse and Lyerly, 1999). Cytokines such as TNF-a, given either alone or 
fused to anti-tumour antibodies, have been shown to induce tum our regression 
(Ockert et al., 1999).
Increasing numbers of tumour specific antigens are being reported and they have 
lead to the development of many cancer vaccine studies. In a recent review of 
cancer vaccines, Finn (Finn, 2003) has observed a move away from vaccines 
based on well-defined tum our antigens, due to dissatisfaction w ith the results 
obtained in the clinic, in favour of vaccines using whole tum our cells or whole 
cell lysates as antigens. These complex antigen preparations include unique 
tum our antigens expressed only on an individual tum our that, by analogy to 
unique tum our antigens seen in mouse carcinogen-induced tum ours might be 
more immunogenic and promote a strong immune response (Srivastava, 2000). 
Experiments performed in mice transgenic for tum our antigens expressed by 
many tumours, but not usually expressed on normal tissues, have shown such 
antigens can elicit a strong immune response and even tum our rejection (Gendler 
and Mukherjee, 2001; Greiner et al., 2002). Finn argues that vaccines based on 
defined tum our antigens should not be under-estam ated as they have been 
successfully used in animal models in which they have been tested almost 
exclusively in tumour prevention, but the poor results in hum ans reflects the use 
of these vaccines as therapeutic agents in advanced disease, often after the failure 
of other treatments (Finn, 2003).
1.2.1 COLORECTAL CANCER.
In recent years a considerable weight of literature has accumulated reporting and 
d iscussing the genetic alterations that underlie  the h isto logical and  
morphological evolution of colorectal tumours. With more sensitive techniques 
available it is now possible to screen gene by gene for potential m utations and 
epigenetic changes that may influence the change of cells from norm al to 
m alignant, and to gain an insight into the functional characteristics that 
mutations might confer on protein-protein and protein-DNA interactions leading
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to the malignant phenotype. This introduction will be confined to a basic review 
of carcinogenesis relating to colorectal cancer, with a bias towards the possible 
role of HLA in tumour progression.
1.2.2 Epidemiology of Colorectal Cancer.
Following lung cancer in men and breast cancer in women, colon cancer is the 
next most common cancer in the western world leading to a cancer-related death. 
In England and Wales approximately 30,000 new cases are diagnosed each year, 
with about 17,000 actual deaths per year (HMSO, 1989; HMSO, 1992). The cases 
do not seem to demonstrate a gender bias and fewer than 20% of the cases occur 
before the age of 50 (Safford et al., 1981). Sites for tum our grow th can be 
anywhere along the large bowel, but appear to be more common in the 
caecum/ascending colon (38%) and the sigmoid colon/rectum (35%).
Most (95%) of these cases are sporadic occurring in individuals with no observed 
family history of colon cancer. About 5% of cases arise in patients w ith an 
inherited predisposition; the best characterized being familial adenom atous 
polyposis (FA?) and hereditary nonpolyposis colorectal cancer (HNPCC). 
Epidemiological studies suggest that environmental factors can have a major 
influence on the incidence rate of colorectal cancer. This has been based on the 
observation that in the 'western w orld ' colorectal cancer occurs at about ten 
times the rate than that in regions such as Eastern Europe, South America, Asia 
and Africa (Waterhouse et al., 1982). Furthermore, migrants from a low risk area, 
such as Japan, that live long term in a higher risk area, like the USA, show an 
increase rate of colorectal cancer incidence (Haenszel and Kurihara, 1968). 
Influences on these increases in incidence have been attributed to geographical 
environm ent, diet and nutritional factors. Red meat, anim al fat, refined 
carbohydrates and alcohol (Giovannucci et al., 1995b; Giovannucci et al., 1994b; 
W illett et al., 1990), in addition to smoking (Giovannucci et al., 1994a) are 
associated with an increase in risk, whilst a diet high in vegetables, fruit, 
vitamins (particularly A, C and E) and physical exercise (Giovannucci et al..
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1995a; Giovannucci and Willett, 1994) have been suggested as protective or 
associated with a lower incidence.
1.2.3 The Normal Large Bowel.
Anatomically, the last 1 to 1.5 metres of the gastrointestinal tract form the large 
bowel which can be sub-divided into six regions: caecum, ascending colon (on 
the right side), transverse colon, descending colon (on the left side), sigmoid 
colon and rectum. The rectum forms the distal region of about 10 cm and ends at 
the anal canal and anus. The large bowel is formed of four cellular layers: 
mucosa (the inner most layer composed of epithelium, lamina propria and 
muscularis mucosa), submucosa, muscularis propria and serosa (see Figure 2).
The mucosal surface is covered by a single layer of low columnar to cuboidal 
epithelium into which regular spaced crypts of LieberKuhn open, these crypts 
extend down into the muscularis mucosa layer (Burkitt et al., 1995). The mucosal 
epithelium is composed of two cell types: (i) the absorptive enterocyte cells, 
which are involved in the cellular transport of water and electrolytes in addition 
to having a secretory function, and (ii) the goblet mucous cells which secrete 
m ucin and other high molecular weight glycoproteins. The rectal m ucosa 
contains a higher number of goblet cells compared to the large bowel and at the 
recto-anal junction the mucosa abruptly stops being replaced by stratified 
squamous epithelium. In the crypts, the epithelium contains both the m ature 
absorptive enterocytes and goblet cells plus immature and undifferentiated 
precursor stem cells and endocrine cells (Potten and Loeffler, 1990).
The lamina propria contains a network of connective tissue, collagen fibres, 
smooth muscle bundles, lymphatics, blood vessels and nerves, w ith occasional 
lymphocytes, plasma and mast cells. The crypts that penetrate into this layer are 
surrounded by a sheath formed of fibroblasts and myofibroblasts (Richman et al., 
1987). These cells synthesize extracellular matrix proteins that contribute to the 
basement membrane, including collagens and fibronectins. The muscularis
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mucosae, a thin layer of smooth muscle, separates the lamina propria from the 
submucosa layer.
The colonic epithelium undergoes a continual process of cellular renewal with a 
rapid turnover every 3 days. Cellular replication occurs in the m iddle (the 
proliferative zone) of the crypts with high rates of cell mitosis and DNA and 
RNA synthesis. New immature cells proliferate and migrate upw ards towards 
the top of the crypt, but by the time they reach the transitional zone, proliferation 
ceases and DNA and RNA synthesis decreases. The process of m aturation begins 
and is completed as the cells move up into the top zone, the maturation zone. In 
this zone the cells become senescent, eventually dying by apoptosis leading to 
them being shed into the lumen. These colonic epithelial cells are clonal, arising 
from a stem cell population at the base of the crypts, and divide and differentiate 
as they migrate up the crypt. This process is carefully regulated to achieve a fine 
balance between a stem cell entering into the poliferative stage, at the bottom of 
the crypt, and cells dying by apoptosis, at the top (Lipkin et al., 1963; Loeffler et 
al., 1986). Such a homeostatic process is vital to m aintain a healthy colonic 
epithelium . Any deregulation of the expansion of cell num bers in the 
proliferative zone could lead to local excesses of growth and development of 
tum ours as proposed in the model of cancer progression by Tomlinson and 
Bodmer, who used colorectal cancer as an example (Tomlinson and Bodmer, 
1995).
1.2.4 Progression to Colorectal Cancer.
Colorectal neoplasia occurs as a result of the pathological transform ation of 
norm al colon epithelium into benign adenomatous polyps which m ay then 
eventually lead to full invasive cancer. An early supporter of this idea was 
Morson who describe a biological progression, taking between 15 and 20 years, 
through a series of distinct morphological and histological stages (Morson, 1962). 
This progression has been termed the 'adenoma-carcinoma sequence' (Muto et 
al., 1975). Histologically, the development of microscopic areas of irregular 
glandular architecture, with no evidence of disordered growth or dysplasia
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(termed 'aberrant crypt foci') have been suggested as areas likely to develop 
benign neoplasic polyps that may precede the outgrowth of a tum our (Nucci et 
al., 1997).
The earliest clinically identifiable event is the presence of polyps. These are tissue 
protrusions of the mucosa layer that extend into the lumen above the mucosal 
surface and arise from abnormal mucosal maturation and inflammation and are 
also seen at sites of regeneration following injury. They have been term ed 
'adenomatous polyps' or 'adenomas' (Norris, 1983).
In adenomas there appears to be continual cell proliferation, particularly in the 
proliferative zone of the crypts, which can result in this zone extending upw ards 
into the upper m aturation zone, with the proliferating epithelial cells showing 
delayed maturation. In addition, this continual disordered proliferation can lead 
to downw ard infolding of the crypt wall, causing a breakdown of the norm al 
crypt architecture, sometimes characterized as a branching pattern  in an 
individual crypt which can lead to the appearance of apparent collisions of 
adjacent crypts (Novelli et al., 1996). Adenomas in the colon have been classified 
according to the histological appearance of the polyp, w ith regard to the 
combination of tubular glands and villous projections, and the degree of 
dysplasia. The three types are: tubular, tubulovillus and villous adenomas. Those 
adenomas thought to have the highest malignant potential exhibit a high degree 
of dysplasia with a villous histology, and a size of greater than 2 cm m ay be an 
indicator (Muto et al., 1975).
The first indication of malignancy is the invasion through the basem ent 
membrane into the lamina propria, followed by further penetration into the 
muscularis mucosal layer. This layer has good connections w ith the lymphatic 
system into which the developing tumour can spread leading to regional lymph 
node métastasés. Continued growth of the tum our may eventually invade the 
submucosal layer and enter the blood system leading to métastasés developing 
in the liver, lungs and bones, as illustrated in Figure 3A.
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Pathologists have classified colorectal tumours according to the architectural and 
structural appearance of the tum our. The most w idely used classification, 
however, is based more on the observation that colorectal tumours first spread 
circumferentially gradually invading the underlying tissue layers, with paracolic 
lymph node involvement being an early event, and haematogenous spread to 
other organs, a much later event. This is the Dukes staging classification (Dukes 
and Bussey, 1958) (see Table 1 and Figure 3A).
TABLE 1
DUKES STAGING CLASSIFICATION.
Dukes A Lesions confined to m ucosa/subm ucosa and no invasion of 
the muscularis propria.
Dukes B1 Lesions penetrate into the muscularis propria.
Dukes B2 Lesions penetrate through the muscularis propria
Dukes C l Lesions have lym ph node m étastasés, bu t the tum our is 
confined to the bowel wall.
Dukes C2 Lesions have lymph node métastasés, but the tum our extends 
through the bowel wall.
Dukes D Lesions have metastatic spread to distant organs.
The prognosis of these various stages range from >95% survival for 5 years for 
Dukes stage A patients to only a 10% survival for 5 years for Dukes stage C2 
patients. [Stage B patients have about 80% survival for 5 years and stage C l 
approximately 40% survival for the 5 years (Dukes and Bussey, 1958)].
1.2.5 Molecular Genetics of Colorectal Cancer.
Colorectal cancer is a genetic disease at the cellular level and like all other 
cancers is characterized by genetic m utation followed by selection. It is not a 
single event, but a multistep process, that may take many years to develop. The 
various stages of the evolution of colorectal cancer that have been described and
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classified by morphology and histology, can be largely explained by particular 
genetic changes. These can take the form either of mutational events, which alter 
and delete/insert nucleotides in the DNA sequence, or epigenetic events, such as 
méthylation changes, that although do not change the genetic sequence, have a 
profound effect on gene expression. Whatever the molecular change is, they 
impart a proliferative advantage to the cell and contribute to the development of 
a malignant phenotype in the form of excessive cell growth, interruption of 
programmed cell death and local invasion as well as the ability to form distant 
métastasés.
Progression to a cancer involves a stepwise accumulation of different mutational 
events, w ith each step conferring a selective advantage to the cell. An initial 
mutational event in a single cell, acquired somatically or inherited, may confer a 
selective growth advantage to that cell, but at this early stage may not outgrow 
its neighbours. Later (possibly after many years) further mutational events occur 
which can confer a selective advantage to the cell, but may not significantly 
increase cell numbers. Tomlinson and Bodmer, using the proliferating cells of the 
colonic crypt as an example, suggested that only after the accumulation of four 
or more such mutational events, will exponential growth occur leading to the 
establishment of a tum our (Bodmer, 1999; Tomlinson and Bodmer, 1995). The 
m alignant phenotype appears to result from the m utational activation of 
oncogenes and the mutational inactivation of tum our suppressor genes and to 
involve at least four to five genes. These m utations can occur in an ordered 
sequence but it is the accumulation of these m utations that leads to tum our 
development, not necessarily the order of events (Bodmer, 1999; Fearon and 
Vogelstein, 1990). Figure 3B indicates some of the genes involved in the 
development of colorectal cancer and the stage at which they are thought to 
occur (Fearnhead et al., 2001; Fearon and Vogelstein, 1990; Woodford-Richens et 
al., 2001).
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FIGURE 3B
The adenoma to carcinoma progression (showing key functions selected for at 
different stages of tumour progression). ,
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1.2.6 Loss of HLA Expression on Colorectal Tumours.
The first report of a hum an tum our cell lacking expression of HLA class I 
described failure to express m ature HLA-A, -B and -C antigens on the cell 
surface of the Burkitts lymphoma cell line, Daudi (Nilsson et al., 1974). Further 
work indicated this complete loss of HLA class I expression was due to the 
failure of Daudi cells to synthesize p2 -microglobulin. This lack of expression, on a 
cell type that would normally express HLA class I, may have been selected for 
during tum our development with the advantage of resistance to T cell immune 
attack (Arce-Gomez et al., 1978). Later the colorectal cell line, LoVo, was also 
show n to lack HLA class I expression and to have a sim ilar loss of P2 " 
microglobulin synthesis (Brodsky et al., 1979b; Travers et al., 1982), though at this
time the cause of the loss of p2 -microglobulin expression remained unknown. In
addition, HLA class I was reported not to be detectable on choriocarcinomas, 
which are derived from progenitor cells, the trophoblasts, that are known to lack 
HLA class I expression. These cells have coodinately switched off HLA-A -B and 
-C expression, while still synthesizing and secreting P2"3Tiicroglobulin (Travers et 
al., 1982).
The generation of monoclonal antibodies, at first w ith specificities for P2 - 
microglobulin and monomorphic determinants of HLA class I (Brodsky et al., 
1979b) and later with polymorphic reactivity with individual HLA class I alleles 
(Fauchet et al., 1984), allowed a more detailed study of HLA class I tissue 
distribution. Immunohistochemical analysis of tissue sections revealed HLA 
class I expression to be lost in examples of quite different tumours. For example, 
6% of hepatocellular carcinomas (Paterson et al., 1988), 19% of ovarian tum ours 
(Kabawat et al., 1983), 20% of non-Hodgkins Lymphomas (Moller et al., 1987) 
and 8% of colorectal carcinomas (Richman, 1987) showed complete loss of HLA 
class I expression. In a small study of 9 colorectal cell lines Makin (Makin, 1985) 
was unable to detect HLA class I in 5 of the cell lines when screening them  by 
ELISA, using antibodies W 6/32 (Barnstable et al., 1978) and BBM.l (Brodsky et 
al., 1979a) which recognize m ature HLA-A, -B and -C complexed w ith  P2 - 
microglobulin and P2 -microglobulin respectively. A more detailed analysis of
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HLA class I allele expression on colorectal tumours, using a panel of monoclonal 
antibodies, showed 1 of the 30 tumours studied lacked all HLA class I expression 
(Smith et al., 1989). This was determined by the lack of reactivity of the tum our 
cells w ith antibodies W 6/32 and BBM.l, however, this tum our showed the 
presence of free HLA-A, -B and -C heavy chains in the cytoplasm by positive 
reactivity with antibody HCIO (Stam et al., 1986). Three other tum ours in this 
study showed down-regulation of HLA class I expression by very weak or focal 
staining w ith the antibodies. However, in the same study frequent loss of 
individual HLA heavy chains was seen. Three out of 13 tumours had specifically 
lost HLA-A2 expression and another 4 of thel3 had lost HLA-A2 and HLA-Bw4, 
probably indicating a haplotype loss in these 4 tumours.
In a similar study of 30 colorectal carcinomas, loss of reactivity with W 6/32 was 
seen in 30% of tumours, but this loss of reactivity was not always associated with 
a loss of expression of P2 "i^icroglobulin (Rees et al., 1988). Using tum our and 
corresponding normal epithelium from each patient, 15 of these individuals were 
shown to type as HLA-A2, but 4/15 of the tumours showed complete loss of 
HLA-A2 expression.
In a larger study of 70 consecutively collected colorectal tumours, 9 (12%) 
showed complete loss of surface expression of HLA class I (judged by lack of 
reactivity w ith W6/32) and an additional 2 (4%) of tum ours had partial loss, 
demonstrated by focal pockets of tum our cells lacking reactivity w ith W 6/32 
(Kaklamanis et al., 1992). Detailed analysis w ith a panel of m onoclonal 
antibodies revealed 5 /9  of the tumours showed neither reactivity at the cell 
surface nor cytoplasmically with any of the reagents recognizing HLA class I and 
p2 -microglobulin. Two tum ours in this study expressed cytoplasmic HLA-A 
heavy chain, but lacked HLA-B and -C and p 2 -microglobulin, and one case
lacked all HLA class I heavy chains, but expressed cytoplasmic p2 -microglobulin. 
In addition, one tum our expressed free HLA class I heavy chains in the 
cytoplasm, but no p2 -microglobulin was present. These results suggest that the 
loss of surface expression of HLA antigens can be the result of different genetic 
mechanisms affecting one or more of the HLA alleles causing either the loss of
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expression of one particular allele product or loss of a complete haplotype of 
HLA-A, -B and -C, which for HLA would represent LOH. The loss of p 2 " 
microglobulin expression would, however, require two separate events to occur 
presumably, though not necessarily, at different times (Smith, 1990).
Several attempts have been made to address the question of w hat sort of genetic 
event leads to the loss of expression of HLA antigens. When searching for the P2 - 
microglobulin gene, Goodfellow et al localized it to chromosome 15. This study 
included the lym phoblastoid cell line D audi and it w as noted that in 
D audi/m ouse hybrids there was a lack of expression of p2 -microglobulin. They 
concluded that this was due to a genetic change in the region encoding P2 - 
microglobulin (Goodfellow et al., 1975a). Lopez-Novet et al. show ed loss of 
expression of HLA-A, -B and -C /p 2 -microglobulin in 14% of colorectal tumours, 
by the lack of reactivity with W 6/32 (Lopez-Nevot et al., 1989). They reported 
heterogeneous expression in the positive tumours, bu t found no correlation 
between HLA class I expression and tumour grade. DNA from tum ours and, for 
control purposes, from surrounding normal mucosa, were digested w ith the 
isoschizomic enzymes MspI and Hpall, which are differentially sensitive to 
m éthylation of CCGG sequences. The resulting RFLP's were analyzed by 
Southern Blotting using an HLA-class I specific probe. No differences were 
reported between tumour and paired normal DNA indicating that there was no 
deletion of genes and no differences in méthylation at the restriction sites used.
In a detailed study of 15 colorectal carcinomas which had lost HLA class I /P 2 - 
microglobulin expression, Momburg and Koch investigated the levels of mRNA 
for HLA class I and p2 -microglobulin (Momburg and Koch, 1989). Using specific
probes for HLA-B8 and P2 -microglobulin, in in situ hybridization studies, they
demonstrated that in three tumour sections no message for p2 -microglobulin was 
present, compared to surrounding norm al mucosal cells, w hilst detectable 
amounts of message for HLA class I was present in both cell types. However, 
these studies were not able to explain the absence of the p2 -microglobulin mRNA 
which was suggested could be either due to down regulation or instability of the
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transcripts. These studies were in contrast to the loss of p2 -microglobulin
expression in the Daudi cell line, where mRNA has been detected, and the failure 
to express explained by the presence of a mutation in the initiation, ATG, codon 
of the P2 -microglobulin gene sequence (Ploegh et al., 1979; Rosa et al., 1983).
When typing a panel of 30 colorectal cell lines. Browning et al. reported a higher 
than expected number of cell lines that appeared to be homozygous for HLA-A 
(Browning et al., 1993). A subsequent study, which included data on HLA-B and 
-DR, suggested that up to 15% of these cell lines had an entire haplotype loss in 
the HLA region (Browning et al., 1996). The colorectal cell line PC/JW , and a 
corresponding normal B cell line (JWC) were included in this study. A complete 
HLA haplotype loss was demonstrated when comparing PC/JW  with the normal 
JWC. Another of the colorectal lines, LS411, showed only a single allele loss for 
H L A -A ll w hen com pared to RN, a corresponding norm al B cell line. 
Conversely, LS174T and HCA-7 typed as HLA-A2, -A30 and HLA-Al, -A2 
respectively, but LS174T was shown to lack expression of -A2 and HCA-7 lacked 
expression of -Al, when each line was analyzed with allele specific antibodies. In 
both cases the relevant mRNA's appeared to be detected by RT-PCR.
Attempts to re-express HLA class I have been reported with the cell line DLD-1 
which lacks P2 "i^ic^oglobulin expression. Browning et al dem onstrated re­
expression of HLA, as indicated by reactivity with the antibody W 6/32, after 
infection of DLD-1 with a recombinant vaccinia virus encoding the hum an p2 “ 
microglobulin gene (Browning et al., 1996). Toshitani et al established two stable 
transfectants of DLD-1, one expressing a (p2-microglobulin/HLA-A2) construct 
and a second, transfected with a plasmid that contained only p2 -microglobulin, 
was shown to re-express endogenous HLA-A2 associated w ith the transfected
p2 -microglobulin. This was determined by reactivity with antibodies W 6/32 (anti
HLA-A, -B, & -C /p 2 -microglobulin) and BB7.2 (anti HLA-A2). In addition, this 
re-expression of endogenous HLA-A2 was upregulated after treatm ent w ith 
ylFN (Toshitani et al., 1996).
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1.3 Research Aims.
At the time this thesis was started (1994), evidence for the loss of expression of 
HLA class I antigens on tum our cells was based on immunohistochemical 
studies. Most of these used the monoclonal antibodies W 6/32 and BBM.l that
recognize surface expression of HLA-A, -B and -C complexed w ith  p 2 -
m icroglobulin and P2 -microglobulin, respectively. In addition, evidence for 
losses of single HLA allele products had been established w ith allele specific 
antibodies, several of w hich had  become available. In add ition , the 
lymphoblastoid cell line Daudi, was the only reported case where a specific 
genetic event had been identified that lead to the com plete loss of P2 - 
microglobulin synthesis, and hence lack of HLA class I expression at the cell 
surface.
In addition, several model systems, using gene constructs, have been reported 
for the study of the re-expression and peptide loading of HLA class I molecules 
in cells lines lacking HLA class I expression. These models have established 
stable transfectants using plasmid vectors, that allow continuous expression of 
HLA class I or HLA class I /p 2 -microglobulin constructs. W ith the advent of 
inducible expression systems, we sort to establish a cell line w ith an inducible 
expression of an HLA-A*0201 /  P2 -microglobulin construct. Such a system would 
allow the analysis of re-expression, peptide loading and functional status of an 
HLA class 1 /p2 -microglobulin construct in cells induced to express the construct, 
w ith the useful availability of un-induced cells to act as negative controls in 
studies of peptide presentation.
The research aims of this thesis were:
1) To investigate, in a panel of established colorectal cell lines, precise mutational 
events in the p2 "iï^icroglobulin gene that could lead to the loss of expression of all 
HLA class I.
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2) To extend the investigation, for mutations in the p2 -i^icroglobulin gene, to 
include a large collection of tumour cells derived from different carcinomas and 
to include where possible control data from paired normal tissue.
3) To investigate if the occurrence of m utations in p 2 "^icroglobulin genes 
correlated with any other genetic event, such as microsatellite instability which is 
associated with errors in the DNA mismatch repair pathway.
4) To identify, at the genetic level, mutations in specific HLA class I alleles that 
could lead to the loss of expression of that allele product.
5) To establish a model inducible system for the expression of an (HLA- 
A"^0201/P2-microglobulin) construct in cell lines lacking expression of HLA class 
I. These experiments were initially attempted in the hum an colorectal cell line 
DLD-1, with additional work carried out in the CHO cell line.
6) To study parameters, such as concentration and time scale of stimulation by 
the inducer, that would influence the inducibility of the (HLA-A'^0201 /  P2 - 
microglobulin) construct. In addition, to verify the functional status of the 
induced construct by the ability to present specific peptides to an HLA-A2 
restricted, peptide specific, cytotoxic T cell line and demonstrate cell lysis in a 
cytotoxic T cell killing assay.
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CHAPTER 2
MATERIALS AND METHODS
2.1 CELL LINES.
2.1.1 Cell Line Culture Techniques.
Approximately 5x10^ cells were cultured in 10ml of either Dulbecco's modified
E4 m edium  (DMEM) supplem ented w ith 10% heat inactivated (55®C for 30 
m inutes) Foetal Calf Serum (FCS) or Iscove's modified Dulbeccos m edium  
(Gibco/BRL, UK) supplemented with 10% heat inactivated FCS. Antibiotics, 
Penicillin 200 lU /m l and Streptomycin 200 pg/m l, were added to both media 
types used. Usually, 75 sq.cm flasks were used, incubated in a hum idified
incubator at 37^C with 10%CO2-
When adherent cells were approaching a confluent culture they were split into 
fresh cultures using one of two different methods:
Method 1) The culture medium was removed and the monolayer washed w ith 
10ml of Phosphate buffered saline (PBSA), then washed a second time w ith Ca 
deficient medium (DMEM modified for suspension cultures, Flow /ICN , UK). 
The culture was then set up with 4ml per 75 sq.cm flask of Ca deficient medium
supplemented with antibiotics and cultured overnight at 37^C in 10%CO2. By 
next day most of the cells appeared rounded and some had detached. To increase 
cell detachment, the flasks were tapped gently and any remaining attached cells 
detached using a rubber policeman. The resulting cell suspension was then set 
up in a new culture flask containing one of the culture media mentioned above. 
Method 2) The culture medium was removed and the cells washed with 10ml of
PBSA. Then 4ml of pre-warmed (37°C) Trypsin/EDTA solution was added and 
the culture incubated for several minutes at 37°C. As soon as the cells were
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detached, 10ml of culture medium containing 10% FCS was added and the cell 
suspension transferred to a 15ml centrifuge tube. The cells were then recovered 
by centrifuging at 1500rpm for 5 minutes at room temperature. The supernatant 
was removed and the cells then set up in a fresh culture flask containing the 
appropriate culture medium. Cells were normally split in the range of 1:4 to 1: 20 
during passage.
Lymphocyte and other cell lines which grew in suspension were norm ally 
cultured in Roswell Park M emorial Institute (RPMI) m edium  No 1640 
supplem ented w ith 10% heat inactivated FCS, Penicillin 200 lU /m l and 
Streptomycin 200 pg/m l. Cultures were incubated in a humidified incubator at
37®C with 5% CO 2 . When these cultures reached confluency, an aliquot of the 
cells was removed and added to a new flask containing fresh medium, normally 
splitting in the range of 1:10 to 1: 50 depending on the cell line.
2.1.2 Colorectal Cell Lines used in these studies.
The colorectal cell lines used in these studies were as follows:
CIO Established in the Cancer & Immunogenetics Lab, CRuk, Oxford
C32 Established in the Cancer & Immunogenetics Lab, CRuk, Oxford
C70 Established in the Cancer & Immunogenetics Lab, CRuk, Oxford
C75 Established in the Cancer & Immunogenetics Lab, CRuk, Oxford
C80 Established in the Cancer & Immunogenetics Lab, CRuk, Oxford
C84 Established in the Cancer & Immunogenetics Lab, CRuk, Oxford
C99 Established in the Cancer & Immunogenetics Lab, CRuk, Oxford
C106 Established in the Cancer & Immunogenetics Lab, CRuk, Oxford
C125PM Established in the Cancer & Immunogenetics Lab, CRuk, Oxford
CaCo2 (Fogh et al., 1977)
CC07 (Katagiri, 1987)
CC20 (Greenhalgh and Kinsella, 1985)
Colo201 (Sample et al., 1978)
Colo205 (Sample at al., 1978)
Colo206 (Sample at al., 1978)
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Colo320DM (Quinn et al., 1979)
Colo678 Not Published From DSMZ-Deutsche, Deposited by Moore, E.G., USA
Colo741 ECACC Collection No 93052621
CX-1 Not Published From DSMZ-Deutsche, Deposited by DKFZ Tumorbank
DLD-1 (Tibbetts et al., 1977)
GP2d (Solic et al., 1995)
GP5d (Solic et al., 1995)
HCA-7 (Kirkland, 1985)
HCA-46 (Kirkland and Bailey, 1986)
HCT-15 (Tibbetts et al., 1977)
HCT-116 (Brattain et al., 1981)
HRA-19 (Kirkland and Bailey, 1986)
HT-29 (Fogh and Trempe, 1975)
HT-55 (Goldin and al, 1981)
LIM1863 (Whitehead et al., 1987)
LoVo (Drewinko et al., 1976)
LS-174T (Tom et al., 1976)
LS-180 (Tom et al., 1976)
LS-411 (Suardet et al., 1992)
LS-1034 (Suardet et al., 1992)
PC/JW  (Paraskeva et al., 1984)
SKCO-1 (Fogh and Trempe, 1975)
SW48 (Leibovitz et al., 1976)
SW403 (Leibovitz et al., 1976)
SW480 (Leibovitz et al., 1976)
SW620 (Leibovitz et al., 1976)
SW837 (Leibovitz et al., 1976)
SW948 (Leibovitz et al., 1976)
SW1116 (Leibovitz et al., 1976)
SW1417 (Leibovitz et al., 1976)
SW1222 (Leibovitz et al., 1976)
T-84 (Murakami and Masui, 1980)
VACO-4A (McBain et al., 1984)
VACO-4S (McBain et al., 1984)
VACO-5 (McBain et al., 1984)
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VACO-IOMS (McBain et al., 1984) 
WIDR (Fogh and Trempe, 1975)
2.1.3 Other (non-colorectal) cell lines used in these studies.
Non-colorectal cell lines used include the following lines
Lymphoblastoid
EVA 1224 (Kirkland, 1985)
BRISTOL-8 From ECACC. Cell line No 85011436
Miscellaneous
CHO.K1 From ATCC. Cell line ref No CCL61
2.2 TUMOUR SAMPLES.
Colorectal tum our samples were obtained with the co-operation of Mr Neil 
Mortensen and Mr Kettlewell (Department of Surgery, John Radcliffe Hospital, 
Oxford) and the material was identified and dissected by Dr Lucas Kaklamanis 
(Department of Pathology, John Radcliffe Hospital, Oxford). Same additional 
colorectal tumour sample were provided by Dr Ian Frayling (St Marks Hospital, 
London).
Ovarian tumours were obtained from Dr Inez Cooke, Ovarian cancer Group, 
ICRF, Institute of Molecular Medicine, Oxford.
Samples from Breast tumours were kindly supplied by Prof. A. Harris, ICRF 
Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, 
Oxford.
Samples of DNA from Lymphoma patients were obtained from Prof. D Mason, 
Haematology Laboratory, John Radcliffe Hospital, Oxford
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Melanoma samples were obtained from Dr Catriona MacGeoch, Hum an Genetic 
Resources Laboratory, ICRF Clare Hall Laboratories, South M imms, 
Hertfordshire and Prof. Ian Hart, Richard Dimbleby ICRF Department of Cancer 
Research, St. Thomas' Hospital, London.
2.3 IMMUNOASSAYS.
2.3.1 Immunofluorescence and Flow Cytometry.
Cell surface membrane expression of various antigens was examined using 
immunofluorescence followed by analysis on a Flow cytometer. Briefly, adherent 
cell cultures were trypsinized and a washed cell pellet (10^ cells) produced as 
described above. Non-adherent cells were washed twice w ith DMEM before
assaying. 50pl of antibody dilution (lOjLig/ml) was then added to the cells and 
incubated on ice for 30 minutes. A negative control containing no antibody was 
also prepared. After washing the cells twice in cold DMEM/2% heat inactivated
FCS, a 1:20 dilution of FITC conjugated goat-anti-mouse (SOpl) was added 
followed by incubation on ice, in the dark, for 30 minutes. Cells were then 
washed twice in cold DMEM/2% heat inactivated FCS and finally resuspended
in SOOjLil of 1% paraformaldehyde in PBS. The cells were stored at 4°C in the dark 
until analysis on a Flow cytometer. Cells were analyzed using a FACScan 
(Beckton Dickinson) for one colour fluorescence (FLl) with side scatter (SSC). 
Antibodies used in these studies were:
BBM.l (p2 -microglobulin) (Brodsky et al., 1979a)
BB7.2 (HLA-A2/AW69) (Brodsky et al., 1979b)
HCA2 (HLA Heavy chain, A locus) (Stam et al., 1990)
HCIO (HLA Heavy chain, B & C loci) (Stam et al., 1986)
L368 (p2 -microglobulin) (Lampson et al., 1983)
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W 6/32 (Mature HLA-A, B & C couple with p2 "i^icroglobulin)
(Barnstable et al., 1978)
Rabbit anti-mouse Polyclonal (Dako, Denmark)
Goat anti-mouse Polyclonal/FITC (Dako, Denmark)
2.3.2 Enzyme-Linked Immuno Sorb ant Assay (ELISA).
The GAG ELISA assay used in these studies was based on that described earlier 
(Durbin and Bodmer, 1987). Adherent cells were grown up on microtiter plates
(Becton Dickinson) to within 3-5x10^ cells per well. The cells were then fixed by 
incubation with 0.025% glutaraldehyde (Sigma) in PBSA for 30 minutes at room 
temperature. Background blocking was then achieved by incubation w ith 0.1% 
gelatin in PBSA for at least 1 hour at room temperature or overnight at 4°C. For
the assay, plates were washed x3 with PBSA/0.2% casein then 50pl of antibody 
dilution (lOpg/ml) added per well and incubated at room tem perature for 1 
hour. Plates were then washed x3 w ith PBSA/0.2% casein/0.2% Tween 20
(Sigma). 50pl of 1:100 dilution of Rabbit-anti-mouse (Dako, Denmark) in 
DMEM/10% ECS was then added per well and incubated for 1 hour at room 
temperature. Plates were washed x3 with PBSA/Casein/Tween 20, followed by 
the addition of a 1:750 dilution of GAG complex (50pl) per well and incubated as 
above. The GAG complex consisted of antibody 4C7, which specifically reacts 
w ith p-galactosidase, coupled with P-galactosidase, Sigma. Plates were washed 
three tim es as described and finally lOOpl of substra te  so lu tion  (4- 
methlyumbelliferyl-p-D-galactoside dissolved in Im M  Mg Cl2/100mM p- 
mercaptoethanol) was added per well and incubated for 30 m inutes at room 
tem perature in the dark. Plates were read in a M icrofluor plate reader 
(Dynatech, UK).
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2.3.3 Cytotoxic T Lymphcyte Assay (CTL Assay).
A hum an HLA-A2 restricted, influenza A m atrix specific, CTL line was 
generated from blood donor PG (Gotch et al., 1987). CTL activity was measured 
in a standard  ^^Cr release assay. Target cells were cultured either w ith 
Ponasterone A (IpM ) for 24 hours to induce HLA expression or w ith fresh 
culture medium only, then trypsinized and washed in culture medium. These 
cells were then labeled with lOOpCi of ^ ^Cr (Amersham, UK) for 1 hr at 37°C, and 
washed twice with culture medium. These cells were then incubated for 1 hr 
w ith  flu m atrix peptide (GILGFVFTL, IpM ) and w ashed x3 w ith  culture 
medium. For the assay, 5 x 10  ^target cells per well were incubated for 5 hrs with 
either CTL's, known to be against the peptide target, at various EffectoriTarget 
(E:T) ratios, medium alone (spontaneous release) or 5% Triton X-100 (maximum 
release). Aliquots (20pi) of supernatant were harvested and ^^Cr release 
determined using a y-plate counter (LKB, UK). The percentage of specific lysis 
was calculated as [(release by CTL's) -  (spontaneous release)] x 100/[(maximum 
release) -  (spontaneous release)].
2.3.4 Immunocytochemistry.
Immunocytochemical detection was performed using the alkaline phosphatase 
method as described by Cordell et al. (Cordell et al., 1984) Briefly, frozen tissue 
sections (7pm thick) were fixed in cold acetone for 10 m inutes at room  
temperature and air dried overnight. Primary mouse monoclonal antibody (50pl) 
was added to the dry sections in a humidified chamber for 30 minutes followed 
by three w ashes w ith  Tris buffered saline (TBS) pH  7.4. A nti-m ouse 
immunoglobulin G (DAKO) and APAAP complex (DAKO), both diluted 1:50 in 
TBS, were added sequentially and each incubated for 30 m inutes at room 
temperature. Each step was separated by a washing period of 5 m inutes w ith 
TBS. These steps were repeated to enhance the intensity of the final staining.
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After a final wash w ith TBS the alkaline phosphate substrate was added and 
incubated for 15 minutes at room temperature. Sections were counterstained 
with haematoxylin and mounted in an aqueous mounting medium.
2.4 MOLECULAR BIOLOGICAL METHODS.
2.4.1 Extraction of DNA and mRNA.
DNA extraction from cell lines was performed by Nucleon II DNA extraction kit 
(Tepnel, UK) according to the manufacturers instructions. Briefly, this involved 
lysing the cells in a buffer containing SDS followed by protein precipitation with 
sodium perchlorate, followed by a chloroform separation. Any remaining protein 
was rem oved by the addition of a silica slurry, which bound the protein, 
followed by centrifugation. The isolated DNA was recovered by ethanol 
precipitation and washing with 70% ethanol and finally resuspended in sterile 
H 2 O. DNA concentrations and purity were estimated by measuring appropriate 
dilutions in a spectrophotometer at 260nm and 280nm. Some early preparations 
of cell line DNA were extracted by using an Applied Biosystems model 340A 
nucleic acid extractor.
DNA from fresh tumours and normal colon epithelial cells was extracted from 
biopsies obtained at the time of surgery. On arrival in the laboratory samples 
were divided into two portions, one portion used for establishment of a cell line 
and the second snap-frozen in liquid nitrogen and cryopreserved until required. 
DNA extraction was performed as described above using the Nucleon II system. 
A slight modification was used during the cell lysis step. Tumour samples were 
cut into pieces as small as possible (approximately 0.5mm) using two scalpels 
and placed into a tube with 6ml of lysis buffer that contained twice the usual 
concentration of SDS. Cell lysis was performed by rotating the preparation for 17 
hours at room tem perature, then sodium  perchlorate was added and the 
extraction continued as described above.
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mRNA was extracted from tissue and cell lines using a Messenger RNA Isolation 
Kit (Stratagene, California, USA). The basic protocol was to lyse the cells in 5ml 
of a proprietary buffer containing Guanidine thiocyanate and |3-mercaptoethanol 
at room temperature. The DNA in this solution was then sheared by passing the 
lysate through a 21-gauge needle. 10 ml of a proprietary elution buffer was then 
added and the whole sample centrifuged at 12,000g to remove cell debris. The 
supernatant was mixed with a slurry of Oligo (dT) cellulose resin and incubated 
for 15 minutes, at room temperature, on a rotary stirrer, and transferred to a 
syringe fitted with a glass fibre filter at the bottom. The slurry was washed three 
times with a high salt buffer followed by one wash with low salt buffer. Finally 
the poly A RNA was eluted from the resin with 400|xl of warm  (68°C) elution 
buffer. The mRNA was then precipitated by adding 1/10 volume of sodium 
acetate (3M) and 2.2 volumes of cold ethanol and recovered by centrifugation 
(13,000rpm in an Eppendorf mini centrifuge). The mRNA was washed once with 
70% ethanol and finally resuspended in RNase free water. Samples were stored 
at -80 °C until use.
2.4.2 Polymerase Chain Reaction (PCR).
A) p2 -Microglobulin
PCR for P2 -rnicroglobulin analysis was performed in 50jil reactions containing all 
four NTF's (each at 200|xM), 0.2|iM of the appropriate prim er combination, as 
show n in Table 2, Ip  g of genomic DNA, 1 un it of A m plitaq (Perkin- 
Elm er/Cetus) and either buffer A or B (primers 32892 and 32894 w ith buffer A 
for leader peptide/exon 1 and primers 31555 and 31557 with buffer B for exon 2). 
Buffer A contained 50mM KCl, lOmM Tris-HCl pH8.3, MgCl2l.5mM and 0.25% 
Nonidet P40. Buffer B contained lOmM Tris-HCl pH8.3, 50mM KCl, 3mM MgCl2  
and 0.01% Triton XIOO. The mixes were over layered w ith one drop of light 
mineral oil (Sigma). Samples were amplified for 30 cycles in a therm al cycler 
(Hybaid, Teddington, U.K.) as follows; for prim er combination 32892/32894;
92°C (30 secs), 68°C (30 secs) and 70^C (2 mins) and for prim er combination 
31555/31557; 920C (30 secs), 60^C (30 secs) and 72°C (2 mins).
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TABLE 2
SEQUENCE OF PCR PRIMERS USED FOR P2 -MICROGLOBULIN ANALYSIS
Primer Sequence (5'-3')
32892 Forward -  Leader Pep/Exon 1 TCCTGATTGGCTGGGCACGC
32894 Reverse -  Leader Pep/Exon 1 CAGAGCGGGAGGGTAGGAGA
31555 Forward -  Exon 2 ACCCTGGCAATATTAATGTGTC
31557 Reverse -  Exon 2 TACACAACTTTCAGCAGCTTAC
The genomic sequence of for p2 "n^icoglobulin is shown in Figure 4 w ith the 
location of primers used for pz-nakoglobulin analysis.
B) HLA-A^OlOl and HLA-A’^ 0101"null" alleles.
For analysis of the HLA-A’^ 0101 and HLA-A*0101"null" alleles the same protocol 
and cycling conditions were followed as described for HLA class I typing 
published elsewhere (Tonks et al., 1999). The primers that distinguish between 
HLA-A*0101 and HLA-A’^ OlOl"null" have been published previously (Bunce et 
al., 1999), and those used in these studies are shown in Table 3.
TABLE 3
SEQUENCE OF PCR PRIMERS USED FOR ARMS-PCR ANALYSIS OF 
HLA-A^OlOl AND HLA-A*0101"Null" ALLELES
Primer Sequence (5'-3')
123381 Forward -  HLA-Al all alleles 
Intron 3 bp240-258
GACGGGAAGAGGATCCCTC
123385 Reverse - HLA-A*0101 
Exon 4 bp 620-638
ATATGTGTCTTGGGGGGGT
123386 Reverse -  HLA-A*01Gl"Null" 
Exon 4 bp 621-639
TATGTGTCTTGGGGGGGGT
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C) Sequencing HLA-A alleles.
PCR conditions, using a pair of primers with HLA-A specificity, used to prepare 
tem plates for sequencing of the HLA-A*01 and HLA-A*^02 alleles were as 
follows: 50|il reactions containing all four NTP's (each at 200|iM), 0.2|xM of each 
prim er (Forward Primer 5'GACGGGAAGACGATCCCTC3' and reverse primer 
5'CTGCAGGCCTGGTCTCCACG3'), 90ng of genomic DNA, 1 unit of Amplitaq 
Gold (Perkin-Elm er/Cetus) and 0.1 unit Pfu Taq (Stratagene) in a buffer 
containing 50mM KCl, lOmM Tris-HCl pH8.3 and MgCl2 lmM . The mixes were 
over-layered with one drop of light mineral oil (Sigma). Samples were amplified 
for 1 cycle of 95°C for 12 minutes followed by 30 cycles in a therm al cycler 
(Hybaid, Teddington, U.K.) of 92°C (30 secs), 68°C (30 secs) and 72°C (2 mins).
2.4.3 Agarose Gel Analysis.
Following PCR, a representative sample of the reaction was usually analyzed by 
gel electrophoresis. The gel consisted of 1-2% agarose (Gibco/BRL) in Ix TBE 
buffer (1 litre H 2 O containing 10.8g Tris base, 5.4g Boric acid and 4ml 0.5M 
EDTA). Before the gel was cast, 3pl of ethidium bromide (lOmg/ml) per 50ml gel 
was added to aid visualization of the PCR product under UV light. Samples (6pl) 
plus Ijxl of loading buffer (0.2% bromophenol blue, 0.2% xylene cyanole and 50% 
glycerol in H 2 O) were loaded onto the gel. Standard size marker was usually a 
Pstl digest of Lamda DNA prepared in loading buffer. A running buffer of IxTBE 
containing ethidium bromide, as above, was used and the gel runs at 100 volts at 
room temperature for approximately 30 minutes. PCR products were visualized 
under UV light on a transilluminator and recorded by Polaroid camera.
2.4.4 Single-Strand Conformation Polymorphism Analysis (SSCP).
Prior to SSCP analysis, PCR reactions were labeled with ^^P. An aliquot (1 |il) of 
PCR product was added to 25 pi of fresh PCR reaction mixture containing the
66
appropriate buffer and primer pairs. Additionally, 50pCi of [a-^^P]dCTP (specific 
activity, 3000Ci/m m ol [lCi=37GBq], Am ersham , UK) were added. PCR 
amplification was then performed for 10 cycles, under the conditions described 
above for each primer combination.
For SSCP analysis, Ipl samples of the ^^P-labeled PCR products were added to 
lOpl of SSCP loading buffer containing 15mM EDTA, 0.05% SDS, and 50% 
(vol/vol) formamide. Samples were then denatured at 95°C for 5 minutes and 
super-cooled. Seven microlitres was loaded on to a 50cm-long non-denaturing 
SSCP gel and electrophoresed at 450volts at room tem perature for 24 hours. 
Analysis of the leader peptide/exon 1 PCR product was achieved on an 8% 
polyacrylamide gel containing 17.5% (vol/vol) glycerol and IxTBE buffer. For 
SSCP analysis of exon 2 PCR products, a 5% polyacrylamide gel containing 10% 
glycerol and IxTBE buffer was used. The running buffer used in both cases was 
IxTBE, and electrophoresis carried out at 400 volts for 20 hours at room 
tem perature , after w hich the gels w ere dried  and bands located by 
autoradiography.
2.4.5 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR).
The analysis of mRNA from the cell lines EVA-1224 and HCA-7 were carried out 
using the Superscript ™II (Reverse transcriptase-DNA polymerase combination) 
First Strand Synthesis System (Gibco/BRL, UK) followed by PCR using primers 
designed in the laboratory. For first strand synthesis, mRNA (approximately 
2|ig) was added to a solution of proprietary  Random Hexam er Prim ers 
(3.5ng/|il) and heated to 70°C for 10 minutes, followed by supercooling on wet 
ice. The following were then added, 2|il of lOx Synthesis buffer (200mM 
Tris/H Cl pH8.4, 500mM KCl) l|xl of lOmM dNTP's, 2|xl lOOmM DTT and Ipl 
Superscript™!! (50units/)Lil) and incubated for 10 minutes at room tem perature, 
50 minutes at 42 °C and 15 minutes at 70 °C. To remove any rem aining single 
strands the sample was incubated for 20 minutes at 37 °C w ith 40 units of 
RNaseH. This reaction was then diluted 1:4 with ddH20 and used as a source of 
template in a 50|il PCR with the following conditions: all four NTP's (each at
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200|iM), 0.2|xM of each prim er (see below), 90ng of genomic DNA, 1 unit of 
Amplitaq (Perkin-Elmer/Cetus) all in a buffer of 16mM Ammonium Sulphate, 
67mM Tris-HCl pH8.4, 6.7mM EDTA, 0.017% BSA and MgCl^lmM. The mixes 
were over layered with one drop of light mineral oil (Sigma). Samples were 
amplified for 5 cycles of 95^C (50 secs), 70°C (50 secs), 72°C (50 secs), then 21 
cycles of 95°C (50 secs), 63°C (50 secs), 72°C (50 secs), and a final 4 cycles of 95°C 
(50 secs), 55°C (50 secs), 72°C (50 secs), in a thermal cycler (Tetrad, MJR, USA). 
Primers used were:
AL-16 (5'GACCAGGAGACACGGAATA30 
AL-x (5'GCCCGTCCACGCACCG3')
AL-13 (5'TGGATAGAGCAGGAGGGT3')
AL-H (5'CAAGAGCGCAGGTCCTCT3')
61998 (5'GAGGGGCTTGGGCAGAC30 
46992 (5'CTTTACAAGCTGT3')
HLA3UTA(5'GAGGGAGCACAGGTCAGCGTGGGAAG3').
2.4.6 H LA  T yp in g .
DNA was extracted from cell lines and fresh tum our samples as outlined in 
section 2.4.1. ARMS-PCR for HLA class I typing was perform ed as described 
elsewhere (Tonks et al., 1999) using a panel of 96 primer mixes designed to give a 
m edium  resolution of HLA-A, -B and -C alleles. Following PCR, amplicon 
detection was achieved using the Alkaline M ediated Differential Interaction 
(AMDI) method (Bartlett et al., 2001) were SYBR green 1 (Molecular Probes, UK) 
diluted 1:5,000 in 200mM 4-[cyclohexlamino]-l-butansulphonic acid (CABS, 
Sigma Aldrich, UK), pH12.7 was added to each reaction and PCR products 
detected by fluorimetry. Software developed in the laboratory by Mr Adam  
Lowe was used to interpret the data.
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2.4.7 Microsatellite Analysis.
Microsatellite analysis was performed using four loci, on different chromosomes, 
containing dinucleotide repeat sequences. The loci used w ere D2S123 
(chromosome 2), D10S209 and AFMbOOl (chromosome 10) and D17S941 
(chromosome 17). In some cases, microsatellite instability was confirmed by 
further analysis of the D13S175 (chromosome 13), D2S378 and D2S119 
(chromosome 2) and D10S197 (chromosome 10). The prim er sequences used 
were taken from the 1993-4 Genethon human genetic linkage map (Gyopay et al., 
1994). The PCR reaction contained 50mM KCl, lOmM Tris/HCl(pH8.3), 1.5mM 
MgCl2 , 0.25% NP40, 200|xM NTP's, 0.2pM of the appropria te  p rim er 
combination, the 5' prim er was labeled w ith a fluorescent tag, 1 un it Taq 
polymerase, and 0.5-l|Lig genomic DNA. Amplification was perform ed on a 
Thermocycler (Hybaid, UK) with 35 cycles of 90°C (1 min), 54°C (30 secs), 72°C 
(30 secs). PCR products were analyzed on an Applied Biosystems ABI337A DNA 
Genotyper. Samples with variability at two or more loci were classified as 
microsatellite unstable.
2.4.8 DNA Sequencing (Single Strand Method).
DNA sequencing of PCR products was performed using the direct solid phase 
sequencing system (Hultman et al., 1990). Briefly, a PCR product for 132- 
microglobulin leader peptide/exon 1 was amplified as described in section 2.4.2, 
but with the 3' primer 32894 biotinylated. The whole of the PCR product was 
purified by running in a 2% low melting point agarose gel using TAE buffer 
(Sambrook et al., 1989) and the product visualized on a UV transillum inator. 
After removing the appropriate band, the DNA was recovered using a Mermaid 
kit (BIO 101 Inc., California, USA) according to the m anufacturer's protocol. 
Single stranded DNA was then isolated using Streptavidin coated Dynabeads 
M280 (Dynal AS, Norway) as described (Hultman et al., 1990). Single stranded 
sequencing was then performed using a Sequenase II kit (USB Corporation, 
Ohio, USA) using 5' prim er 32892 to prim e the sequencing reaction. On
completion of the reaction the samples were heated to 85°C for 5 min then super
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cooled. The immobilized template DNA was then removed using a m agnet 
(Dynal AS). Samples were electrophoresed in a standard  6 % denaturing 
polyacrylamide gel, followed by gel drying and autoradiography. Sequencing in 
the opposite direction was achieved by using biotinylated 32892 prim er in the 
PCR reaction and non-biotinylated 32894 to prime the sequencing reaction. 132- 
microglobulin exon 2  was sequenced in a similar way using the appropriate 
combination of biotinylated and non-biotinylated primers. However, in this case 
the DNA was recovered from agarose gel purification w ith a Geneclean II kit 
(BIO 101) because of the larger size (361 bp) of this exon product.
2.4.9 DNA Sequencing (PCR/Automated Method).
For sequencing by the automated ABI system, regions of DNA for sequencing 
were first expanded by PCR as described above in section 2.4.2. An aliquot of the 
PCR was analyzed by gel electrophoresis (as described in section 2.4.3) to 
establish that a clean single band had been produced. The product was purified 
using a Nucleon (Tepnel, UK) PCR 'Clean up ' kit according to the manufacturers 
protocol and finally eluted in 5)Li1 of water. The sequencing reaction was 
performed using the ABI Prism 'BigDye Terminator' Kit (Applied Biosystems, 
UK) w ith the following components in the reaction: tem plate (from PCR 
reaction) 5|il, sequencing primer (50mg/ml) Ipl and BigDye reaction mix 4pl. 
This reaction was over-layed with one drop of mineral oil and then amplified in
a thermal cycler (MJR, DNA Engine Tetrad) as follows: 25 cycles of 96°C (30
secs), 50 °C (15 secs), 60 °C (4 mins), then held at 15 °C. The extension product
reaction was then ethanol precipitated and finally dissolved in 4fil of ABI sample 
buffer. Prior to analysis on an ABI 377 sequencer, the samples were denatured at
98 °C for 5 mins, then supercooled on iced water. Sequences were analyzed using 
the Sequencher 3.0 software (ABI PRISM).
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2.4.10 Cloning and Sequencing.
In the case of sequencing directly from PCR products where two HLA-A loci 
were represented in the amplicon mix, clearer sequence data were obtained after 
cloning from this mix. PCR was performed as described above (2.4.2) and the 
reaction monitored for product purity by analyzing an aliquot on agarose gel 
electrophoresis (see 2.4.3). This PCR product was then cloned using the PCR- 
Script™ Amp Cloning Kit (Stratagene) following the m anufacture's protocol. 
This procedure involves the blunt ending of the PCR product followed by 
ligation into the pPCR-Script Amp SK(+) vector. In this reaction a continuous 
supply of blunt ended cut vector is available from the activity of the restriction 
enzyme Srfi which cuts at the 5'GCCC/GGGC3' site in the cloning region of the 
vector. The blunt ended PCR product is ligated into this site w ith the aid of T4 
DNA ligase. The resultant plasmid is introduced into XLIO-Gold Kan bacteria 
and plated out on to standard agar plates containing ampicillin, X-gal and IPTG. 
(The vector pPCR-Script Amp SK(+) is derived from pBluescript and contains the 
lacZ gene allowing blue white selection in the presence of X-gal and IPTG). After
overnight incubation at 37 °C, white colonies were picked and individually
grown up in 3ml cultures. Plasmids from these clones were isolated using the 
QIAprep m iniprep kit system (Qiagen, UK) according to the m anufactures 
instructions. The quality of the plasmid recovered from the miniprep extraction 
was sufficiently high enough to allow an aliquot to be included in the sequencing 
reaction without further purification. Usually the plasmid was sequenced using 
the ABI system described above in section 2.4.8.
2.4.11 Plasmid/Construct Development.
The (pcDNA-p2M15-A2) construct containing full length p 2 "^icroglobulin
cDNA (including the leader peptide sequence), a (GGGGS)g linker and HLA-A2 
cDNA has been described before (Toshitani et al., 1996). The restriction sites of
construct (pcDNA-P2M15-A2) were changed to a Nhel site (5') using prim er
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5'CGGGCTAGCATGTCTCGCTCCGTGGCCTTA3' and a Hind III site (3') using 
prim er 5'GCCCAAGCTTGAGGTCGACTCTAGAGGATCC3' in a PCR reaction 
using cloned Pfu DNA Polymerase (Stratagene, UK) in conditions recommended 
by the manufacturer. Cycling temperatures used were 30 cycles 95°C (1 min), 
65^C (Imin), 72°C (2.5 mins) followed by 1 cycle of 72°C (5 mins). Similarly, the
restriction sites of a construct containing only the p2 ^ k ro g lo b u lin  gene
(pcDNA-p2 M), reported by the same authors, were also changed by a similar
PCR te c h n iq u e  u s in g  th e  fo llo w in g  p r im e rs :  5 ' p r im e r
5'CGGGCTAGCATGTCTCGCTCCGTGGCCTTA3, containing a Nhel site and 3' 
prim er 5'GGGATCGAGACATGTAAAAGCTTTCA3' containing a Hind III site. 
Following PCR, each amplicon was digested with Nhe I and Hind III, then gel 
purified before they were ligated into the appropriately digested cloning site of
vector pIND (Invitrogen, UK). These plasmids were designated (pIND-p2M15-
A2) and (pIND-p2 M) respectively. The sequence of each insert was confirmed by 
the Sanger sequencing method as described in section 2.4.8 (Sanger et al., 1977).
2.4.12 Maxi-preparation of Plasmids.
Plasmids for transfection experiments were prepared using an Endofree Plasmid 
Maxi Kit (Qiagen, UK). Basically, bacteria from a 300ml overnight culture were 
harvested by centrifugation (1200g) and the bacteria lysed for 5 mins at room 
tem perature in 25mM Tris/H Cl (pH 8 ), lOOmM NaOH, 0.5% SDS containing 10 
lU /m l RNase. The preparation was neutralized w ith IM  potassium  acetate 
(pH5.5) then filtered through a QIAfilter cartridge (Qiagen, UK). The filtrate was 
mixed w ith ER (Endotoxin Removal) buffer (Qiagen, UK) and incubated at 4PC 
for 30 mins, then bound to an Anion Exchange Resin (Qiagen, UK) and set up in 
a column apparatus. After washing with a low salt buffer the plasmid DNA was 
eluted with a high salt buffer and then ethanol precipitated in the usual way. 
Finally, the plasm id DNA was dissolved in endotoxin free w ater. The 
preparation was stored at -20^C until use.
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2.4.13 In vitro-Translation Assay.
To confirm that the plasmid (pIND-p2M15-A2) contained the p2 "^icroglobulin-
linker-HLA-A2 construct, and that this insert coded for a protein of the expected 
size, an in i;/tro-translation assay was performed. The assay was based on the 
TnT Coupled Reticulocyte Lysate System (Promega, USA) and was performed 
according to the m anufacturer's protocol. Briefly, a reaction m ixture was 
assembled containing TnT Rabbit Reticulocyte Lysate, reaction buffer, amino 
acid mixture (minus Methionine), [^ S^] Methionine (l,OOOCi/mmol, Amersham, 
UK), RNasin (Ribonuclease Inhibitor) and template in the form of plasm id
(pIND-p2M15-A2). The reaction was performed in a total volume of 50pl at 30°C
for 90 minutes. An aliquot (10|xl) of the reaction was mixed with an equal volume 
of 2x reducing sample buffer (O.IM Tris/HCl pH6.8, 20% glycerol, 4% SDS, 2mM 
DTT and 0.001% Bromophenol Blue) and boiled for 10 minutes. The sample was 
electrophoresed in a 12.5% polyacrylamide/SDS gel (Laemmli, 1970). The gel 
was then dried down and bands visualized by autoradiography using Hyperfilm 
(Kodak, UK).
2.4.14 Transfection and Induction.
The cell lines, DLD-1 and CHO.KI, were maintained as described in section 2.1 
above. DLD-1 cells (10^) were co-transfected with either (pIND-p2 M) or (pIND-
P2 M I 5 -A2 ) (l|ig) and (pVgRXR) (Ipg) (Invitrogen, UK), using the Lipofectamine
Plus system (Gibco/BRL) according to the m anufacturer's protocol. [pVgRXR 
expresses the heterodimeric ecdysone receptor necessary in the inducible system 
illustrated in Figure 5]. The transfection reaction was allowed to continue 
overnight (17 hours) and then the cells were passaged by trypsinization and set
up in fresh 90mm dishes at 2.5x10^ cells/m l. Stable co-transfectants of cells
containing integrated DNA from both plasmids was achieved in E4 culture
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FIGURE 5
An illustration of the Ecdysone inducible expression system.
Promotor No. 1 Promotor No. 2
RXR PRSV RXR P CMV Vg EcR
DNA Sequence
1 !
DNA Sequence
VP16
RXR
VgEcR
Product
(DBD) DNA Binding Domains
DBDDBD
Ponasterone A
E/GREx5 Sequence on pIND
Indudtion
VP16
Pa HSPpIND
DBDDBD
GENE
Ponasterone A
E/GRExS
Transcription Activated by 
A HSP via VP16 Modified 
Ecdysone Receptor
Gene Product
The RXR construct, containing promotors 1 and 2, once transfected is continuously expressing 
the RXR and VgEcR proteins, each of which has a DNA binding domain. At the time of 
stimulation with Ponasterone A, these two DNA binding domaind are able to bind to the 
appropriate sequences on the plND, upstream of the HSP promotor, allowing transcription of 
the required gene/construct to proceed.
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medium supplemented with Geneticin (G418) at 1.5mg/ml and Zeocin at 
lOOpg/ml.
A similar protocol was employed to transfect either (plND-(32M) or (plND-
P2 M I 5 -A 2 ) and (pVgRXR) into the cell line CHO.KI, however, this line was
m aintained in Iscove's modified Dulbecco's m edium  as described above in 
section 2.1. For dual selection of CHO.KI co-transfectants, G418 was used at 
Im g /m l and Zeocin at lOOpg/ml.
Co-transfections of both cell lines used were maintained in selection medium for 
10-12 days at which time visible clones were picked and transferred to individual 
culture wells. W hen sufficient cells had grown, aliquots w ere set up in 
quadruplicate in m icrotitre plates. Duplicate wells were stim ulated w ith 
Ponasterone A, IjiM (Invitrogen, UK), in appropriate culture m edium  for 24 
hours. Control cells, in duplicate, were incubated in culture m edium  only. 
Microtitre plates were then screened for positive clones using an ELISA assay as 
described in section 2.3.2.
2.4.15 Magnetic Bead Selection of Tranfectants.
Selection of colorectal cell line DLD-1 that had been co-transfected, using the
inducible Ecdysone system with either (plND-p 2 M) or (plND-P2M15-A2), was
attem pted using a magnetic bead attachm ent protocol. Expression of the 
transfected construct was induced w ith Ponasterone A, as described above in 
section 2.4.14. After 24 hours the cells were harvested by trypsinization and cells
washed at APC in DMEM containing 1% heat inactivated ECS. A 1:2 dilution of 
supernatant from antibody L368 (anti-p2 microglobulin) was added and the cells
incubated for 30 mins at 4 °C, then w ashed twice at 4 °C, w ith  DMEM 
containing 1% heat inactivated ECS. Following centrifugation the cell pellet was 
mixed with 200pl of a sterile, pre-washed, suspension of affinity purified goat-
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anti-mouse IgG coated magnetic beads (M-450, Dynal, UK), 5x10^ beads/lxlO ^
cells, and incubated for 30 mins at 4 2ml of DMEM/1% heat inactivated ECS 
was then added and the tube containing the cell/bead suspension placed in a 
magnet holder. The magnetic beads with attached cells were allowed to migrate 
towards the magnet which then allowed the unattached cells, in suspension, to 
be removed by pipetting. This magnetic separation process was repeated twice 
more. The resulting pellet of magnetic beads with attached cells was dispersed in 
5ml of culture medium and set up in a culture flask. After incubating for 7 days 
most of the beads had became detached from the viable cell population and were 
removed from the flask during routine culture medium changes.
2.4.16 Cloning by Limiting Dilution.
Clones that grew out in selection medium in the primary transfection culture see 
2.4.14 above, were hand picked and tested for their responsiveness to stimulation 
by Ponasterone A and expression of the transfected construct. Once such a clone 
had been identified it was subjected to single cell cloning by limiting dilution. To 
achieve this the adherent cells in culture were trypsinized as described above. 
After w ashing the cells in culture m edium  they w ere counted using a 
haemocytometer and diluted, in culture medium, to obtain a cell suspension of 
2xl0^per ml. Then lOOpl of this cell suspension was then added to each of 32 
wells in a 96 well flat bottom microtitre plate. The cell suspension was further 
diluted 1:1 and a similar volume added to the next 32 wells of the microtitre 
plate. Einally, the cells were diluted 1:1 again and lOOpl added to each of the 
remaining 32 wells of the plate. The aim of this method was to plate out, on 
average, 2,1 and 0.5 cells per microtitre plate well. Plates were then incubated in 
standard  conditions and fed every seven days. W hen the cultures w ere 
approximately 50% confluent each clone was trypsinized and transferred to 
larger plates. Single cell cloning was achieved when approximately 1 /3  of the 
wells, in one of cell dilution regions in the microplate, were seen to be growing 
healthy clones.
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2.5 BIOCHEMICAL TECHNIQUES
2.5.1 Cell Lysis.
Cultured cells were harvested and counted then lysis performed at 5x10^/m l in 
ice cold lysis buffer (150mM NaCl, 1% NP40, 0.5% Deoxycholate, 0.1% SDS, 
50mM Tris pH7.5, PMSF (lOOpg/ml) and Aprotinin, Leupeptin and Pepstatin-A 
all at Ipg /m l) for 30 mins at 4°C. The cell lysates were first frozen and thawed 
then sonicated for 1 minute. Finally, the lysates were centrifuged at 16,000g for 
15 mins at 4°C to remove any cell debris. Aliquots of cell lysate were frozen at 
-70°C until required.
2.5.2 SDS PAGE and Western Blotting.
Aliquots of cell lysate, usually lOOpl (equivalent to 0.5x10^ cells) were added to an 
equal volume of 2x reducing sample buffer (O.IM Tris/H Cl pH6.8, 20% glycerol, 
4% SDS, 2mM DTT and 0.001% Bromophenol Blue) and boiled for 10 minutes. 
Samples were electrophoresed on 8.5 - 18.5% polyacrylam ide/ SDS gels 
(Laemmli, 1970) then transferred on to Hybond nitrocellulose blotting membrane 
(Amersham, UK ) using standard Western Blotting techniques (Towbin et al., 
1979). Transfer was carried out for 17 hours at 4°C with 30V. Unreactive sites on 
the nitrocellulose were blocked by incubating in Phosphate buffered saline (PBS) 
containing 5% low fat dried skimmed milk (Tesco, London, UK). The membrane 
was then incubated in an appropriate dilution of mouse monoclonal antibody for 
1 hour at room temperature, followed by five washes in PBS/5% low fat dried 
skim med milk. Rabbit anti-mouse / Horse radish peroxidase conjugate was 
added at 1:10,000 dilution and incubated for 1 hour at room temperature. After 5 
washes in PBS/5% low fat dried skimmed milk, the blot was developed using 
Enhanced Chemiluminescence (ECL, Am ersham , UK) according to the 
manufacturers instructions and exposed to Hyperfilm (Kodak, UK).
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2.5.3 Isoelectric Focussing.
Isoelectric focussing was used to discrim inate HLA molecules of similar 
molecular weight that could not be resolved using conventional SDS/PAGE. The 
basic method is described in the 1987 International Histocompatibility Workshop 
(Yang, 1987). Cells w ere m etabolically  labeled w ith  [^^S]Methionine 
(l,OOOCi/mmol, Amersham, UK) in Methionine free Dubecco's modified Eagles 
medium, supplemented with 10% dialyzed, heat inactivated ECS for 17 hours. 
Cells were then harvested, washed once with PBSA, then lysed in a lysis buffer 
consisting of 150mM NaCl, 1% NP40, 0.5% Deoxycholate, 0.1% SDS, 50mM Tris 
pH7.5, PMSE (lOOpg/ml). The lysate was pre-cleared, by incubating for 1 hour at 
4°C, with a preparation of washed Pansorbin A (Calbiochem, California, USA). 
HLA class I products were then immunoprecipitated by incubating the lysate for 
1 hour at 4°C with HLA class I specific antibody W 6/32, followed by isolation 
w ith Pansorbin A. Einally, the im m unoprecipitates were incubated w ith 
N euram inidase (Sigma Aldrich, UK) for 1 hour at 4°C. Samples were 
resuspended in sample buffer (O.IM Tris/H Cl pH6.8, 10% glycerol, 2% SDS, 
Im M  DTT and 0.001% Bromophenol Blue) and boiled for 10 minutes prior to 
loading on a 30% acrylamide gel containing ampholines, pH3.5-10. pH5-7 and 
pH6-8 (Sigma Aldrich, UK). Gels were run for 17 hours at 10mA. The gel was 
then fixed in 10% acetic acid, washed and treated with Amplify (Amersham, UK) 
followed by drying. Bands were detected by autoradiography using X-ray film 
with an overnight exposure.
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CHAPTER 3
RESULTS
3.1 Screening for Mutations in the p2"ii^icroglobulin Gene.
3.1.1 Colorectal Cancer Cell Lines.
DNA was extracted from 52 established colorectal carcinoma cell lines and 
examined for mutations in the leader peptide/exon 1 region and exon 2 of the ^2~ 
microglobulin gene. The leader peptide/exon 1 region and exon 2 were analyzed 
separately; PCR products were produced using the series of oligonucleotide 
prim ers and conditions described in Materials and M ethods, section 2.4.2.
Samples of these PCR reactions were then labeled with P and analyzed by the
SSCP technique using different conditions for electrophoresis of the amplicons as 
described in Materials and Methods, section 2.4.4. Eight of the 52 colorectal cell 
lines examined by SSCP showed band shifts, 5 in the leader pep tide/exon  1 
region and 3 in exon 2, as shown in Table 4. An example of the band shifts seen 
during SSCP is shown in Figure 6.
All the samples demonstrating a band shift were sequenced using PCR products 
as templates, in the direct solid phase sequencing system (Hultman et al., 1990), 
the protocols for template preparation and sequencing, performed by the Sanger 
m ethod (Sanger et al., 1977), are described in Materials and Methods, section 
2.4.8. The overall results are summarized in Table 5. Lovo is homozygous for a
CT deletion in an 8 bp (CT)^ repeat sequence located in the leader peptide/exon
1 sequence as shown in Figure 7. The pair of cell lines GP2d and GP5d, which are
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TABLE 4
The panel of colorectal cancer cell lines studied showing the location of 
mutations found in the P2 -microglobulin gene.
(Figures in brackets indicate cell lines derived from the same individual.)
Cell Line P2 -Microglobulin Mutation
T84 -
VACO 5 -
VACO 4S 1 -
VACO 4A 1 -
VACO lOMS -
HRA19 Leader peptide/exon 1
SW 948 -
SW 837 -
SW 620 2 -
SW 480 2 -
SW 48 2 muts: Lead, p ep /ex  1 & ex 2
SW 403 -
SW 1417 -
SW 1222 -
SKCO-1 -
PC/JW -
LS180 3 -
LS174T 3 -
LS 1034 -
LoVo Leader peptide/exon 1
CX-1 4 -
HT 29 4 -
WIDR 4 -
HCT 116 -
HCA7 -
HCA46 -
DLD-1 5 2 mutations in exon 2
HCT-15 5 2 mutations in exon 2
C125PM -
COLO 320DM -
COLO 206 6 -
COLO 205 6 -
COLO 201 6 -
CC20 -
CC07 -
CAC0 2 -
C99 -
C84 Exon 2
C80 -
C75 -
C70 -
C32 -
C106 -
CIO -
SW 1116 -
GP2d 7 Leader peptide/exon 1
GP5d 7 Leader peptide/exon 1
LS 411 -
COLO 741 -
HT 55 -
LIM 1863 -
COLO 678 -
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FIGURE 7
Autoradiograph from a sequencing gel of P2 microgIobuIin leader 
peptide/exon 1 PCR products from a wild-type control and the colorectal
cancer cell line LoVo.
Wild Type
Sequence LoVo
G A T C  G A T C
Single strands were isolated from PCR products using magnetic bead 
technology and sequenced by the /Sanger" method as described in Materials 
and Methods, section 2.4.8. Samples were: a normal lymphoblastoid B cell 
line (Left panel) showing wild-type sequence, and LoVo (right panel) 
showing a CT -> deletion in the 8 bp repeat region. This region is indicated
by the arrows.
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derived from the same patient, both exhibit homozygous frame shifts, similar to 
that identified in LoVo, in the (CT)^ repeat element of the leader peptide/exon 1 
sequence. SW-48 and HRA-19 show different 4-bp deletions (CTCT for SW-48 
and TCTT for HRA-19) in the same region of the leader peptide sequence, 
however, the presence of the wild-type sequence at these positions indicated that 
these cell lines were heterozygous for their respective mutations. For control 
purposes, the Burkitt lymphoma cell line, Daudi, was sequenced and shown to 
have a homozygous G->C mutation in the initiation ATG of the leader peptide 
sequence (data not shown) and was in agreement w ith data reported earlier 
(Rosa et al., 1983).
The colorectal cell line C84 has a heterozygous G->A point mutation in codon 32 
of exon 2 (see Table 5 and Figure 8) changing an Asp to an Asn. The cell lines 
DLD-1 and HCT-15, which are derived from the same patient, both demonstrate 
two mutations in exon 2 as shown in Figure 9. A point m utation (G->A) was 
found at the last base of intron 1 (between exon 1 and exon 2), and a C->A point 
mutation in codon 10 changes a Try into a stop codon.
The colorectal cell lines that were demonstrated by sequencing to have a m utant 
p2 -microglobulin gene were examined for expression of p2 "i^icroglobulin by 
ELISA assay using a panel of monoclonal antibodies. The cell lines SW-48, GP2d, 
GP5d, DLD-1 and HCT-15 showed no reactivity with antibody W 6/32 (which 
recognizes mature HLA-A, B and C complexed with p2 -microglobulin) and the
absence of free p2 "^^^icroglobulin chains was confirmed in these cell lines by the
lack of reactivity with the p2 -microglobulin specific antibodies L368 and BBM.l,
see Table 6. LoVo has previously been shown to be deficient in p2 -microglobulin 
expression (Brodsky et al., 1979b). HRA-19 and C84 are both heterozygous for
different single p2 -microglobulin mutations and show intermediate levels of P2 - 
microglobulin expression with antibodies W 6/32 and BBM.l. However, HRA-19 
demonstrates reduced reactivity with antibody L368 whilst C84 appears to have 
normal reactivity with L368. The colorectal cell line HT-29 is included in the data 
shown in Table 6 as a positive control.
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TABLES
Mutations of p^-microglobulin in colorectal cancer cell lines identified by SSCP 
and sequencing.
Cell Line
LoVo
Exon
Leader
sequence
Homozygous/
Heterozygous
Homozygous
Mutation Stop Codon
CT deletion at Codon36 
Codons 13-15+
HRA-19 Leader Heterozygous TCTT deletion at Codon23 
sequence Codons 14&15+
GP2d/
GP5d
Leader Homozygous CT deletion at Codon 36 
sequence Codons 13-15+
SW-48 Leader Heterozygous CTCT deletion at Codon 23 
sequence Codons 13-15+
SW-48 Heterozygous A deletion 
Codon 47
at Codon 82
C84 Heterozygous G - > A  
Codon 32
Asp -> Asn
DLD-1/
HCT-15
Heterozygous C - > A  
Codon 10
at mutation 
Codon 10
DLD-1/
HCT-15
Heterozygous G -> T No stop
Last base in intron 1 codon
+numbers represent codons in the Leader sequence.
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FIGURE 9
Autoradiograph from a sequencing gel of p2 microglobulin exon 2 PGR 
products from a wild-type control and the two colorectal cancer cell lines 
HCT-15 and DLD-1 (derived from the same patient).
Wild Type 
Sequence HCT-15 DLD-1
G A T C  G A T C  G A T O
Single strands were isolated from PCR products using magnetic bead technology 
and sequenced by the 'Sanger" method as described in Materials and Methods, 
section 2.4.8. Samples were: a normal lymphoblastoid B cell line (Left panel) 
showing wild-type sequence; HCT-15 (Middle panel) and DLD-1 (right panel) that 
show two heterozygous mutations, C -> A (Upper arrow) and G -> T (lower arrow).
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TABLE 6
HLA class I and p^_microglobulin expression in colorectal cancer cell lines 
exhibiting a mutation in P^.microglobulin, determined by ELISA.
Cell line Mutation
Location
Homozvgous/
Heterozvgous
W6/32
Antibodies
L368 BBM.
HT-29 None 3389 4000 2857
LoVo Leader seq. Homozygous * $ *
HRA-19 Leader seq. Heterozygous 923 2865 305
SW-48 Leader seq. 
& exon2
Both
Heterozygous
141 184 492
GP2d Leader seq Homozygous 22 54 ND
GP5d Leader seq Homozygous 61 77 ND
HCT-15 2 mutations 
in Bxon2
Both
Heterozygous
0 0 370
DLD-1 2 mutations 
in Exon 2
Both
Heterozygous
75 92 234
C84 Bxon2 Heterozygous 1588 4000 1795
* Previously shown to to deficient for P^-microglobulin (Travers, Arklie et al. 1982) 
N D  - Not Done
The ELISA was performed as described in Materials and Methods, section 2.3.2. 
Results shown are the readout from Microfluor plate reader, with a maximum 
reading of 4000.
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3.1.2 Fresh Tumour Samples.
A collection of 280 tum our samples (147 Colorectal, 30 Melanoma, 48 Breast, 21 
Ovarian and 34 Lymphoma) was assembled from various sources (as indicated 
in Materials and Methods, section 2.2) and DNA extracted from all samples and 
examined for mutations in the leader peptide/exon 1 region and exon 2 of the p2 " 
microglobulin gene. This was performed by PCR followed by SSCP as described 
above for the colorectal cell lines (section 3.1.1). The types of tum our examined 
and the frequency of p2 -microglobulin mutations identified are shown in Table 7. 
Nine of the 147 colorectal tumours in the collection exhibited p2 -microglobulin 
m utations, identified as band shifts during SSCP analysis. An example is 
illustrated in Figure 10. In contrast only one of the remaining 133 non-colorectal 
tumours examined contained a P2 -microglobulin mutation.
Samples demonstrating a band shift by SSCP were sequenced directly from PCR 
products. A m agnetic bead technique was used to isolate single strands 
(Hultman et al., 1990) which were then sequenced by the Sanger method (Sanger 
et al., 1977), as described in Materials and Methods, section 2.4.8. In the colorectal 
tumours, six mutations were identified in the leader pep tide/exon l sequence; 
two in exon 2 and one tum our (C43) contained a point m utation at the base 
before the intiation ATG. Seven of the p 2 -microglobulin m utations in the 
colorectal tumours occurred at repeated elements. A 2 bp deletion in the 8 bp 
(CT) 4  repeat region in the leader pep tide  sequence w as found to be 
overrepresented in this group, ocurring in three of the seven, C14, C108 and 
13971/92. These are similar to the frame shift deletions seen in the colorectal cell 
lines LoVo, GP2d and GP5d except that in the fresh tum our samples the wild 
type sequence is also present (see Figure 11 showing the sequence obtained for
tum our C14). Tumour StM78 contained a minus (TG) frameshift in a (TG) 2  repeat
sequence and 3624/91 showed a G->C point m utation in a (CG ) 2  repeat, both 
these repeated sequences are located in the
TABLET
p2 "niicroglobulin mutations in tumours from different sites.
Tumour Number analyzed Number with p2 -m 
Mutations
Colorectal 147 9
Melanoma 30 0
Breast 48 0
Ovary 21 0
Lymphoma 34 1
TOTAL 280 10
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FIGURE 11
Autoradiograph from a sequencing gel of p2 i^icroglobulin Leader 
peptide/exon 1 PCR products from a wild-type control and fresh colorectal
tumour C14.
C14 W ild type
G A T C G A T C
ÿ
Single strands were isolated from PCR products using magnetic bead technology and 
sequenced by the 'Sanger" method as described in Materials and Methods, section 2.4.8. 
Samples were: a normal lymphoblastoid B cell line (right panel) show ing w ild-type  
sequence and C14 (Left panel) showing a Heterozygous CT deletion (indicated by the 
arrows) in the 8 bp CT repeat region in the leader peptide sequence.
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TABLE 8
Mutations of P2 -nriicroglobulin in fresh colorectal tumours identified by
SSCP followed by sequencing.
SAMPLE LOCATION MUTATION SITE
C14
C43
C84T
C108
StM78
StM185
3624/91
3822/93
13971/92
Leader sequence CT deletion
Base before ATC 
mutation
Exon 2
Leader Sequence 
Leader sequence 
Exon 2
Leader sequence 
Leader sequence 
Leader sequence
C -> A point 
upstream of ATC
C -> A point 
Mutation
CT deletion
TC deletion
A deletion
C -> C point 
mutation
CT -> CC 
CT deletion
(CT)4
Bases 37-44* 
(GA)2
Non repetitive 
sequence
(CT)4
Bases 37-44* 
(TC)2
Bases 24-27* 
(A)5
Codons 47/48+ 
(CC)2
Bases 30-33*
Non repetitive 
sequence
(CT)4
Bases 37-44*
* Numbers represent base position in the Leader sequence 
+ Codon number
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TABLE 9
Expression of p2 -microglobulin in fresh colorectal tumours exhibiting 
a p2 -microglobulin gene mutation.
Tumour
Number
Mutation
location
P^-rnicro globulin 
expression*
C14 Leader seq/exonl Low**
C43 Base before ATG Low**
C84T Exon 2 Low**
C108 Leader seq/exon 1 Low**
3624/91 Leader seq/exon 1 Not detectable
3822/93 Leader seq/exon 1 Not detctable
13971/92 Leader seq/exon 1 Not detectable
StM78 Leader seq/exon 1 N/D+
StM185 Exon 2 N/D+
* Immunocytochemical detection using antibodies W6/32 and 
BBM.l as described in Materials and Methods, section 2.3.4. 
Tumour expression was determined by comparing the intensity of 
staining to that of lymphocytes and surrounding stromal cells.
**Low reactivity implies heterozygous p2 -microglobulin mutation.
+ Not Done
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leader peptide sequence. Tumour (C43) contained a G->A point mutation in the 
base immediately preceding the ATG initiation codon and also occurred in a
(GA) 2  repetitive sequence. StM185 contained a single A deletion in an (A)g repeat
located in exon 2. Only two mutations were seen in non-repetitive sequences, in 
tum our 3822/91 (CT->GG change in the leader peptide/exon 1 region) and C84T 
(G->A point m utation in exon 2), see Table 8. In the group of non-colorectal 
tumours, one m utation was found in a lymphoma, which was localized to the 
leader peptide/exon 1 region, but was not further sequenced or investigated.
Seven of the nine m utated tumours were examined by immunocytochemistry 
w ith antibodies W 6/32 and BBM.l, which recognize m ature HLA-A, B and C 
complexed with p2 "^^icroglobulin and free P2 -microglobulin chains, respectively. 
In all the cases examined the expression of p2 -microglobulin was reduced in 
comparison to that in adjacent normal stromal cells and lymphocytes present in 
the section. In three cases, p2 -microglobulin was undetectable, see Table 9, 
suggesting that these tumours could be homozygous for their respective p2 - 
microglobulin mutations.
3.2 Microsatellite Analysis.
Microsatellite instability can be used to detect defects in DNA mismatch repair. 
From the panel of colorectal cell lines 40 were analyzed at three or more CA 
repeat microsatellite markers as described in Materials and Methods (Section 
2.4.7). Loci used were taken from the 1993-4 Genethon hum an genetic linkage 
map and include D2S119, D2S123, D2S378 (chromosome 2), D10S197, D10S209 
and AFMbOOl (chromosome 10), DS13175 (chromosome 13) and D17S941 
(chromosome 17) (Gy op ay et al., 1994). Those cell lines showing evidence of 
alterations at two or more m icrosatellites were considered to exhibit 
microsatellite instability. In addition, a sub-set of 71 fresh colorectal tumours was 
analyzed at three or more marker loci and, in 37 of these cases normal DNA was 
available which allowed a more accurate assessment of microsatellite instability 
by the comparison of peak patterns obtained for normal and tum our DNA as 
shown in Figure 12.
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FIGURE 12
Microsatellite analysis of a colorectal tumour sample and normal epithelium 
from the same patient, using di-nucleotide repeat marker D2S123.
TUMOUR
1200  -
600  -
NORMAL
1200  -
600  -
PCR was performed using the appropriate primer pair for D2S123, w ith the 5' 
primer fluorecently tagged. The PCR conditions are described in Materials and 
Methods, section 2.4.7. Dilutions of PCR products were made in denaturing 
buffer and analyzed in a 6% polyacrylamide denaturing gel on an ABl 377A  
Genotyper. Samples were: Upper panel, DNA from Fresh tum our C108; Lower 
panel, DNA from Normal colon epithelia from patient C108.
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TABLE 10
Microsatellite status of the colorectal cancer cell lines and fresh 
colorectal tumour samples that exhibited a 
P2 -microglobulin mutation.
CELL LINES
Sample
LoVo
DLD-1 (1) 
HCT-15 (1) 
SW48 
C84
GP2d (2)
GP5d (2)
HRA-19
HCA-7
LS174T
LS411
Bo-Microglobulin Microsatellite 
mutation status’^
+
+
+
+
+
+
+
+
Unstable
Unstable
Unstable
Unstable
Unstable
Unstable
Unstable
ND^’^
Unstable
Unstable
Unstable
FRESH TUMOURS
C14
C43
C84T
C108
StM78
StM185
3624/91
3822/93
13971/92
+
+
+
+
+
+
+
+
+
Stable
Stable
Unstable
Unstable
Stable
Unstable
Stable
Unstable
Unstable
"^Microsatellite status determined by instability at two or more loci. 
For details see Materials and Methods, section 2.4.7.
** ND -  Not Done
(1) DLD-1 and HCT-15 are derived from the same patient
(2) GP2d and GP5d are derived from the same patient
96
Ten of the 40 colorectal cell lines analyzed were judged to have multiple peaks, at 
two or more marker sites, and were called microsatellite unstable. Seven of these 
cell lines contain mutations in the p2 "i^icroglobulin gene and three contained no 
p2 -microglobulin mutations, see Table 10.
Seventy one DNA samples, from fresh colorectal tumours and including the 37 
samples where corresponding normal material was available were analyzed. 
Seven (10%) showed evidence of alterations at two or more microsatellite loci 
and were considered to exhibit microsatellite instability. The microsatellite status 
of the fresh colorectal tumours that contained a mutation in the P2 -microglobulin 
gene is shown in Table 10.
3.3 A mutation in the HLA-A"^0101 gene found in the colorectal 
cell line HCA-7.
The colorectal cell line, HCA-7, and the normal B lymphoblastoid cell line, EVA- 
1224 (derived from the same individual) were HLA class I typed at the DNA 
level using an ARMS-PCR based assay, followed by detection using the AMDI 
technique, as outlined in Materials and Methods section 2.4.6. A series of 96 allele 
specific primers was used for typing and the results shown in Figure 13(A&B). 
At the HLA-A locus HCA-7 and EVA-1224 both type as -A^^OlOl, -A*0201 and 
both have the same alleles at the HLA-B and C loci, see Figures 13(A&B).
To investigate HLA-Al expression at the protein level, samples from the cell 
lines HCA-7 and EVA-1224 were subjected to isoelectric focusing. Cultures from 
these cell lines were metabolically labeled with [^^SjMethionine for 17 hours as 
described in Materials and Methods, section 2.5.3. After harvesting and lysing 
the cells, lysates were pre-cleared by adsorption with Pansorbin A, then HLA 
class I products immunoprecipitated with antibody W6/32, followed by analysis 
on an isoelectric focusing gel containing ampholines to create a pH  gradient. 
Bands were detected by autoradiography. As shown in Figure 14, HCA-7 and
97
FIGURE 13A
HLA typing of normal Lymphoblastoid cell line EVA-1224 derived from 
the same patient as colorectal cancer cell line HCA-7
A Locus
I
X
I
Primer mix
B Locus
f f l œ
Primer mix
C Locus
Primer mix
For legend to Figure 13A, see page 78
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FIGURE 13B
HLA typing of the colorectal cancer cell line HCA-7, derived from 
the same patient as Lymphoblastoid cell line EVA-1224.
A Locus
Primer mix
B Locus
I
Primer mix
C Locus
1 1
Primer mix
For legend to Figure 13B, seepage 78
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FIGURE 14
Isoelectric focusing of HLA class 1 and P2 -iriicroglobulin in colorectal 
cancer cell line HCA-7 and corresponding normal B cell line EVA-1224.
IICA-? tVA-1224
•HLVA2
— p-lM
—HLVBÎ1
HLA-B37
HCA-7 and EVA-1224 cells were metabolically labeled with [35S] methionine 
and immunoprecipitates isolated using antibody W 6/32 as described in Materials 
and Methods, section 25.3. The immunoprecipitates were analyzed on a 
single dimensional isoelectric focussing gel.
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EVA-1224 both express HLA-A2, HLA-B51 and -B37 and p2 -microglobulin, but 
HLA-Al is not detectable in HCA-7.
These data confirming lack of expression of the protein for HLA-Al in HCA-7 
and good evidence that it contained the gene, lead to an investigation at the 
mRNA level for HLA-Al message. Preparations of mRNA were isolated from 
both HCA-7 and EVA-1224 cell lines according to the protocol described in 
Materials and Methods, section 2.4.1. RT-PCR was then perform ed, initially, 
using Random Hexamer Primers in the Superscript Reverse Transcriptase First 
strand synthesis system, followed by PCR using allele specific primers for HLA- 
A^^OlOl (and HLA-A'^0201 for control purposes) as described in Materials and 
Methods, section 2.4.5. Figure 15 shows the different primer combinations used 
for mRNA analysis and their relative positions along the mRNA sequence. This 
approach revealed that HCA-7 contained only a short length of message for 
HLA-A*0101, compared to probable full-length message seen in EVA-1224 (see 
Figure 16). The data imply that the message for HLA-A*0101 in HCA-7 is intact 
from the beginning of exon 1 to at least the first half of exon 3, but 3' from here is 
missing. Both the cell lines, however, appear to have full-length messages for 
HLA-A^0201.
In the first 12 bases of HLA-A’^ 0101 exon 4 the sequence contains a run of 7 
repeated cytidine (C) residues: 5'—CACCCCCCCAAC—3'. In certain rare 
individuals this region has been shown to include an additional cyditine, 
increasing the run of cytidines to eight (Bunce et al., 1999). Individuals w ith this 
frame shift of an additional cytidine have been reported not to express the gene 
product and the allele concerned has been designated "null". Primers designed 
to analyze this region by ARMS-PCR were therefore used to examine the 
beginning of exon 4 in HLA-A*0101 in the cell lines HCA-7 and EVA-1224. Assay 
conditions are described in Materials and Methods, section 2.4.2. The preliminary 
results indicated that EVA-1224 typed as having an HLA-A'^OlOl allele and 
HCA-7 an HLA-A*0101 "null" allele, as shown in Figure 17.
Sequencing of this cytidine repeat region was performed by PCR using HLA-A 
locus specific primers (ATCTCTCTCCCCCTCTCAC [intron 3, bp 362-380]
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TABLE 11
Sequencing of clones from PCR products of the colorectal cancer cell line 
HCA-7 and lymphoblastoid cell line EVA-1224, which are derived from
the same individual.
Cell line and
Clone number Sequence Allele
HCA-7 1 CAGACCCCCCCCAAGA Al"NulT
2 CAGACCCCCCCCAAGA Al"NulT
3 CAGACGCCCCCAAAA A2
4 CAGACGCCCCCAAAA A2
5 CAGACCCCCCCCAAGA Al"NulT
6 CAGACGCCCCCAAAA A2
7 CAGACCCCCCCCAAGA Al"NulT
8 CAGACCCCCCCCAAGA Al"NulT
EVA 1224 1 CAGACGCCCCCAAAA A2
2 CAGACGCCCCCAAAA A2
3 CAGACGCCCCCAAAA A2
4 CAGACCCCCCCAAGA A1
5 CAGACGCCCCCAAAA A2
6 CAGACCCCCCCAAGA A1
7 CAGACGCCCCCAAAA A2
8 CAGACCCCCCCAAGA A1
106
FIGURE 18
Sequence data from the cytidine repeat regicn of HLA-A*0101 of representative 
clones from HAC-7 and EVA-1224.
HCA-7
a
EVA-1244
fl [  C C C C C C fl fl G fl C fl
HLA-A* locus ARMS-PCR products from HAC-7 and EVA-1224 were cloned in the PCR-Script AMP 
cloning system and resulting clones sequenced using the Big-Dye protocol and analysed on an ABI377 
sequencer. (See Materials and Methods, sections, 2.4.2,2.4.9 and 2.4.10.) Representative sequence 
traces for HLA-A*0101 are shown for HCA-7 upper panel and EVA-1224, lower panel.
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forward prim er and CTGCCATGTGCAGCATGAG [exon4, bp 846-865 reverse 
primer]) in the conditions detailed in Materials and Methods, section 2.4.2. This 
was followed by cloning in PCR-Script™ Amp Cloning System and sequencing 
using the Big-Dye automated sequencing technique as described in Materials and 
Methods, sections 2.4.9 and 2.4.10 respectively. Eight clones were sequenced 
from both EVA-1224 and HCA-7 and the results are shown in Table 11. Three of 
the clones from EVA-1224 sequenced as HLA-A'^OlOl, containing 7 repeated 
cytidines, and the other five as HLA-A*0201. In HCA-7, three of the eight clones 
sequenced as HLA-A'^0201 whilst the remaining five clones showed a sequence 
containing 8 repeated cytidines (see Figure 18) which is similar to the HLA- 
A^0101"nuir' allele.
3.4. Re-expression, using an inducible expression system, of HLA 
class I and P2-microglobulin.
The plasmids (pcDNA-P2 M), containing an insert of p2 "^^icroglobulin including 
leader peptide sequence, and (pcDNA-p2M-15A2), containing leader peptide 
sequence, p2 -microglobulin, a 15 amino acid linker and HLA-A’^ 0201, have been 
reported earlier (Toshitani et al., 1996). The restriction sites of these constructs 
were changed to 5' Nhe I and 3' Hind III as described in Materials and Methods, 
section 2.4.11, followed by ligation into the vector (pIND). These plasmids were 
named (pIND-p2 M) and (pIND-p2M-15A2) respectively. Mini preparations were 
grown up and used to confirm the sequence of each insert. The sequences are 
shown in Figure 19 (pIND-p2 M) and Figure 20 (pIND-P2M-15A2). Following 
confirmation of the sequences the plasmids (PIND-P2 M) and (pIND-p2M-15A2) 
were grown up as maxi preparations in an endotoxin free system as described in 
Materials and Methods section 2.4.12.
Confirmation that the plasm id (pIND-p2M-15A2) contained an insert that 
encoded for a protein of the expected size, was achieved by perform ing an in 
yffro-translation assay. The protocol used for the TnT coupled Reticulocyte 
Lysate system is described in section 2.4.13 of Materials and Methods. After
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separation of products by electrophoresis, autoradiography revealed a single 
band at approximately 57 kDa (see Fig 21 which shows results from duplicate 
experiments) and is the expected size, adding together 12 kDa and 45 kDa, for
p2 -microglobulin and HLA-A*0201 respectively. A similar in pztro-translation
assay was performed for the (pIND-p2 M) insert that confirmed a product of 12 
kDa, data not shown.
3.4.1 Transfections into the colorectal cell line, DLD-1.
The colorectal cell line DLD-1 lacks expression of HLA-A, B and C due to two 
non-complementary heterozygous mutations in the p2 -microglobulin gene (see 
section 3.1.1 above) and therefore provides a good candidate cell line for 
studying the re-express HLA molecules at the cell surface. This was attem pted 
using the ecdysone inducible expression system.
Prior to transfecting the colorectal cell line, DLD-1, a killing curve assay was 
performed to ascertain the concentration required for complete cell death when 
using the two selection agents Geneticin (G418) and Zeocin. Cultures of the cells 
were grown in increasing concentrations of the agents and cell viability counted 
after 10 days of exposure to the agents. From the data in Figures 22 and 23> 
concentrations of 1.5 m g/m l for G418 and O.lmg/ml Zeocin were chosen. (The 
Figures also show the killing curves for the cell line CHO used in later 
experiments, see section 3.4.3).
The plasmid (pIND-p2 M) and Ecdysone receptor plasmid (pVgRXR) were co­
transfected into the DLD-1 cell line and primary clones resistant to the selection 
agents, G418 and Zeocin, grown out as described in Materials and M ethods 
section 2.4.14. These primary clones were picked and sub-cultured in 96 well 
plates, in duplicate. One culture was stimulated for 24 hours with Ponasterone A 
(l|xM), whilst the second culture had no Ponasterone A added and served as an 
unstim ulated control. These duplicate cultures were then assayed by ELISA 
using antibody L368 (anti-p2 -microglobulin) according to the protocol in
111
FIGURE 21
Autoradiograph from an invitro translation assay of the (pIND-p2M15-A2)
construct.
Track 1 Track2 Track 3
—*
—
— M
—
The invitro translation assay was peformed as described in Materials and 
Methods, section 2.4.13 using the TnT coupled reticulocyte lysate system. 
Following the assay the products were electrophoresed on a 12.5% 
polyacrylamide gel and labeled products detected by autoradiography.
The assay was performed in duplicate (Tracks 1 and 2) and molecular weight 
size markers run in Track 3.
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Materials and Methods section 2.3.2. The data for DLD-1/(PIND-P 2 M) primary 
clones are shown in Figure 24.
A similar co-transfection of (pVgRXR) and (pIND-p2M-15A2), the plasm id 
containing the P2-microglobulin-HLA-A'^0201 construct, was perform ed and 
primary clones picked and assayed by ELISA as described above; data for these 
primary clones are shown in Fig 25.
From each of the transfections, two primary clones were chosen that grew well in 
selection medium and, from the ELISA data, contained some cells which reacted 
w ith the antibody L368 after stimulation and apparently expressed either P2 - 
microglobulin or the p2-microglobulin-HLA-A*0201 construct. These were clones
3 and 19 for DLD-l-(pIND-P2 M) and 18 and 24 for DLD-l-(pIND-p2M-15A2) (see
Figures 24 and 25). In an attempt to speed up the isolation of cells reactive with 
the antibody L368, clones were grown up and stimulated with Ponasterone A to 
express the constructs. Positive cells were then selected by staining the cells with 
antibody L368 followed by selection using magnetic beads coated with goat-anti 
mouse, as described in Materials and Methods section 2.4.15. Seven days after 
each magnetic bead sort the number of positive cells in the culture was estimated 
by immunofluorescence. Four rounds (of growing, stimulating and sorting) were 
performed for each clone and, as shown in Table 12, the number of positive cells 
appeared to increase with each additional sort.
On completion of four sorts w ith magnetic beads, the positively selected cells 
were grown for approximately 28 days, 4 passages, and then samples analyzed 
by ELISA assay. This was to check the responsiveness of the cells to Ponasterone 
A for construct expression. Similar treatment was performed with the negative, 
magnetic bead unselected, portion of the fourth sort. As can be seen from Table 
13 the two clones 18 and 24 from DLD-l-(pIND-P2M-15A2) were not responsive 
to Ponasterone A. The positives from the 4* sort of both these clones reacted with 
antibody L368 when they had not been stimulated with Ponasterone A. Similar 
results were seen after 7 passages (see Table 13). The negatives from the 4‘^  sort 
appeared not to react with L368. Magnetic beads did not efficiently sort clones
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TABLE 12
Analysis, by immunofluorescence, of DLD-1 transfected clones following 
stimulation for 24 hours with Ponasterone A (ImM) and sorting with
magnetic beads*.
Cell line (Construct) After After
Clone Number Pre-sort lf_sort** 4^ sort**
DLD-l-(pIND-p2M)
Clone 3 >1% 10% 90%
Clone 19 >1% 15% ND
DLD-l-(pIND-P2M-15A2)
Clone 18 >1% 10% 95%'*'
Clone 24 >1% ND 50%'^
* Clones were stained with L368 antibody and selected with Goat anti-mouse 
coated magnetic beads as described in Materials and Methods, section 2.4.15. 
One week later clones were analysed by immunofluorescence using antibody 
L368, followed by Goat anti-mouse FITC.
** Figures shown represent the number of cells positively staining (%)
+ Analysis performed using antibody W6/32.
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TABLE 13
Analysis by ELISA,* of clones of transfected DLD-1 cells after four sorts with
magnetic beads.
Construct-Clone After 4 passages
UNSTIM STIM'
After 7 passages
DLD-1- (pIND-p2M15-A2)
Clone 18 (Positives from sort)
Clone 18 (Negatives from sort)
Clone 24 (Positives from sort)
Clone 24 (Negatives from sort)
DLD-1- (pIND- P 2 M)
Clone 3 (Positives from sort)
Clone 3 (Negatives from sort)
Clone 19 (Positives from sort)
Clone 19 (Negatives from sort) 4000
UNSTIM STIM+
3813 3797 4000 4000
414 431 495 463
4000 4000 4000 4000
643 816 816 815
2662 2777 4000 4000
2252 2083 3444 3144
4000 4000 4000 4000
4000 4000 4000
* ELISA using antibody L368 as described in Materials and Methods, section 2.3.2. 
Results are shown as ELISA units ( Maximum reading 4000)
+ Stimulated with Ponasterone A as described in Materials and Methods and 
analysed 24 hours after stimulation.
119
from the DLD-l-(pIND-p 2 M) transfection as the data show little difference in the 
ELISA results for the positive and negative sorts (see Table 13).
3.4.2 Transfections into the cell line CHO.
The transfection experiments using the plasmids (pIND-p2 M) and (pIND-p 2 M- 
15A2) in an inducible expression system with the colorectal cell line DLD-1 failed 
to produce a stable clone that re-expressed HLA in response to the inducer 
Ponasterone A (see section 3.4.2 above). In an attem pt to test the inducible 
expression system in a cell line that was easier to grow and clone, a series of 
transfections was performed in the Chinese hamster ovarian cell line, CHO. To 
check that CHO would make a good candidate cell line to work with, it was 
assayed a) by ELISA with the antibody L368 (anti-p2 -microglobulin) and b) by 
immunofluorescence with W 6/32 (anti-HLA-A,-B&-C/P 2 -microglobulin) and 
BB7.2 (anti-HLA-A2). The CHO cells were negative in both assays w ith all 
antibodies. In addition, the concentration of selection agents G418 and Zeocin, 
required to kill all CHO cells in 10 days, was determined and found to be 
Im g /m l and O.lmg/ml, respectively (see section 3.4.2 and Eigures 22 and 23).
Either (pIND-p2 M) or (pIND-p2M-15A2) were co-transfected with the Ecdysone 
receptor plasmid (pVgRXR) into CHO cells and primary clones resistant to the 
selection agents, G418 and Zeocin, grown out as described in Materials and 
M ethods section 2.4.14. Prim ary clones were picked and sub-cultured in 
duplicate, in 96 well plates. One culture was stim ulated for 24 hours w ith 
Ponasterone A (l|iM ), whilst the second culture had no Ponasterone A added 
and served as an unstim ulated control. These duplicate cultures were then 
assayed by ELISA using antibody L368 (anti-P2 -microglobulin) as described in 
Materials and Methods section 2.3.2. Approximately 100 clones were assayed for 
each transfection and the clones with results above background are show in
Figure 26 for (pIND-P2M-15A2) and Figure 27 for (pIND-p2 M).
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One prim ary clone from each transfection was chosen to sub-clone, by limiting 
dilution, as described in Materials and Method section 2.4.16. The clones selected 
were those with the highest difference, from the ELISA data, between stimulated 
and background (unstimulated) duplicates. Primary clone 9 was chosen from the 
(pIND-p2M-15A2) transfection and prim ary clone 48 from (pIND-p 2 M). In the 
latter case there were several clones which demonstrated maximal readings for 
the ELISA assay (4000), but clone 48 had the lowest background (unstimulated) 
reading, see Figure 27. When the sub-clones had grown sufficiently to assay, they 
were set up in duplicate cultures, one being stimulated with Ponasterone A, and 
assayed by ELISA with antibody L368 as described above for the prim ary clones, 
and the other duplicate frozen for storage. Approximately 24 sub-clones were
screened in each case and the results for (pIND-P2M-15A2) clone 9 are shown in 
Figure 28 and for (pIND-p2 M) clone 48 in Figure 29. The best sub-clones were 
chosen by the same criterion used to select the primary clones. Thus, sub-clones 
9 /9 , 9/11 and 9/20 were selected from the (pIND-P2M-15A2) transfection and 
sub-clones 48/3 and 48/18 from the (pIND-p2 M) transfection.
The ELISA data indicated that the sub-clones could be induced to express a 
construct product that reacted w ith antibody L368, bu t these data did not 
differentiate between surface membrane and cytoplasmic expression. To address 
this, the sub-clones were initially induced with Ponasterone A for 24 hours, then 
stained by immunofluorescence with antibody L368 (details in M aterials and 
Methods, section 2.3.1). Sub-clone 9/20 showed strong positive reactivity on 95% 
of the cells, whilst sub-clones 9/9, 9/11, 48/3 and 48/18 were only very weakly 
positive on 5-25% of the cells. In addition, the sub-clones from (pIND-p2M-15A2) 
clone 9 were similarly examined with antibody BB7.2 (anti-HLA-A2) and again 
sub-clone 9/20 was strongly positive on 95% of cells and 9 /9  and 9/11 were only 
faintly reactive on 10-25% of cells. These immunofluorescence experiments were 
repeated and analyzed by Flow cytometry, the FACScan data being show n in 
Figure 30 for sub-clones of (pIND-p2M-15A2) clone 9 and Figure 31 for the two 
sub-clones of (pIND-p2 M) clone 48. These results indicate that the only clone 
inducibly expressing, at the cell surface, was (pIND-p2M-15A2) sub-clone 9/20
123
Ni
T5
•S
î
en
ON
I
?in
C2.i
§
I
t
sW
T30)t-f ■om 03
3 coE 3-t-jco £c3 0)gg □
m m
cr> w
o o o o o O O o o oo o o o o o O o oin o in o ID o in o inM3 M3 CN CN «—
(s;iun vsna) 89ei
co
n«N
g
03
:S
1
0>-r en
1 o> 'OT3 C ObO O hC
.S 3 BI i s.s en 73
X S>s u 03
ÎH enT3 O)
C < 1.3 (Cy g SX»
•S
1
SenfC
1
Co a
1
Ph
u 73.(U en
cn 03C B CC«s 03 nOa 1 3cT .S
< tn 73OlÔ ÿ. ,o
% 1 1
CO.
ô I •Ss■8 3
sB? <
g
c o 3
u NOT-4 w
TH
CN 73'V. 0 (Uo O en
" 0
i %
03i
C/) 1 1
1 1 I
b g UfO V<D(C'j-l •cOhii 3
y (Q
g
S
.g 1o 373o> ü
ON X> 030) 'C .y1$ iu Q 73
124
RI
g
1
î
In
Iî
ûS
i
I
I
I
Iw
■ O
0 )
-*-■ • o
CD eu
-t—'
3 m
h 3
I - '
CD
E
C •*-f
3 ( 0
El □
------
o O o o o o o o o
o o o o o o o o
o i n o i n o i n o i n
T f r o CM CM — ■»—
(S lIN n VSI13) 09£1
T3
•ri
uen
’S
.§
n
m
g rv(NO 3 C
•■2 Tl O
â ec ■g
13
%
«
en
•J3 13
c o 1 1 1
1^ x>TJ
C
i
2
-g ce
CD
-6 1 1
ID i
<
eu
Sice
(/)(Q g S
S .Sc en 13o 2 eu
K> •J3U 1
Ph V
CM Q£LU
tD 1 1
1
%
—
E
3
Z 1
13
a
J3
3 3o
LU
Z i 1 î
en o ê
o o
. J
u
§
1
ç/ü
g
bO
1
3
u
a g •§
r ^ 3 ■£ î 3
en 'o
i
CD 'S CD G
c \D w
’“ i
i n %
%
en
(N
C 1
1 ■•g t0) c
K)
h
en
en
ce
13
ec T3 C
CM .§ X
ce
fX
1
1
V I
S
C u
fC 13
2 Si
. 2 ce
e » >H
Oj ces
g S "%
G  . S §
125
FIGURE 30
FACS ANALYSIS OF SUB-CLONES OF (pIND-P2MI5-A2) USING 
ANTIBODIES L368 (anti-g^M) AND BB7.2 (anti HLA-A*2).
Subclones were stimulated with Ponasterone A and stained with antibody as described in 
Materials and Methods. Control ( ' ) L368 (m— ) BB7.2 ( ----------• T
Sub-clone
9/9
FL1-H
Sub-clone
9/11
Sub-clone
9/20
Control
Unstimulated
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FIGURE 31
FACS ANALYSIS OF SUB-CLONES OF (pIND-^M) USING 
ANTIBODy L368 (anti-P^M).
Subclones were stimulated with Ponasterone A and stained with antibody as described in 
Materials and Methods. Control ( ---------- ) L368 ( — ).
Sub-clone
48/3
Sub-clone
48/18
8
ai-H
Control 
Unstimulated
FL1-H
127
which, with reactivity seen with both antibodies L368 and BB7.2, was most likely 
expressing the construct (p2-microglobulin-HLA-A*0201).
Confirmation that (pIND-p2M-15A2) sub-clone 9/20 was expressing the (P2 - 
microglobulin-HLA-A'^0201) construct was achieved by W estern Blotting. 
Duplicate cultures of sub-clone 9/20 were established, then one culture 
stimulated with Ponasterone A for 24 hours, while the other culture contained 
m edium  only and served as an unstimulated control. Then the cultures were 
harvested, counted and lysed. Samples of lysates, with equivalent cell numbers, 
were then electrophoresed (in reducing conditions) by SDS-PAGE, following by 
overnight transfer and probing with antibody L368 as described in Materials and 
Methods section 2.4.2. The autoradiograph shown in Figure 32 detects a band at 
approximately 57 kDa in the stimulated sub-clone 9/20 track, which is absent in 
the unstimulated track. This band is the same size as the product seen in the in 
vitro translation experiment run w ith the plasmid (pIND-p2M-15A2) prior to 
transfection (see Figure 21). The normal EBV transformed B cell line, Bristol-8, 
was included in the Western Blot (Figure 32) for control purposes, and exhibits a 
band at approximately 12 kDa, which is the expected size for p2 -microglobulin 
when run in reducing conditions in SDS-PAGE.
Expression of the (p2-microglobulin-HLA-A’*’0201) construct by sub-clone 9/20 
was investigated with respect to the concentration and time scale of stimulation 
with the inducer Ponasterone A. Concentrations of Ponasterone A, ranging from 
O.OOlpM to lOpM were added to a series of duplicate cultures of sub-clone 9/20. 
After 25 hours the clones were assayed by ELISA, using the antibody L368 as 
described in Materials and Methods, section 2.3.2. The results, shown in Figure 
33, reveal that at very low concentrations, between O.OOlpM and O.OlpMvery 
little induction is seen after 25 hours, bu t at concentrations above IpM , 
maximum readings are seen in the ELISA assay. A similar series of duplicate 
sub-clone 9/20 cultures, with concentrations of Ponasterone A ranging from 
0.25jiM to IpM, was monitored at 0,1, 2,4, 8,18,24 and 30 hours after adding the 
inducer. Stimulation was again m easured by ELISA using antibody L368. 
Detectable reactivity with L368 was seen after two hours, and by approximately 
18 h o u rs  the  low est co n ce n tra tio n  of P o n a s te ro n e  A u se d
128
FIGURE 32
Western Blot of CHO sub-clone 9/20 cells for inducible expression of the 
(PIND-P2 MI5 -A2 ) construct when stimulated with Ponasterone A.
Track 1 Track 2 Track 3 Track 4
160 kDa
105 kDa  
75 kDa
50 kDa
35 kDa
30 kDa
25 kDa
15 kDa
10 kDa
Cells were counted and lysed in RIPA buffer as described in Materials and Methods,section2.5.1. 
for Western Blotting, 1 x 10^  cell equivalents were run in each track on an 18.5% polyacrylamide 
SDS gel and transferred and probed with antibody L368 as outlined in Materials and Methods 
section 2.52. Detection was by ECL.
Samples were: Track 1, Molecular weight markers; Track 2 Bristol-8 normal B cell line, used 
as control for endogenous p2 inicroglobulin; Track 3, CHO (pIND-P2ml5-A2) sub-clone 9, 
unstimulated control; Track 4 CHO (pIND-P2ml5-A2) sub-clone 9 stimulated for 24 hours 
with Ponasterone A (l|im) before harvesting the cells.
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(0.25|iM) had induced a maximum response in the ELISA (see Figure 34). 
Inducible expression on the cell surface was also analyzed w ith respect to time 
and concentration of inducer. A similar series of experiments to those just 
described, was perform ed using different times and concentrations of 
Ponasterone A, and the cells then examined by immunofluorescence using 
antibody W 6/32, followed by Flow cytometric analysis in a FACScan. Surface 
expression of the (p2-microglobulin-HLA-A*0201) construct was see after 12 
hours with IpM  Ponasterone A, see Figure 35, panel B. Ponasterone A at O.lpM 
induced little or undetectable amounts of the construct on the cell surface after 24 
hours of culture in the presence of the inducer (Figure 35, panel D).
To examine the functional capability of the (p2-microglobulin-HLA-A'^0201) 
construct at the cell surface, a stimulated sample of sub-clone 9/20 was tested as 
targets in a cytotoxic T lymphocyte assay. The target cells w ere initially 
established as duplicate cultures of sub-clone 9/20 cells (together w ith duplicate 
cultures of untransfected CHO cells, to serve as negative controls). One of each 
duplicate culture was stimulated with Ponasterone A for 24 hours as described in
Materials and Methods section 2.3.3. After labeling the cells w ith ^^Cr, half of
each cell preparation  was incubated w ith  influenza A m atrix  pep tide 
(GILGFVFTL) for 1 hour (see section 2.3.3), and half remained untreated for 
control purposes. Effector cells were the Human HLA-A2 restricted, influenza A 
matrix peptide specific CTL line, PG (Gotch et al., 1987). The CTL assay was 
performed as described in Materials and Methods section 2.3.3 using E:T ratios 
from 10:1 to 1.25:1. As can be seen from Figure 36 the stimulated, peptide pulsed 
sub-clone 9/20 cells acted as efficient targets for the PG effector cells, w ith 
approximately 50% lysis, at the highest E:T ratio. Control unstimulated sub-clone 
9/20 cells (with or w ithout peptide pulse) and stimulated non-peptide pulsed 
sub-clone 9/20 cells were not lysed by the effector PG cells. In addition, the 
control untransfected CHO cells, however treated, failed to be lysed in the assay 
by PG effector cells, see Figure 37.
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CHAPTER 4
DISCUSSION
4.1 Mutations in the pj-microglobulin Gene.
At the time this thesis was started (1994) there were lim ited data on the 
frequency of loss of HLA class I expression in colorectal, and other tumours. 
F urtherm ore, m ost of the available inform ation  w as derived  from  
immunocytochemical analysis using monomorphic, and later polym orphic, 
antibodies. The exception was the Burkitts lymphoma cell line, Daudi, in which 
Goodfellow et al. suggested the lack of HLA class I expression in human-mouse 
hybrids was due to a loss of p 2 -microglobulin caused by a genetic fault on 
chromosome 15 (Goodfellow et al., 1975a). Later, this genetic fault was shown to 
be a mutation in the initiation codon of the p2 "^^icroglobulin gene, and coupled 
w ith LOH, led to the loss of p2 "naicroglobulin and hence the loss of HLA class I 
expression (Rosa et al., 1983). The colorectal cell line, LoVo, was also shown to 
lack p2 -microglobulin expression, leading to the absence of HLA class I on the 
cell surface, but the mechanism behind this loss had not been explained (Brodsky 
et al., 1979b; Travers et al., 1982).
In this thesis, therefore, the starting point was to devise an assay for screening 
cells for m utations in the p2 -microglobulin gene. The approach used was to 
amplify by PGR, approximately 300 bp regions of genomic DNA, followed by
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analysis with the SSCP technique and then sequencing any candidates identified 
by SSCP. In the initial study of 52 colorectal cell lines, 8 were identified with 
m utations in the p2 "iriicroglobulin gene, giving a frequency of 15.4% in the cell 
lines. If cell line pairs are taken into account (DLD-l/HCT-15 and GP2d/GP5d 
are pairs of cell lines from the same patients), 6 tum ours from a total of 43 
patients (see Table 4) show p2 -microglobulin mutations, representing a frequency 
of 14% in the colorectal tumour derived cell lines. In two large studies (99 and 70 
cases) of colorectal tumours, using immunocytochemistry, reduced or total loss 
of HLA class I was reported in 17% and 23% of tum ours respectively 
(Kaklamanis et al., 1992; Lopez-Nevot et al., 1989). These studies took into 
account both total and reduced levels of HLA class I and losses of individual 
HLA class I alleles, therefore, the lower incidence of m utations in p2 - 
microglobulin, in this study, is in keeping with these data.
In the study of 280 fresh tumours, including colorectal, melanoma, breast, ovary 
and lymphoma (see Table 7) ten mutations in p2 -microglobulin were found by 
SSCP (9/147 colorectal carcinomas and 1/133 non-colorectal tumours). Thus, 
among the tum ours analyzed, P2 -microglobulin m utations were significantly 
(p<0.02) overrepresented in the colorectal carcinomas. In all of the fresh tum our 
DNA samples, both the wild-type and m utated p2 -microglobulin alleles were 
present. This may indicate heterozygosity for p2 -microglobulin m utations or 
m ight reflect contamination w ith norm al tissue. However, 7 of the 9 fresh 
tum our samples identified with p2 -microglobulin mutations were also examined 
by immunocytochemistry. In three of these samples the tum our cells showed no 
reactivity w ith antibodies W 6/32 and BBM.l, see Table 9, indicating that these 
tum ours were probably hom ozygous for their respective p2 -microglobulin 
mutations, but the others were presumably heterozygous.
The identification of defects in DNA mismatch repair (or mutator phenotype) has 
been linked with microsatellite instability. In the panel of 40 colorectal cell lines, 
10 demonstrated microsatellite instability. Seven of these contained m utations in 
the p2 -m icroglobulin gene (see Table 10, HRA-19 was not analyzed for 
microsatellite instability). Three lines exhibited microsatellite instability bu t did
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not have mutations in P2 -microglobulin. However, one of these, HCA-7, has been 
reported not to express HLA-Al, but a normal lymphoblastoid B cell line from 
the same patient expressed HLA-Al (Smith, 1989) and LS174T lacks expression 
of HLA-A2. Both the colorectal cell lines HCA-7 and LS 174T type positively, at 
the DNA level, for the respective alleles that are not expressed (Browning et aL, 
1996). A third colorectal cell line, LS411, shows loss of expression of HLA-A2 and 
HLA-Al 1, when compared to a corresponding normal lymphoblastoid B cell 
line, RN, so that in this case two genetic events have occurred. LS411, when 
typed at the DNA level, showed the absence of an HLA-Al 1 gene, indicating 
gene loss perhaps due to LOH, but the HLA-A2 gene was present. However, 
when LS411 was analyzed with antibody BB7.2 (recognizing HLA-A2, -A69) in 
an ELISA assay, no reactivity was seen, suggesting selective loss of expression of 
HLA-A2 (Browning et al., 1993).
In the study of fresh colorectal tumours, 71 were analyzed for microsatellite 
instability and 7 (10%) showed evidence of alterations at two or more 
microsatellite loci and were judged to be unstable. These observations are 
consistent w ith an earlier study, reporting 10-15% of sporadic colorectal 
carcinomas exhibiting microsatellite instability (Peltomaki et al., 1993). No 
instability was detected among the normal DNA samples (<3%). Instability was 
observed in five of the nine tumours with p2 "^riicroglobulin mutations, see Table 
10. These include tum ours that are hom ozygous or heterozygous for p2 - 
microglobulin loss, as well as apparent heterozygotes in which p2 -microglobulin 
expression was considerably reduced, see Table 9. Mismatch repair defects are 
therefore significantly more common amongst tumours w ith p2 -microglobulin 
mutations (5/9) than in colorectal carcinomas in general (p<0.01). Microsatellite 
instability has been reported to be infrequent in melanoma (Quinn et al., 1995) 
and breast cancer (Yee et al., 1994) and is consistent w ith the m uch lower 
frequency of P2 -microglobulin mutations (1/133) found in these tum ours, and 
other carcinoma types, in the study.
If the data from colorectal cell lines and fresh tumour studies are combined, then 
16 mutations were identified in 15 individual tumours. (Several pairs of cell lines
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were used in the study and some samples exhibited two different mutations.) 
Ten m utations were seen in the Leader pep tide/exon 1 region, 7 of which
occurred in the same 8 bp (CT)^ repeat sequence. Five of the seven were
microsatellite unstable. One of the seven (tumour C14) was microsatellite stable 
and (HRA-19) was not analyzed for instability. It does appears, therefore, that
this 8 bp (CT) 4  repeat sequence is particularly vulnerable to errors in DNA
replication, especially slippage of 2 or 4 bp, and is not efficiently repaired in cells 
show ing m icrosatellite instability. Instability at m icrosatellite sites is a 
recognized marker for mismatch repair-defects. An increased m utation rate 
alone is unlikely to account for the observed frequency of p2 "iï^icroglobulin 
m utations in mismatch repair-defective colorectal tum ours. Of 16 m utations 
identified in the p2 -microglobulin gene, from 15 tumours, at least four did not 
demonstrate microsatellite instability (the cell line HRA-19 was not analyzed for 
instability). The high frequency of p2 -microglobulin mutations among tum ours 
w ith a normal spontaneous mutation rate implies the contribution of a second 
factor influencing the emergence of tumours with mutations in p2 -microglobulin. 
In both the colorectal cell lines and fresh tumours studied, the m utation was 
associated w ith a significant reduction in expression of p2 -microglobulin (see 
Tables 6 and 9). The selective advantage gained by consequent loss of expression 
of HLA class I molecules at the cell surface with the loss in ability to present 
HLA-associated antigens is therefore the most likely contributing factor. The 
prim ary  role of HLA class I /p  2 -m icroglobulin complexes, in im m une 
surveillance, is the presentation of peptide antigens to circulating cytotoxic T 
lymphocytes and the loss of this role would give the tum our a distinct survival 
advantage from T cell attack. Not all the tum ours in the study w ith  P2 - 
microglobulin abnormalities exhibit complete loss of p2 -microglobulin expression 
and several cases of heterozygous mutations were identified. These tum ours 
appear to express intermediate levels of HLA class I (see Tables 6 and 9) which in 
itself might be a selective advantage to these tumours by limiting the efficiency 
of peptide presentation. This could be particularly relevant in tumours exhibiting 
microsatellite instability where increased numbers of potential peptide antigens 
are generated.
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4.2 Mutations in specific HLA class I alleles.
The colorectal cell line HCA-7 has been of some intrigue since the report by Mark 
Smith that it lacked expression of HLA-Al, but that a corresponding normal B 
lym phoblastoid cell line, EVA-1224, derived from the same patient, clearly 
expressed this allele (Smith, 1990). He indicated that data from both ELISA and 
immunocytochemical assays, using antibody Mabl42.2 (which recognizes HLA- 
A l [Dr. S. Radka and Genetic Systems]), supported the suggestion that the 
colorectal cell line had selectively lost expression of HLA-Al. Stimulation with 
ylFN increased HLA-A2 expression in both cell lines, but after stimulation for 24 
hours, the expression of HLA-Al could not be re-established on HCA-7 cells. 
Later, w hen an HLA-A locus typing system had been developed, based on 
typing the DNA using allele specific primers in PGR, Browning et al showed that 
both HCA-7 and EVA-1224 typed for HLA-Al and -A2 and suggested that the 
loss of HLA-Al expression in HCA-7 was due to some other mechanism than 
gene loss (Browning et al., 1993). The HLA-A locus typing of these two cell lines 
was repeated using the AMDI technique, with additional data for HLA-B and C 
loci showing identical typing for both cell lines, confirming they are derived 
from the same individual (see Figure 13A&B).
In this thesis, the genetic event leading to the loss of HLA-A'^OlOl expression in 
HCA-7 has been identified as an insertion of an additional cytidine residue into a 
run of 7 cytidines (bp 621-627), located at the beginning of exon 4 (Figure 18 and 
Table 11). Investigation of the mRNA, using a series of allele specific primers for 
the analysis, indicated that a short message for HLA-A*0101 was seen in HCA-7, 
compared to an apparent full length in EVA-1224. (The primers used for this 
assay covered the HLA-A'^OlOl gene from the middle of exon 2, at the 5' end, to 
beyond exon 8 in the untranslated region, 3' to exon 8 [see Figure 15].) In HCA-7 
the message is probably the length of the first three exons of HLA-A'*’0101, 
because with primers AL-16 and AL-x, a RT-FCR product was present, bu t w ith 
primers AL-16 and 61998,46992 and HLA3UTA no amplicon was seen in the RT-
FCR, as shown in Fig 16. In exon 4 the (C)y island is next to a (GA) which
contributes to the splice site between exons 3 and 4. It is therefore plausible that
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the insertion of an additional cytidine into this (C)y run will have a negative
influence on the splice site formation, leading to a short message being 
translated. By comparison both cell lines appear to contain full-length messages 
for HLA-A^0201.
The insertion of a cytidine into the {C)j  sequence, at the beginning of exon 4 of
HLA-A*^0104, has been noted (Laforet et al., 1997) and the individuals carrying 
this HLA-A*0104"null" gene lack expression of the allele product on the surface
of their cells. A similar insertion of a single cytidine into this (C)y island has also
been reported for HLA-A*2411"nulT' (Magor et al., 1997). In these cases the 
cytidine insertion has been suggested to be the result of slipped-strand 
mispairing (Parham, 1997). The finding here, in the colorectal carcinoma cell line
HCA-7, of a cytidine insertion into the {C)y sequence is more likely to be the
result of an un-repaired mismatch, that occurred during DNA replication, since 
the cell line has been reported to carry the m utator phenotype (Branch et al.,
1995). A lthough HCA-7 appears to have the HLA-A’^ 0101"null" allele, the 
corresponding normal B cell, EVA-1224, clearly types as HLA-A*0101. Therefore, 
strictly speaking, HCA-7 carries a m utated HLA-A*0101 gene w ith the same 
sequence as that proposed for the HLA-A*0101"null" allele.
The cytidine repeat sequence at the beginning of exon 4 in the HLA class I is 
interesting when looking at the different alleles. The HLA-A*^ loci fall into two 
groups in this region, HLA-A^Ol, H I, ^23, H4, *30, *31, *36, *80 and *3303
alleles have the (C)y sequence in this region, whilst most other HLA-A* alleles
have a (C)g repeat at this point. HLA-B* alleles have 5, 6 or 7 (C) repeats and 
some of the *C alleles only have 4 repeated (C)'s. The risk, therefore, of a ''null" 
allele being created may be hierarchical amongst the HLA alleles according to the 
num ber of cytidines in this region (Bunce et al., 1999). If this is true for the 
appearance of "null" alleles, then there is the possibility that, especially in 
mutator phenotype positive tumours, this tendency will be the same and HLA-A 
alleles may be mutated more frequently than HLA-C alleles.
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4.3 Re-expression of HLA and p2-microglobulin.
Many defects in the expression of HLA and other molecules involved in the HLA 
pathway have been reported in tumours and these defects have been attributed 
to selection for escape from T cell immune attack (Bodmer et ak, 1993). Such 
changes include transporter defects leading to the loss of effective antigen 
processing as described in the cell lines RMA-S and .174T (Cerundolo et al., 1990; 
Townsend et al., 1989). Several early attempts to express MHC constructs have
been reported. Mottez et al. were able to express a mouse K^/P 2 -microglobulin
construct in monkey COS-1 cells and demonstrate surface expression by 
specific antibodies and the binding of HIV viral peptides that had previously 
been shown to bind strongly to native (Mottez et al., 1991). Similarly, surface
expression of a mouse H-2D^/p2-naicroglobulin was shown on KJ29 hum an
kidney carcinoma cells after transfection of a single gene construct. In this case 
the product of this construct was demonstrated to be capable of presenting an 
HIV gplOO peptide, pl8I10, by pulsing the transfetced cells w ith peptide, then
showing specific cell lysis by the H-2D^ restricted T cell hybridoma, B4.2.3 (Lee
et al., 1994).
The hum an colorectal cell line, DLD-1, was known to completely lack expression 
of HLA-A, B and C genes, although at the time, the underlying genetic defects 
leading to this loss of expression were unknown (Smith, 1990). This cell line has 
been useful in constructing models for re-expressing HLA molecules and for 
studying the functional contribution of other transporters, proteasom es and 
associated molecules in the pathway of antigen presentation by the HLA system. 
Studies using DLD-1 and a single chain HLA-A*0201 /  p2 -microglobulin construct 
showed surface expression of the construct with functional capabilities. This was 
demonstrated in two ways, first by exogenously pulsing the transfected DLD-1 
cells with a flu matrix 1 peptide antigen (M58-66), followed by specific lysis in a 
CTL assay using a T cell clone which recognized the flu antigen in an HLA-A2 
restricted manner. Additional functional evidence was shown by endogenously 
infecting the tranfected DLD-1 cells w ith the recombinant vaccinia (Ml-Vac) 
product and showing specific lysis in a CTL assay using the same T cell clone.
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However, the CTL recognition was only detectable after stimulation of the DLD- 
1 cells with IFN-y, which was suggested indicated an underlying defect, other 
than the loss of HLA expression, in the antigen processing pathway (Toshitani et 
aL, 1996).
These experiments introducing HLA molecules into cells that normally do not 
express them, or re-expressing HLA molecules in tum our cells that have lost 
HLA expression due to a specific gene m utation, have been useful for 
understanding some aspects of the peptide antigen presentation pathw ay. 
However, in these experiments negative controls were always a compromise, 
being either untransfected cells or cells transfected w ith the em pty plasm id 
vector (Lee et al., 1994; Toshitani et al., 1996). With the advent of the Ecdysone 
Inducible Expression System, transfected cells constitutively express the DNA 
binding proteins RxR and VgEcR, but only express the gene of interest in the 
presence of an inducer, Fonasterone A (see Figure 5). In experiments using this 
system, the control cells take the form of transfected cells that are not exposed to 
the inducing agent (No et al., 1996).
Re-expression of HLA class I on the colorectal cell line, DLD-1, was attem pted 
using the Ecdysone Inducible Expression system with two constructs, one for p2 " 
microglobulin (pIND-p 2 M) and one for a single chain p 2 -microglobulin- 
(GGGGS)3linker-HLA-A*0201 (pIND-p2M-15A2). Initially, individual clones 
were isolated and analyzed by ELISA. Two clones from each transfection were 
selected, see section 3.4.2, and bulk cultures grown. Further selection of cells 
responsive to the inducer, Fonasterone A, was attempted using magnetic bead 
technology. After four rounds of magnetic bead selection, it appeared, as shown 
in Table 12, that the number of cells positively staining with antibody L368 (anti- 
p2 -microglobulin) had increased in each clone with additional rounds of the bead 
selection. However, it became apparent that the cells positively selected were, in 
fact, not responsive to the inducer, and had integrated the (pIND-p 2 M) and 
(pIND-p2M-15A2) plasmids in such a way that the expression of the constructs 
was permanently on. This was shown by growing representative samples of the 
bead-sorted clones in microtitre plates and stimulating w ith Fonasterone A and 
assaying by ELISA as performed in the initial analysis following transfection.
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Table 13 shows that after 4 bead sorts and culturing for approximately 4 weeks (4 
passages) and 7 weeks (7 passages) the unstimulated control cells expressed the 
respective constructs as strongly, by reactivity with antibody L368, as those cells 
exposed to the inducer. At this stage attem pts were m ade to clone these 
'perm anently on' cultures by limiting dilution to try and find a sub-clone that 
was responsive to the inducer. This was not successful (data not shown) and 
after screening over 500 sub-clones the attem pt was abandoned. A similar 
cloning by limiting dilution was performed with examples of the prim ary clones 
isolated post transfection and not bead sorted, but again no sub-clones 
responsive to the inducer were identified.
Following these unsuccessful attempts to express the single chain (p2M-15A2) 
and (P2 M) constructs in DLD-1 colorectal cells, using the Ecdysone inducible 
expression system, a second attem pt was made to establish this system in 
CHO.Kl Chinese hamster ovary cells. This line was chosen because of its ease to 
grow in culture and transfect, and additionally did not react w ith the antibodies 
L368 and W6/32. Using CHO cells, successful transfections of both (pIND-p2h4- 
15A2) and (pIND-p 2 M) plasmids was achieved and the initial clones isolated 
appeared to be responsive to the inducer, Fonasterone A. Following cloning by 
limiting dilution, two sub-clones from each of the (pIND-p2M-15A2) and (pIND- 
P2 M) transfections were identified and these demonstrated expression of the 
respective constructs to be under the control of the inducer, see Figures 26-29. 
Further analysis of these clones revealed that the stimulated (pIND-p 2 M) clones 
reacted positively w ith antibody L368 in ELISA, bu t were negative w hen 
analyzed by immunofluorescence and FACscan. This indicated that these sub­
clones, although expressing p2 m icroglobulin in the cytoplasm , w ere no t 
expressing it on the cell surface. One of the (pIND-p2M-15A2) sub-clones, 
num ber 9/20, however, showed expression of the construct on the cell surface 
and that this expression was under the control of the inducer. In addition, 
expression in this sub-clone was shown to be under the influence of both  
concentration and length of time of stimulation by the inducer, see Figures 33 
and 34.
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Cells from the (pIND-p2M-15A2) sub-clone 9/20 were stimulated to express the 
construct at the cell surface and were then pulsed w ith influenza A matrix 
peptide. Recognition of these cells was then achieved in a cytotoxic T cell assay
involving an HLA-A*2-restricted CD8^ T cell clone raised to the flu A matrix
peptide. Transfected, unstimulated sub-clone 9/20 cells, also pulsed w ith flu 
peptide were not recognized in this assay, see Figures 36 and 37.
Similar cytotoxic T cell recognition has been reported with the colorectal cancer 
cell line, DLD-1, stably transfected with the (pcDNA-P2M-15A2) plasmid and 
pulsed with the flu matrix peptide (Toshitani et al., 1996). In addition, the DLD-1 
transfectant, after treatment with ylFN, was able to present antigen (influenza 
matrix 1 protein, Ml-Vac) that had been introduced into cells by infection with 
recombinant vaccinia virus. This study extends the data by expressing the P2 M- 
15A2 construct in an inducible expression system and shows that the construct 
maintains a functional capacity. In earlier work wild type p2 microglobulin was 
introduced into DLD-1 cells by infection w ith recom binant vaccinia virus 
encoding the hum an p2 microglobulin gene. In this case only m arginal re­
expression of p2 microglobulin and HLA-A*2 was seen. If the DLD-1 cells were 
pre-treated with ylFN before infection, HLA class I was restored (Browning et al.,
1996). Such a finding was suggested to indicate that the DLD-1 cells also 
contained another defect in HLA class I expression and that defect m ight be in 
the TAP processing of antigen, since a similar defect in HLA class I expression 
had been reported in the cell line T2 (Salter and Cresswell, 1986). Peptide 
expression by HLA class I has now been achieved using a single chain construct
of peptide linked to the 5' end of p2 naicroglobulin with a (GGGS)^ spacer and the 
3' end of P2 microglobulin linked by a second (GGGS)g spacer to the a l  domain of
HLA-A*2 (Greten et al., 2002). In these experiments CD8^ T cells, raised against
the peptide, were shown to recognize COS cells transiently expressing the single 
chain product. This single chain construct has also been linked w ith a third
(GGGS)g spacer placed between the a3 domain of HLA-A*2 and an IgG l heavy
chain sequence. This complex has been expressed in J558L cells and the resulting
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proteins used to form multivalent complexes that have been used to isolate 
peptide specific CD8^ T cells from human peripheral blood.
4.4 Concluding Remarks.
Loss of p 2 microglobulin as an underlying cause for lack of all HLA class I 
expression has been reported in studies based on immunocytochemical analysis 
of colorectal tumours (Momburg and Koch, 1989; Rees et al., 1988; Smith, 1989) 
and colorectal cell lines (Arce-Gomez et al., 1978). The present study identifies 
some of the genetic events that lead to the failure of p2 microglobulin expression. 
Loss of p2 microglobulin expression has profound effects on peptide presentation 
to cytotoxic T cells because of the requirement of all HLA class I molecules to 
combine with p2 microglobulin for effective antigen presentation. The data here 
also indicates that loss or reduced p2 microglobulin expression can arise through 
mutation in the P2 microglobulin gene, and that this event is particularly likely in 
colorectal tumour cells with defects in DNA mismatch repair. These tum our cells 
are potentially prime targets for cytotoxic T cells because they will express many 
neoantigens derived from genetically altered proteins. Tumour cells that survive 
this imm une surveillance may have had to undergo a particularly  severe 
selective pressure to escape T cell killing through the loss of HLA class I 
expression.
Loss of HLA class I expression may also result from m alfunction of other 
molecules involved in the HLA class I assembly pathway. Failure to identify the 
presence of TAPI correlated with a lack of HLA class I expression at the cell 
surface in colorectal cancers (Kaklamanis et al., 1994) and cervical carcinomas 
(Cromme et al., 1994). Loss of tapasin has been investigated in the .220 B cell line 
and although HLA class I molecules have been detected on the cell surface they 
appear to be only poorly expressing a limited number of peptides, indicating that 
tapasin is crucial in peptide binding to HLA class I-p2 niicroglobulin moieties 
(Grandea et al., 1995). Lack of expression of calnexin, however, appears not to 
affect the expression of HLA class I-p2 inicroglobulin and normal presentation of
147
peptides was seen in the calnexin deficient cell line CEM-NKR (Scott and 
Dawson, 1995).
The loss of expression on tumours of a complete HLA class I haplotype, as a 
m eans of escaping immune surveillance, has been reported (Smith, 1989). 
Complete HLA class I haplotype loss was also seen in several colorectal cancer 
cell lines that were typed by PCR, at the DNA level (Browning et al., 1996). The 
underly ing  m echanism s suggested for these cases w ere chrom osom al 
nondisjunction  or m itotic recom bination. M onoclonal an tibodies w ith  
polym orphic reactivity have been used to record the loss of expression of 
individual HLA class I alleles in colon carinomas (Brodsky et al., 1979b; 
Kaklamanis et al., 1992; Smith, 1989). Different alleles can present different 
antigenic epitopes to cytotoxic T cells and therefore selective loss an individual 
HLA class I allele will have the consequences of reducing the peptide repertoire 
presented. A tum our expressing an epitope that elicitates a particularly severe 
cyotoxic T cell response would be under strong selective pressure to loose that 
expression which could be achieved by the loss of the relevant HLA class I allele. 
It has been suggested that this is evidence of immune selection (Brodsky et al., 
1979b).
Many support the hypothesis that loss of HLA class I expression can lead to the
failure of tum our cells to present peptide epitopes to CD8^ cytotoxic T cells
(Arce-Gomez et al., 1978; Bodmer, 1987; Branch et al., 1995), bu t this brings about 
a paradox, in that cells lacking expression of HLA class I are liable to attack from 
NK cells, whereas tumours appear to escape this form of imm une surveillance. 
The NK cells express a series of natural cytotoxic receptors (NCR), including 2B4 
and NKp80, which bind to ligands on tumour cells. These and other coreceptor 
interactions provide the 'on ' signal for NK activity, but in norm al cells an 'off' 
signal from the HLA-class I-specific inhibitory receptor appears to be stronger, 
when it interacts with HLA class I, preventing serious cell damage. In tum our 
cells lacking HLA class I, the 'on ' signal would be expected to dom inate. 
However, in these tum ours other unknow n ligands m ay in teract w ith  NK 
receptors involved in the NK cell-target recognition, and in the case of some
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tumours, these are still affective interactions providing an 'o ff  signal to the NK 
cells preventing tumour lysis (Moretta et al., 2001).
The clinical importance of HLA class I loss in colorectal carcinomas is largely 
unknown. There is no correlation between HLA class I loss and Dukes staging, 
which is still the most widely used prognostic indicator used in practice. One 
study, looking at the overall expression of HLA class I w ith antibody W 6/32, 
found no correlation post-operatively between tumour recurrence and HLA class 
I expression on the primary tumour (Moller et al., 1991). However, there is some 
evidence to suggest that tumours that have lost HLA class I expression are likely 
to have a poorer prognosis (Bodmer, 1987). These tum ours m ay be more 
"aggressive" and as they progress are more likely to acquire changes on their cell 
surface, in the form of tumour antigens, that could be recognized by cells of the 
immune surveillance system. As a result these tumours would be subjected to 
stronger selection by the development of immunity to cytotoxic T cell attack 
through reduced or lost expression of HLA class I and antigen presentation. 
However, in a recent study of colorectal tumours reduced expression of HLA 
class I was seen in 63% and complete loss in 7% (Menon et al., 2002). Reduced or 
absent HLA class I expression correlated with a lower tum our stage and longer 
disease-free survival. In this study most of the loss of HLA class I expression was 
attributed to mutations in p2 inicroglobulin and half of these mutations occurred 
in tumours exhibiting a m utator phenotype. The suggestion was m ade that the 
longer survival could be due to elimination of HLA class I negative cells by 
natural killer cells or by an attenuated tum our aggressiveness often seen in 
tumours with a mutator phenotype.
The m utator phenotype, characterized by DNA m ism atch repair defects, 
com bined w ith  a selective p ressure  have been associated w ith  the 
overrepresentation of mutations in the transforming growth factor-p receptor 
type II (TGF-p receptor II) in colorectal tumours (Markowitz et al., 1995). This 
gene also contains a series of repeated sequences that are subject to frameshift 
m utations in microsatellite unstable colorectal tum ours, leading  to the 
inactivation of the TGF-p receptor II. Endometrial tum ours are not norm ally 
responsive to the TGF-P factor and mutations in the TGF-p receptor II have rarely
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been found in these tumours (Myeroff et al., 1995). Thus the acquisition, in the 
colon carcinomas, of a mutation in a specific hotspot, in the sequence of TGF-p 
receptor II, and selective pressure were both required for the development of 
tumours with an altered genotype.
The loss of HLA class I expression, whether it be total loss due to mutations in 
p2 microglobulin or loss of a single HLA class I allele, appears to compromise the 
presentation of peptide epitopes to cytotoxic T cells. The results shown here 
demonstrate that these losses of HLA class I expression can be explained by 
genetic events both in the P2 microglobulin gene and in a specific HLA class I 
allele. Re-expression of HLA class I has been acheived by transfecting a hum an 
p2 microglobulin-HLA class I single chain construct into the CHO ham ster cell 
line, using an inducible expression system, and the expression of the construct 
demonstrated to be controlled by an inducer, Fonasterone A. The transfected 
stimulated CHO cells were capable of presenting an influenza A matrix peptide 
antigen, in an HLA-A2 restricted manner, to a human cytotoxic T cell clone. CHO 
cells expressing the p2 microglobulin-HLA class I single chain construct, using the 
inducible expression system, should be useful in the future for studying the 
pathway of peptide antigen presentation. The system could be used to pulse the 
transfected stim ulated CHO cells w ith different peptide antigens and to 
investigate the efficiency of presentation, in this caes, by HLA-A2. Furthermore, 
the CHO cells could be infected with viral antigens and upon stimulation with 
Fonasterone A, used to study peptide antigen processing involving proteasome 
and transporter molecules in addition to the p2 ^^kroglobulin/HLA complex. 
Such studies may be useful in the development of anti-cancer vaccines.
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